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SUMMARY AND OUTLINE 
 
 To date, with one exception, HIV still cannot be cured. This emphasizes the crucial 
importance of diagnosis and treatment, on one hand, and prevention on the other. In this thesis, 
we approached HIV prevention from multiple angles. After a general introduction into HIV 
epidemiology and biology we begin by asking the question: How fast HIV is transmitted in 
Switzerland? In this work (chapter I), we showed that HIV in Switzerland is being transmitted 
very rapidly, with 43% of all transmissions occurring within the first year of the infection. Since 
many of the infected individuals are still not aware of their HIV positive status during the first 
year of infection, this emphasizes the importance of early diagnosis and demonstrates that the 
HIV epidemic in Switzerland cannot be contained only by treating all the diagnosed HIV 
positive individuals and that additional tools are needed. In this regard, Pre-Exposure-
Prophylaxis (PreP) is currently the most promising one. 
 While PreP is currently in its infancy in Switzerland, prevention of HIV with 
antiretroviral therapy after possible exposure to the virus (Post-Exposure-Prophylaxis (PEP)) is 
available since almost two decades. What was not clear, however, is how accurately PEP is 
prescribed. In chapter II we investigated whether PEP is prescribed in situations that correspond 
to the highest risk of infection and withheld in situations that had no or a minute risk. At large, 
the answer is affirmative. We found that despite the hectic environment of the emergency room 
and the fact that most of the decisions were not made by infectious diseases specialists, the 
decisions accuracy rate stood at around 80%. Naturally, we also identified situations in which 
decision-making can still be improved and suggested ways on how to do so, for example by 
trying to reach out to the source partner.  
 In chapter III, we proceed with prevention, but this time we investigate whether hidden 
patterns recovered from Big Data can facilitate prevention and generate epidemiologically 
relevant insights. We used more than three decades of Swiss HIV cohort data with more than 
400,000 clinical visits to show that some stable HIV-infected partnerships can be found in 
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cohort studies just because the patients frequently attend the clinic visits together. Using the 
clinical visits dates, and after extensive validation, we could detect twelve transmission pairs 
of a mixed ethnicity with a large median age gap. These patients harbored HIV-1 of 
predominantly non-B subtypes, which suggests that those infections were imported into 
Switzerland.   
 While the incidence of HIV among Men-who-have-sex-with-Men (MSM) in 
Switzerland is relatively stable, the incidence among injecting-drug-users (IDUs) has been 
almost eliminated. This is despite the fact that Switzerland had one of the largest open-drug-
scenes in Europe during the early 1990s. This phenomenal success in terms of HIV prevention, 
is often attributed to the implemented harm reduction package (needle and syringe exchange 
and opioid substitution therapy). To examine that, we performed in chapter IV a quantitative 
evaluation of the cumulative impact of the implemented harm reduction measures. By 
combining a mathematical model with the unique data from the Swiss HIV Cohort Study 
(SHCS), the SHCS drug-resistance sequence database, national epidemiological data and data 
from previous works, we demonstrated that overall, harm reduction prevented around 15,000 
HIV cases, 1980-2015. In addition, using a phylogenetic analysis, we demonstrated that the 
benefits of harm reduction extend beyond the population of injecting-drug-users, with around 
2,500 averted spill-over infections to the general population. 
 From HIV prevention among injecting-drug-users we proceed with the problem of HIV 
and coinfections. Some subgroups of HIV positive individuals often maintain high levels of 
sexually risky behavior even after being infected with HIV. This exposes them to other 
sexually-transmitted-infections (STIs), like Syphilis, Gonorrhea and Chlamydia. The rates of 
STIs in the HIV positive population has been increasing over the last 10 years, which requires 
more studies that assist in optimizing screening and prevention strategies.  In chapter 5, we 
systematically describe the characteristics and risk factors of individuals with a sexually 
transmitted infection (STI) in a well-characterized cohort of mainly men-who-have-sex-with-
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men (MSM) with a prior diagnosis of primary HIV-1 infection (Zürich Primary HIV Infection 
study). We found a very high STI prevalence (33%), mostly asymptomatic at presentation, and 
identified three independent factors associated with a positive STI screen: i) anal intercourse, 
ii) reporting condomless sex, and iii) reporting any recent recreational drug use. These results 
highlight the importance of a more frequent (ideally 3-monthly) screening in high-risk 
populations as identified in this study, and demonstrate the potential of relying on self-reported 
sexual risk behavior and drug use data for screening prioritization. 
 Finally, from the prevention of HIV infection and other STIs, we move on to prevention 
of chronic illness, and specifically atherosclerosis in aging people living with HIV. This is a 
pertinent question since nowadays HIV positive individuals on successful antiretroviral therapy 
exhibit a life-expectancy that lags only few years behind the HIV negative population. 
However, since some HIV drugs have a deleterious effect on the lipids profile, and in light of 
the fact that some antiretroviral drugs interact with statins, there is a benefit also in the 
examination of life-style variables that might assist in preventing or reversing atherosclerosis. 
In chapter VI, we conclude this thesis with an analysis that examines the association between 
dietary habits, physical activity and total cholesterol in aging people living with HIV. 
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ZUSAMMENFASSUNG 
 Im Jahr 2016 übertraf die Anzahl der HIV Fälle in der europäischen Region der WHO 
erstmals die 2 Millionen Schranke. Gemäß des aktuellsten WHO/ECDC Reportes wurden im 
Jahr 2015 in den 50 Ländern der europäischen WHO Region 153.407 neue HIV Fälle 
diagnostiziert. Die epidemiologischen Einflussfaktoren unterscheiden sich jedoch nach wie vor 
im Westen und Osten Europas. In Westeuropa treiben hauptsächlich Männer, die Sex mit 
Männern haben (MSM), die Epidemie voran. In dieser Arbeit konnten wir vor allem den 
Einfluss von Transmissionen von Schweizer MSM während kürzlicher HIV Infektion und nach 
Unterbrechung der Behandlung genauer untersuchen. Des weiteren wurde im Rahmen einer 
Studie kritisch untersucht und charakterisiert, inwiefern die Verschreibung von 
Postexpositionsprophylaxe, welche vor allem von MSM gebraucht wird, die zukünftige HIV 
Prävention verbessern kann. Im Kontrast zu Westeuropa steht Osteuropa, wo Personen die 
Drogen injizieren die größte Risikogruppe darstellen. Erstaunlicherweise ist die Anzahl der 
AIDS Fälle in dieser Region in den letzten 10 Jahren um 80% angestiegen. Da die Schweiz in 
den 1980er Jahren eine Epidemie von Opium-Abhängigen durchmachen musste, könnten 
daraus wertvolle Erkenntnisse gewonnen werden, welche heute potenziell relevant für die HIV 
Prävention in Osteuropa sein könnten. Insbesondere wurde die essenzielle Rolle der 
Schadensverminderung beleuchtet, welche sowohl eine Eindämmung der Epidemie unter 
Personen, die Drogen injizieren, aber auch in der allgemeinen Bevölkerung erzielt hat. Des 
weiteren konzentriert sich diese Arbeit jedoch nicht nur auf die Prävention von neuen HIV 
Infektionen, sondern auch auf die Verbesserung der Gesundheit von Personen, die bereits mit 
HIV leben müssen. Dies wurde auf zwei Ebenen bearbeitet: (i) Wir haben eine hohe Rate an 
asymptomatischen sexuell übertragbaren Infektionen (STIs) gezeigt, sowie eine erhöhte 
Risikobereitschaft im Sexualverhalten von Patienten, welche während der kürzlichen Phase der 
HIV Infektion diagnostiziert wurden. Außerdem wurden epidemiologische Risikofaktoren für 
STIs identifiziert und empfohlen, dass intensivere Screenings durchgeführt werden sollten. (ii) 
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Wir haben die Ernährungs- und Bewegungsgewohnheiten von alternden HIV-positiven 
Patienten untersucht und die Ergebnisse mit den totalen Cholesterinwerten korreliert, in der 
Absicht die Prävention von koronaren Herzerkrankungen zu erleichtern. 
 Zusammenfassend haben wir in dieser These beabsichtigt zu verschiedenen Bereichen 
der HIV Prävention und klinischen Praxis beizutragen, in der Hoffnung sowohl 
Präventionsanstrengungen als auch Behandlungen zu verbessern. 
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GENERAL INTRODUCTION 
The global burden of HIV 
 According to the latest UNAIDS report, currently 36.7 million people are living with 
Human Immunodeficiency Virus (HIV) worldwide (Figure 1)1.  In 2015 alone, there were 2.1 
million new infections and 1.1 million Acquired Immune Deficiency Syndrome (AIDS) related-
deaths.  
Figure 1. The global number of people living with HIV by year. Source: UNAIDS 1. Dashed 
lines represent uncertainty interval.  
 
 Most people with HIV live in Africa, with 19 million in Eastern and Southern Africa, 
and 6.5 million in the Western and Central parts.  An estimated number of 2.4 million HIV 
infected live in Western and central Europe and North America altogether (Figure 2). 
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Figure 2. Adults and children estimated to be living with HIV (2015), by geographical region. 
Source: UNAIDS 1.  
 
Disease progression 
 HIV infects CD4 T cells and if untreated gradually causes immunodeficiency and 
subsequently death from AIDS related cancers or opportunistic infections2,3. Except for a first 
brief episode during the acute phase4 which is defined up to three months since seroconversion, 
the infection can be asymptomatic for years, until the AIDS stage is reached. The latter is 
characterized by severe immunodeficiency that leads to life-threatening opportunistic infections 
like Pneumocystis pneumonia 5 and fatal cancers like Kaposi Sarcoma6.  
 The viral load temporally peaks within few weeks after transmission and within 3 to 6 months 
reaches a set-point value which is relatively stable for a few years and can predict both disease 
progression and the risk of transmission7 (Figure 3).  
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Figure 3. Natural course of untreated HIV infection, source:2  
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Host and viral factors  
 Both host and viral factors were shown to shape the severity of the clinical course of 
HIV infection. From the host perspective, younger age at infection and carriage of two different 
Human Leukocyte Antigen (HLA) B alleles increase host infection tolerance and are associated 
with a slower diseases progression. Even more important is the resistance gene beta-chemokine 
receptor 5 (CCR5). This receptor serves as the main docking point for HIV upon entrance into 
the CD4 cell8,9. A 32−nucleotide deletion (delta-32) in this gene was shown to confer resistance 
to the establishment of HIV infection in homozygous individuals10,11. More on the host side, 
Rusert and Kouyos et al. showed that individuals of black ethnicity have higher post-infection 
induction rates of Broadly neutralizing antibodies (bnAbs) i.e. antibodies that are capable of 
neutralizing several viral strains, as compared to whites12.  
On the virus side, viral genetics was shown to explain around one-third of the set-point viral 
load13–16 and there is evidence that the rate of the decline of the CD4-cell counts in the recipient 
and the viral-load independent pathogenicity (“per pathogen pathogenicity”) are also partly 
determined by the viral genotype14,17.   
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The origins of HIV 
 HIV is a Retrovirus, that belongs to the Lentivirus genus. It is closely phylogenetically 
related to Simian-Immunodeficiency-Virus (SIV) and studies have shown that HIV emerged 
from several cross-species transmission events from non-human primates (Figure 4),18. 
Accordingly, the HIV virus is classified in to two types HIV-1 and HIV-2, the latter was a result 
of a cross-species transmission from Sooty mangabeys, and has a reduced virulence as 
compared to HIV-119. HIV-1, which constitutes the clear majority of infections worldwide, is 
further subdivided into four phylogenetic lineages, M N O and P. HIV-1 Group M,  which 
originated from chimpanzees (Figure 5), is the most prevalent group, and the main causative 
agent of the HIV pandemic 20. This group is further subdivided into subtypes and sub-subtypes, 
designated as A1, A2, A3, A4, B, C, D, F1, F2, G, H, J, and K, in addition to many circulating 
or unique recombinant forms. The various subtypes can differ by around 35% in the envelope 
(Env) glycoproteins of the virus 21,22,23. The genetic variation within subtypes is lower an can 
range between 15% to 20% in Env 22.  Subtype B is the predominant subtype in Europe and 
North America. The strong geographic segregation of subtypes makes them useful for 
epidemiological surveillance and for detection of HIV introductions from other countries24. 
However, subtypes might also provide clinical insights as there is evidence, that there is 
heterogeneity in disease progression between subtypes 25,26. For example, even after adjusting 
for a set-point viral load, HIV-1 subtype D was associated with a faster disease progression as 
compared to subtype A27.  
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Figure 4. The Origins of human AIDS viruses.  Source:20.   
 
 
14
Figure 5. Phylogenetic and geographic relationships between SIVcpz (Simian 
Immunodeficiency Virus from Chimpanzees) and Human Immunodeficiency Virus (HIV) , 
adapted from 28 and 29 . The phylogeny is based on partial envelope region (180 amino acids).  
HIV-1 group M is nested between two SIVcpz clusters.  
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 One of the main reasons for why the immune system cannot successfully control the 
HIV infection is the very fast mutation rate of HIV (10-4 to 10-5 per nucleotide)30,31. This high 
rate is explained by the lack of proofreading ability of the reverse-transcriptase (RT). It was 
estimated that every possible single-point mutation will occur at least once each day in an 
infected individual, when all the infectious particles are considered32.  
 
Main transmission routes and risk groups 
 Several transmission routes are known for HIV. Among them is sexual transmission, 
parenteral (either via infected needles or a blood transfusion) and a vertical transmission, i.e. 
from mother to child. The per sexual act transmission risk of HIV is not high, and was estimated 
to be around 2% (Table 1)33. This transmission risk is also not uniform when stratified by the 
type of sexual intercourse, with receptive anal sex having the highest estimated risk (138 per 
10,000) and receptive oral the lowest (less than 4 infections per 10,000 exposures). The 
predominant transmission routes vary by geographic region. While in Europe and North 
America, the epidemic is driven by sexual transmission, that is mainly associated with Men-
who-have-sex-with-Men (MSM), in Eastern Europe and Central Asia, 51% of all newly 
diagnosed HIV is attributed to people who inject drugs1. In Sub-Saharan Africa, which suffers 
from a generalized epidemic, with some countries, as South Africa, having a prevalence of 
19.2% (18.4%-20.0%), the predominant transmission route is sexual among heterosexuals. 
Recently, there is a growing evidence that age-mixing patters, and specifically, sexual 
relationships between older men (aged 25–40) and young women (aged <25), are driving the 
epidemic in Africa34,35.   
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Table 1. Risk of HIV infection by exposure route, adapted from 33. 
 
Highly-Active Antiretroviral therapy (HAART)  
 To date, except for the unique case of the “Berlin patient”, HIV still cannot be cured 36. 
This is because upon infection the virus integrates into the human immune cells, and can be re-
activated from this latent reservoir even after several years. On the positive side, since 1996, a 
combination of antiretroviral drugs, can halt the diseases progression and allow individuals to 
reach life-expectancy that is almost identical to general population 37.  
 HAART can be effectively used not only to treat, but also to prevent the establishment 
of the infection, either as Post-Exposure Prophylaxis (PEP)38: administrating ART soon after 
potential exposure to the virus, or as Pre-Exposure-Prophylaxis (PreP)39: when a high-risk HIV 
negative individuals are prescribed antiretroviral drugs as protection from a possible exposure.  
 For treatment, the latest JAMA guidelines (2016), recommended HAART immediately  
upon HIV diagnosis regardless of CD4 cell counts40. This is primarily because of patient-level 
benefits in terms of a delayed time to AIDS41 and reduced latent reservoir 42–44. The beneficial 
effect of immediate ART was recently shown to include also the reduction in the risk of a broad 
spectrum of severe bacterial infections in HIV-positive people45 with high CD4 cell count 
(above 500 cells per mL). 
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But there is also a population-level benefit, that stems from the concept of Treatment-as-
Prevention (TasP), that is based on large clinical trials which demonstrated that virally 
suppressed HIV positive individuals are not infectious to others 41.  The recommended starting 
regimen is combining two nucleoside reverse transcriptase inhibitors (NRTIs) and an integrase 
strand transfer inhibitor (InSTI)40.  
 Globally, in 2015, 36.7 million people were living with HIV, but only 60% of them 
were aware of their infection. As a result, only 17 million (46%) were actually on ART, with a 
very large variability between regions 46, and many are still not achieving viral suppression 
while on ART due to resistance, poor adherence or drug shortages. However, the trend of ART 
coverage is increasing (Figure 6). 
 In 2013, the UNAIDS set a target of “90-90-90”, that by 2020, 90% of people living 
with HIV will know their status, 90% of the diagnosed will receive a sustained antiretroviral 
therapy, and 90% of people on ART will be virally suppressed47.  
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Figure 6. The global number of people living with HIV on antiretroviral therapy, 2010-2015.  
Source 46.  
 
HIV in Switzerland 
 The HIV epidemic in Switzerland started early, with first AIDS related Kaposi sarcoma 
case reported in 1982, in Ticino, in a male patient that returned from the US 48. Historically, the 
epidemic in Switzerland was driven by two main risk groups: Men-who-have-Sex-with-Men 
and injecting drug users. Kouyos et al. showed using phylogenetic analysis that there was 
probably no self-sustaining heterosexual epidemic in Switzerland49. Along the same line, Turk 
et al. showed a diminishing HIV transmission among Swiss heterosexuals far below the 
epidemic threshold50. As in other western countries the most prevalent HIV subtype in 
Switzerland is subtype B26.  
 While the epidemic among IDU was contained, partly due to harm reduction, as 
described in chapter IV of this thesis, the HIV incidence among MSM remained relatively stable 
(Figure 7)51.  
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Figure 7. Annual number of HIV diagnosis by sex and infection route, 2010 – 2015. Source: 
BAG 51. Abbreviations: MSM – Men-who-have-Sex-with-Men, IDU – injecting drug-users. 
 
 The epidemiology of HIV in Switzerland is shaped by an interplay between behavioral 
and biological factors. On the social front, recent analysis showed an increase in condomless 
sex with occasional partners, among HIV positive MSM enrolled in the SHCS52. This trend is 
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potentially linked to the so called “Swiss Statement” that was made in 2008 which stated that 
the risk of HIV transmission for individuals on successful ART and that are in a stable 
partnership, is negligible53. While the direct causal effect of the statement on sexual risk 
behavior remains debated, there are several reports suggesting that the statement has 
contributed to increased condomless sex. For example, Shilaih et al. has showed that the 
incidence of syphilis in the Swiss HIV Cohort Study, strongly increased since 200854.  
 
Antiretroviral Resistance in Switzerland 
 Unfortunately, due to the high mutation rate and a high within-patient diversity, the 
virus can develop and maintain resistance that can be either acquired or transmitted55. Acquired 
resistance is a result of poor adherence56 or drug supply shortage57. Transmitted resistance, is 
found in patients that have never experienced HAART, but were infected with a resistant virus 
in the first place58.  
 A recent analysis by Scherrer et al. that examined ART experienced patients enrolled in 
the Swiss HIV Cohort Study in the period 1999 to 2013, showed that emergence of acquired 
drug resistance almost stopped, with less than 0.4% of the patient that initiated ART after 2006, 
having a three-class resistance59. Concerning transmitted drug resistance (TDR) the median 
prevalence of resistance to any drug in the SHCS, from 1998 to 2012, was 9.1% (range, 2.2%-
15.6%)60.  The same study also demonstrated that transmission of antiretroviral drug resistance 
is transiently reduced by the introduction of new drug classes60. However, since the introduction 
of integrase-strand transfer inhibitor (INSTI), the resistance rates to this drug-class in 
Switzerland remained persistently low (0.1%)61.  
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The interaction of HIV with other STIs 
 The epidemiological interplay between other sexually transmitted infections (STIs) and 
HIV can be bi-directional. On one hand, there is evidence suggesting that some STIs (i.e 
Syphilis, Gonorrhea, Genital Ulcer Disease (GOD)), can both increase the susceptibility of the 
HIV negative partner for the establishment of HIV infection and also increase the infectiousness 
of the HIV positive partner62–64. On the other hand, people that are already HIV positive, and 
especially Men-who-have-Sex-with-Men often remain in a high risk for the acquisition of 
additional STIs54,65,66, due to continuous or cyclical sexual risk behavior54. In a cross-sectional 
study from Bern65, Switzerland, the combined rates of laboratory-diagnosed and self-reported 
bacterial STI among HIV positive individuals in the year before the study were high: 27.7% 
(95% CI 21.1, 36.7%) among MSM, 1.5% (95% CI 0.2, 10.3%) among heterosexual men and 
6.4% (95% CI 2.1, 21.0%) among women. The optimal STI screening frequency remains to be 
determined67 which is further complicated by a high rate of asymptomatic STIs that can reach 
90%68.  
 
Phylogenetic studies of HIV 
 A phylogenetic tree depicts the evolutionary history and relatedness between species, 
between individuals, or even between individual genes.  In a perfectly sampled population, the 
closer are two members on the tree, the more closely they are related to the same common 
ancestor. In the HIV field, phylogenetic approaches were successfully applied to a plethora of 
research questions. Among the most frequent applications are:  
(i) Shading light on evolutionary history and introduction events. For example, it was shown 
that 1920s Kinshasa (in what is now the Democratic Republic of Congo) was the source of the 
early HIV-1 spread in human populations69.  Another phylogenetic work showed that HIV-1 
subtype B USA epidemic, from where HIV was later introduced to Europe70, originated from a 
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pre-existing Caribbean epidemic71. This jump to the USA was estimated to have happened via 
New York, between 1969–197471. 
(ii) Utilizing phylogeny for elucidation of transmission dynamics and epidemiology. This 
research front swiftly emerged in the last decade and is fueled by a dramatic increase in the 
availability of HIV sequences, as a byproduct of a clinical drug resistance testing to optimize 
treatment72. In Switzerland alone, phylogeny was already used to elucidate the degree of mixing 
between different risk groups49, to identify drivers of onward transmission73 and to calculate 
the basic reproductive number (R0) of HIV74, which was estimated to be 2.29 75. For the 
heterosexual population, the R0 was recently estimated to be 0.44 (95%-confidence interval 
0.42-0.46), which is far below the epidemic threshold50.  
Since incomplete sampling can be rarely ruled out, phylogenetic proximity cannot be 
interpreted as a direct transmission event76,77, which is a widely recognized limitation.  
 (iii) Detecting heritability of disease related traits. In other words, what fraction of a trait 
variance can be explained by viral genetics as opposed to host related factors. By implementing 
phylogenetic methods, it was shown that viral genetics partly determines the set point viral 
load13, the rate of decline of the CD4 cells14 and the virus load adjusted pathogenicity17.  
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HIV as chronic disease: Aging, Ischemic Heart disease and Nutrition 
 
 Although life expectancy in HIV-positive people on ART has improved worldwide in 
recent years, important gaps still remain in comparison with the general and HIV-negative 
population78. Studies have shown that in comparison to HIV uninfected individuals, HIV 
positive people suffer from higher incidence of cardiovascular disease (CVD), bone, metabolic, 
neurocognitive and other aging comorbidities79,80,81. HIV-associated inflammation, persistent 
immunodeficiency, cumulative toxic effects from exposure to antiretroviral drugs, all have been 
implicated as potential causes82. In the D:A:D: Study it was shown that the incidence of 
myocardial infarction increased with cumulative exposure to ART83. In a recent study, 
subclinical coronary artery stenosis was also associated with a longer treatment with HAART84. 
HAART is associated with HIV lipodystrophy, dyslipidemia, diabetes mellitus and insulin 
resistance85.  However, those effects strongly depend on the individual drug and side-effects 
are more benign for newer regiments86. Nevertheless, all these metabolic disturbances 
contribute to the elevated risk of CVD87. This adds up to the fact that HIV positive individuals 
generally tend to have a high rate of traditional risk factors for CVD like smoking and 
hyperlipidemia88, Figure 8. Increased obesity rates were recently demonstrated in the Swiss 
HIV Cohort Study as well89.  All this makes understanding the contribution of dietary habits 
and physical activity a pertinent task which carries a possible prevention potential90,91, as those 
are modifiable risk factors.  
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Figure 8.  HIV and Ischemic Heart Diseases: Etiopathogenesis of HIV-Associated Coronary 
Artery Diseases, adapted from88:  
 
 
 
 
 
  
dysfunction, and coagulation disorders, ultimately
leading to atherosclerosis.
ATHEROSCLEROSIS. Recent research focus has
shifted to the detection of subclinical atheroscle-
rosis as a surrogate for clinical events. The typical
plaque in HIV-infected patients is a noncalciﬁed
atherosclerotic plaque, but calcium oxalate crystal
deposits (atherosclerotic oxalosis) within the plaques
have been described in HIV-infected patients on
cART (31). Direct HIV infection of the coronary
vascular wall appears to stimulate proliferation of
vascular smooth muscle cells, and thereby promotes
atherosclerosis. Detection of the HIV protein p24
by ﬂuorescence microscopy in smooth muscle
cells from tissue sections of human atherosclerotic
plaques obtained from HIV-infected individuals
supports this hypothesis (32).
Noninvasive imaging, such as carotid intima-media
thickness (CIMT) and coronary computed tomography
angiography (CCTA), indicates an increased preva-
lence of subclinical atherosclerosis in HIV-positive
patients compared with HIV-negative patients
(33–35). A meta-analysis of 13 observational studies
suggests a trend toward more increased CIMT in
HIV-infected patients compared with HIV-negative
patients (33). As early as childhood, HIV-infected
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The etiopathogenesis of HIV-associated coronary artery disease is multifactorial. Inﬂammation is the hallmark of HIV infection. There is interplay between
the direct effects of HIV infection, attendant inﬂammation, traditional risk factors prevalent in HIV infection, and side effects of some antiretroviral
therapy regimens. These occur in a milieu of variable environmental and as yet unknown genetic factors. HIV ¼ human immunodeﬁciency virus.
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CHAPTER I 
“HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major 
Drivers of New Infections in the Swiss HIV Cohort Study” 
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Research in context 
 The impact of transmission during recent HIV infection is a crucial determinant of the 
success of Treatment-as-Prevention (i.e. treating HIV early not only for the benefit of the 
individual but also to prevent onward transmission, since treated individuals are not infectious) 
as a strategy to curb the HIV pandemic, because recently infected patients are often unaware of 
their infection and therefore remain untreated. Yet, previous studies have shown discrepant 
estimations of the fraction of transmissions attributable to recent infection ranging from less 
than 10% to 70–80%. In this work we combined the unique data from the Swiss HIV Cohort 
Study (SHCS), the associated drug resistance database and the Zurich Primary HIV Infection 
Study (ZPHI) to empirically determine the impact of recent-phase transmission in a 
representative population: Using molecular epidemiology approaches, we identified 
transmission-pairs with available seroconversion dates and found that over 40% of transmitters 
transmitted the virus in the first year of infection and over 30% within the first 6 months of 
infection. Transmission during the chronic infection phase was strongly and significantly 
associated with late-start of antiretroviral therapy (ART) and high chronic phase virus load, 
underlining the importance of ART for preventing chronic-phase transmission. Finally, a 
substantial fraction (>15%) of chronic phase transmission events occurred during treatment 
interruptions. These findings underline that Treatment-as-Prevention should be complemented 
by efforts for early diagnosis and measures for optimizing treatment continuity. Interestingly, 
four months after this study was published, a research group from the Imperial College London 
published1 an independent analysis of the ATHENA cohort from the Netherlands, in which they 
found that 43% of all transmitters transmit within the first year of infection, which matches 
exactly our reported estimate.   
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HIV-1 Transmission During Recent Infection and
During Treatment Interruptions as Major Drivers of
New Infections in the Swiss HIV Cohort Study
Alex Marzel,1,2 Mohaned Shilaih,1,2 Wan-Lin Yang,1,2 Jürg Böni,2 Sabine Yerly,3 Thomas Klimkait,5 Vincent Aubert,7 Dominique L. Braun,1,2 Alexandra Calmy,4
Hansjakob Furrer,9 Matthias Cavassini,8 Manuel Battegay,6 Pietro L. Vernazza,10 Enos Bernasconi,11 Huldrych F. Günthard,1,2 and Roger D. Kouyos1,2, for the
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Background. Reducing the fraction of transmissions during recent human immunodeﬁciency virus (HIV) infection is essential
for the population-level success of “treatment as prevention”.
Methods. A phylogenetic tree was constructed with 19 604 Swiss sequences and 90 994 non-Swiss background sequences. Swiss
transmission pairs were identiﬁed using 104 combinations of genetic distance (1%–2.5%) and bootstrap (50%–100%) thresholds, to
examine the effect of those criteria. Monophyletic pairs were classiﬁed as recent or chronic transmission based on the time interval
between estimated seroconversion dates. Logistic regression with adjustment for clinical and demographic characteristics was used to
identify risk factors associated with transmission during recent or chronic infection.
Findings. Seroconversion dates were estimated for 4079 patients on the phylogeny, and comprised between 71 (distance, 1%;
bootstrap, 100%) to 378 transmission pairs (distance, 2.5%; bootstrap, 50%). We found that 43.7% (range, 41%–56%) of the trans-
missions occurred during the ﬁrst year of infection. Stricter phylogenetic deﬁnition of transmission pairs was associated with higher
recent-phase transmission fraction. Chronic-phase viral load area under the curve (adjusted odds ratio, 3; 95% conﬁdence interval,
1.64–5.48) and time to antiretroviral therapy (ART) start (adjusted odds ratio 1.4/y; 1.11–1.77) were associated with chronic-phase
transmission as opposed to recent transmission. Importantly, at least 14% of the chronic-phase transmission events occurred after
the transmitter had interrupted ART.
Conclusions. We demonstrate a high fraction of transmission during recent HIV infection but also chronic transmissions after
interruption of ART in Switzerland. Both represent key issues for treatment as prevention and underline the importance of early
diagnosis and of early and continuous treatment.
Keywords. HIV recent (early) infection; treatment as prevention; treatment interruptions; HIV transmission; endgame.
Human immunodeﬁciency virus (HIV) remains an immense
public health threat, with a global prevalence of 35.3 million in-
fected individuals in 2013 [1]. Whereas in most high-income
countries the incidence of male-female transmission has been
stable or decreasing, the incidence of male-male transmission
is rising or remains high [2]. In this context, one pivotal ques-
tion is the relative contribution of the early and chronic disease
phases to HIV transmission. Previous studies have shown dis-
crepant estimations of the fraction of transmissions attributable
to recent infection ranging from <10% [3] to 70%–80% [4].
Knowing the burden of early-phase transmission is important
for public health policy, especially in the context of the latest ef-
forts to introduce immediate and early antiretroviral therapy
(ART)—that is, “treatment as prevention” (TasP)—as one of
the main global containment strategies of the HIV pandemic
[5]. A growing body of evidence suggests that once an HIV-
positive individual is diagnosed and successfully treated with
ART, the hazard of onward transmission drops dramatically [6,7].
A high proportion of recent-phase HIV transmissions will
compromise the effectiveness of TasP for several reasons.
First, a substantial fraction of recently infected patients are
still unaware of their HIV-positive status and thus remain un-
treated and infectious [8]. Secondly, infectiousness during pri-
mary HIV-infection has been estimated to be up to 26 times
higher than during later (pre-AIDS) stages of the infection
[9],which is further supported by a higher HIV-1 concentration
in semen [10]. Finally, ongoing transmission of drug-resistant
viral variants by patients unaware of their infection may com-
promise the effectiveness of ART [11].
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In this work, we addressed this question by retrospectively
analyzing transmission pairs from the unique data from the
Swiss HIV Cohort Study (SHCS), the associated drug resistance
database, and the Zurich Primary HIV Infection Study (ZPHI).
The aims of this study were to determine the fraction of HIV
transmissions that occurs during recent infection and to evalu-
ate HIV transmission in relation to the timing of ART initiation.
METHODS
Study Population: SHCS Drug Resistance Database and ZPHI
The SHCS is a large prospective multicentered, study estab-
lished in 1988 [12]. During the biannual outpatient follow-up
visits, extensive clinical and demographic data are collected
for each participant. The drug resistance database contains
HIV sequences for approximately 60% of the patients in the
SHCS. The SHCS is highly representative of the HIV epidemic
in Switzerland, with an estimated coverage of ≥45% of all HIV
cases, 69% of all patients with AIDS in Switzerland and 72% of
all ART-treated individuals [12]. The ZPHI [13, 14], speciﬁcally
enrolls patients with documented acute or recent primary HIV-
1 infection.
Phylogenetic Tree Construction
A total of 19 604 partial pol sequences from 10 970 SHCS cohort
participants (40% of patients had ≥2 sequences) were pooled
with 90 994 background sequences from the Los Alamos data-
base. The phylogenetic tree was generated (see Supplementary
Text 2 for details) with FastTree software (version 2.1.7, SSE3,
OpenMP) [15] using a generalized time-reversible model. Sup-
port values for internal nodes were derived based on 100 boot-
strapped trees. With use of the R package APE (version 3.1) [16]
and custom scripts, potential transmission pairs were identiﬁed
as monophyletic pairs if their genetic distance and bootstrap
support values met the predeﬁned thresholds of 104 combina-
tions of genetic distance (1%, 1.5%, 2%, and 2.5%) and boot-
strap (50%–100% in 2% increments) support. This was done
to estimate the effect of various transmission cluster deﬁnitions
on the dependent variable, because there is no consensus on op-
timal thresholds [17].
Estimation of Infection Dates
Seroconversion dates were estimated based on a hierarchical
algorithm (Figure 1; see Supplementary Text 1 for detailed
description), which relied on participation in the ZPHI,
Figure 1. Hierarchical algorithm for the determination of the infection dates for patients enrolled in the Swiss HIV Cohort Study (SHCS) (n = 18 572). Abbreviation: HIV,
human immunodeficiency virus.
116 • CID 2016:62 (1 January) • HIV/AIDS
39
immunological markers, dates of HIV-positive/negative tests,
clinical symptoms and ambiguous nucleotides [18, 19].
Classiﬁcation of Transmission Pairs as Recent or Chronic
After construction of the phylogenetic tree and the estimations
of the patients’ infection dates, a time interval between the in-
fection dates of themembers of each phylogenetically established
transmission pair was calculated (Supplementary Figure 1).
Clusters with an interval of ≤6 or ≤12 months within a pair
were classiﬁed as recent transmission (to account for variable
deﬁnitions of the duration of recent infection [20], 2 analyses
were performed, 1 for each threshold), and those with an inter-
val of >6 or >12 months as chronic transmission.
Determining the Potential Transmitter and the Infection Window of the
Recipient Within Each Pair
By default, a “transmitter” was deﬁned as the member of the
pair with the earliest seroconversion date. For the analysis of
transmission in relation to time of ART initiation, we also de-
ﬁned for each potential recipient the most plausible infection
window. Its upper bound is given by the ﬁrst positive HIV
test. Its lower bound is given by the latest of 3 dates: (1) 90
days before the last HIV negative test; (2) for individuals with
a diagnosis of primary HIV infection (categories I and II in
Supplementary Text 1), 365 days before the ﬁrst HIV positive
test; and (3) 730 days before the ﬁrst positive test, if the patients’
seroconversion date was estimated based on a resistance test
with <0.5% of ambiguous nucleotides within 3 years after diag-
nosis and a ﬁrst CD4 cell count >250/μL [18].
Estimation of Infectiousness During the Chronic Phase
Among the phylogenetically inferred transmitters, we identi-
ﬁed risk factors associated with the relative odds of being a
chronic- or recent-phase transmitter using logistic regression.
To quantify the transmission potential [21] during the chron-
ic phase, which depends both on viral load (VL) magnitude
and the duration with detectable VL, we calculated for each
patient with ≥2 chronic-phase RNA measurements, the area
under the curve (AUC) of the log10-transformed RNA VL
from the end of the recent infection (1 year after the sero-
conversion date) to the last laboratory result of the chronic
phase. To facilitate the regression interpretation, this variable
was standardized (such that its mean is zero and one unit is
one standard deviation). For the comparison of chronic-
phase post-ART and pre-ART transmitters, VL AUC was cal-
culated from the time of ART initiation to the last RNA
measurement.
Table 1. Clinical and Demographic Characteristics of the Study Population
Characteristic All SHCS Phylogenetic Tree
Distance: 1%; Bootstrap:
100%a
Distance 1.5%; Bootstrap:
80%a
Distance 2.5%; Bootstrap:
50%a
Patients, No. 18 572 10 970 142 428 744
Age at diagnosis, mean (IQR), y 34 (26.4–40) 34.5 (26.5–40) 36.4 (29–42) 36 (28.6–42) 35.3 (28–41)
Sex, No. (%)
Male 13 369 (71.98) 7799 (71.09) 122 (85.92) 363 (84.81) 632 (84.95)
Female 5203 (28.02) 3171 (28.91) 20 (14.08) 65 (15.19) 112 (15.05)
Risk group, No. (%)
MSM 6929 (37.3) 4205 (38.3) 93 (65.5) 271 (63.3) 463 (62.2)
Heterosexuals 6118 (32.9) 3919 (35.7) 40 (28.2) 102 (23.8) 158 (21.2)
Injection drug users 3281 (17.7) 1627 (14.8) 6 (4.2) 35 (8.2) 76 (10.2)
Other 2244 (12.1) 1219 (11.1) 3 (2.1) 20 (4.7) 47 (6.3)
Subtype, No. (%)
B 8314 (75.8) 8314 (75.8) 96 (67.6) 335 (78.3) 616 (82.8)
Non-B 2656 (24.2) 2656 (24.2) 46 (32.4) 93 (21.7) 128 (17.2)
Ethnicity
White 12 528 (67.5) 8495 (77.5) 116 (81.7) 371 (86.9) 660 (88.9)
Other 6039 (32.5) 2472 (22.5) 26 (18.3) 56 (13.1) 82 (11.1)
RNA viral load, median (IQR),b
log10 copies/mL
4.65 (3.96–5.2) 4.65 (4–5.2) 4.81 (4–5.41) 4.82 (4.18–5.45) 4.76 (4.11–5.36)
CD4 cell counts, median (IQR),
cells/μL b
342 (167–546) 370 (200–562) 420 (291–622) 440 (302–636.5) 471 (319.5–655.5)
ART start year, median (range) 1999 (1986–2014) 2000 (1986–2014) 2009 (1990–2013) 2008 (1990–2013) 2008 (1990–2014)
Time to ART, median (IQR), mo 20.8 (6.03–50.7) 21.5 (6–51.55) 14.5 (2.68–32.93) 14.7 (3.1–36.6) 16.6 (4.27–40.58)
Cohort recruitment year, median
(range)
1997 (1981–2014) 2000 (1984–2014) 2008 (1989–2013) 2007 (1989–2013) 2006 (1987–2013)
Progressed to AIDS, No. (%) 6657 (35.8) 3032 (27.6) 11 (7.7) 40 (9.3) 73 (9.8)
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; MSM, men who have sex with men; SHCS, Swiss HIV Cohort Study.
a Based on pairs with available seroconversion dates.
b Earliest treatment-naive measurement after enrollment.
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Statistical Analysis
Statistical analysis was performed with R software (version
3.0.3; http://cran.r-project.org).
Ethics
Ethical approval of the SHCS and the ZPHI and written in-
formed consent for all participants were obtained.
RESULTS
Data Description
Of 18 572 SHCS participants, 10 970 (59%) had≥1 sequence in the
SHCS drug resistance database and were hence considered for
further analysis (Table 1). Their year of HIV diagnosis ranged
from 1984 to 2014. Of these patients, 7799 (71%), were men,
8314 (75%) were infected with subtype B, 4205 (38%) were men
who have sex with men (MSM), and 8495 (77%) were white. De-
pending on the phylogenetic threshold, 3%–20.6% of the patients
represented on the phylogenetic tree were members of a putative
transmissionpair (Figure 2). Seroconversiondates couldbe estimat-
ed for 4079 patients represented on the phylogeny, 82% with diag-
nosis during the ﬁrst year after seroconversion. As expected, stricter
bootstrap thresholds were associated with fewer transmission pairs
(Figure 2) (Spearman ρ =−1; P < .001 for all 4 distances). For all
104 phylogenetic thresholds the predominant risk group among
transmission pairs was MSM, ranging between 62% and 66%.
Figure 2. Outline of this study. Each bar represents a different combination of bootstrap and genetic distance thresholds. Black numbers above the bars represent the number
of transmission pairs that correspond to the specific combination; red numbers, the number with available seroconversion dates for both members; blue numbers at the x-axis,
ascending bootstrap thresholds; green and yellow asterisks, data sets used for the main logistic regression and sensitivity analyses, respectively. Abbreviations: HIV, human
immunodeficiency virus; N, number of pairs; SHCS, Swiss HIV Cohort Study.
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Estimation of HIV Transmission During Recent Infection
To estimate the fraction of transmissions attributable to recent in-
fections, we selected potential transmission pairs using 104 differ-
ent combinations of bootstrap and genetic distance. For each
combination, we calculated the fraction of the recent-phase trans-
mission (see “Methods” section). Overall, we found a high frac-
tion of transmission during recent infection. This fraction was
higher, but not proportionally higher, when recent infection
was deﬁned as ﬁrst year of infection (vs the ﬁrst 6 months) and
increased with the strictness of the criterion used to deﬁne trans-
mission pairs. When recent HIV infection was deﬁned as the ﬁrst
year since seroconversion, the median fraction of transmission
during recent infection was 43.7% and ranged from a minimum
of 41% (95% conﬁdence interval [CI], 36%–46%) for a bootstrap
of 50% and a distance of 2.5% to a maximum of 56.5% (95% CI,
45%–67%) for a bootstrap of 100% and distances of 2% and 2.5%.
When recent HIV infection was deﬁned as 6 months since sero-
conversion, the median fraction of transmission during recent in-
fection was lower (31.6%) and ranged from a minimum of 28%
(95%CI, 23%–33%) with a bootstrap of 50% and distance of 2.5%
to a maximum of 42.3% (95% CI, 32%–54%) with a bootstrap of
100% and distances of 2% and 2.5%.
For all 4 distance thresholds, a positive correlation was ob-
served between the bootstrap thresholds and the recent-phase
(12-month) transmission fractions (Figure 3) (Spearman
ρ > 0.70; P < .001). Thus, a higher bootstrap threshold resulted
in a higher fraction of recent-phase transmission. Importantly,
the fraction of recent transmission increased sharply for higher
bootstrap values (>92%), indicating that high bootstrap thresh-
olds may bias the selection toward recently infected transmission
pairs. For the 6-month deﬁnition of recent HIV infection the cor-
relation between bootstrap and the fraction of attributable recent-
phase transmissions was even stronger, and was signiﬁcant for all
4 genetic distances tested (Spearman ρ > 0.93; P < .001). Thus,
our phylogenetic analysis indicates that a large share of infections
can be attributed to recent-phase transmission but that the exact
proportion varies depending on the deﬁnition of a transmission
pair (bootstrap and distance thresholds) and the duration of
recent infection (12 vs 6 months).
Risk Factors for Chronic Transmission
HIV-1 transmission in the chronic phase, as opposed to the re-
cent phase, was strongly associated with higher AUC of chron-
ic-phase VL and delayed initiation of ART. Logistic regression
was applied to the data set that corresponded to a genetic dis-
tance of 1.5% and bootstrap of 80% (Table 2). These thresholds
were chosen as a compromise between 3 criteria: (1) avoiding
the above-mentioned selection bias toward recent infection,
Figure 3. Swiss HIV Cohort Study–based estimation of transmission during recent human immunodeficiency virus infection. Red numbers represent the fraction of trans-
missions during recent infection, according to a definition of recent infection as 12 months since seroconversion; green numbers, recent transmission fraction for a definition of
6 months since seroconversion. In all, 104 combinations of genetic distance (1%, 1.5%, 2%, or 2.5%) and bootstrap (50%–100% in 2% increments) support values are shown;
vertical lines represent 95% confidence intervals for proportion. Abbreviation: HIV, human immunodeficiency virus.
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which occurs for very strict criteria; (2) providing a fair statisti-
cal power (170 complete cases); and (3) minimizing the proba-
bility of false-positive clustering. In a bivariate analysis,
transmitting HIV during chronic infection was positively corre-
lated with time until the initiation of ART (odds ratio, 1.5/y;
95% CI, 1.26–1.8) and with higher chronic-phase VL AUC
(2.62; 95% CI, 1.74–3.97) (Table 2). In the multivariable
model, both time to ART and the AUC of HIV plasma RNA
during the chronic phase remained signiﬁcantly associated
with higher odds of chronic as opposed to recent transmission
(adjusted odds ratio, 1.4/y [95% CI, 1.11–1.77] and 3 [1.64–
5.48], respectively). Thus 1 standard-unit change in chronic
VL AUC was associated with 3-fold increased odds of chron-
ic-phase HIV transmission compared with recent-phase trans-
mission, after adjustment for potential confounders and time to
initiation of ART. Moreover, we found—only in the multivariable
analysis—that later transmission years were associated with
chronic-phase transmission, and higher baseline CD4 cell counts
with recent transmission. In a sensitivity analysis, we found sim-
ilar results with the more lenient criteria of 1.5% distance and
50% bootstrap (Supplementary Table 1). In summary, we showed
that increased delay to initiation of ART shifts the relative odds of
transmission toward the chronic phase. Moreover, our data indi-
cate that the total RNAVL in the chronic phase increases the rel-
ative odds of transmitting HIV during this phase, even after
adjustment for treatment initiation.
Transmission in Relation to ART Initiation
To explain the above-mentioned, ART-adjusted association of
total chronic-phase VL with chronic-phase transmission, we
further examined the chronic-phase transmitters (n = 121) in
relation to ART initiation. Our data show that a substantial frac-
tion of chronic-phase transmission occurred after ART was
started by the transmitter.
For 54 of 121 chronic-phase transmitters (45%), the seroconver-
sion date of the recipient was after the ART initiation date of the
transmitter. In line with post-ART transmission, the mean post-
ART VL AUC of post-ART transmitters was higher than that of
pre-ART transmitters (0.17 vs −0.38; P = .002, Wilcoxon rank
sum test) (Figure 4). Restricting the transmitters’ VL measure-
ments only to those obtained during the recipients’ infection win-
dow (see “Methods” section) further corroborated transmission
after ART: 44 of 54 transmitters had ≥1 VL measurement in
the relevant period, and 35 of these 44 transmitters had ≥1 VL
value >400 copies/mL [22] with a median nonzero maximal VL
of 70 800 copies/mL (range, 2340 to 4.99 × 106 copies/mL). The
Table 2. Logistic Regression Analysis for Chronic Versus Recent Phylogenetically Linked Human Immunodeficiency Virus Transmittersa
Variable Bivariate OR (95% CI) P Value Multivariable OR (95% CI) P Value
Age at infection 0.96 (.93–.99) .01 0.97 (.93–1.01) .11
Sex
Male Reference . . . . . . . . .
Female 1.04 (.49–2.23) .92 2.43 (.6–9.94) .22
Risk group
MSM Reference . . . . . . . . .
Heterosexuals 1.08 (.56–2.1) .81 0.61 (.15–2.52) .49
Injection drug users 0.92 (.33–2.51) .86 0.54 (.09–3.38) .51
Subtype
Non-B Reference . . . . . . . . .
B 1.4 (.72–2.73) .32 1.28 (.45–3.67) .65
√CD4 cell countsb 1.02 (.98–1.07) .34 0.93 (.87–1) .04
Transmission year 0.99 (.93–1.06) .82 1.13 (1.02–1.26) .02
Time to ART (years) 1.5 (1.26–1.8) <.001 1.4 (1.11–1.77) .005
Chronic RNA VL AUC 2.62 (1.74–3.97) <.001 3 (1.64–5.48) <.001
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; MSM, men who have sex with men; OR, odds ratio; VL AUC, viral load area under the curve.
a Of 170 transmitters (complete cases), 94 were chronic and 76 recent. Chronic transmission was defined as >1 year since seroconversion (coded as 1); recent transmission, as ≤1 year (coded
as 0); phylogenetic linkage thresholds: bootstrap, 80%, genetic distance 1.5%.
b Earliest treatment-naive measurement after enrollment.
Figure 4. Total post–antiretroviral therapy (ART) viral load area under the curve (VL
AUC) of pre-ART (green) and post-ART (red) transmitters. The median post-ART VL AUC
of post-ART transmitters was higher than that of pre-ART transmitters (based on 121
chronic transmitters selected using a bootstrap of 80% and a genetic distance of 1.5%).
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remaining 9 transmitters might represent a nondirect transmission
pair (eg, with a missing intermediate transmitter) or a false-posi-
tive cluster; alternatively, the intermittent VL rebounds might have
been missed by the 3–4 monthly VL measurements.
Finally, we determined in more detail the treatment status of
the 35 VL-conﬁrmed post-ART transmitters. For 18 transmit-
ters, the date of ART initiation for the transmitter lay within the
transmission window for the recipient. Hence, even though the
estimated seroconversion date suggests post-ART transmission,
we cannot exclude for those patients the possibility that the
transmission occurred shortly before ART (Supplementary Fig-
ure 2A). Thus, these individuals transmitted either brieﬂy
before or brieﬂy after ART initiation. For the remaining 17
transmitters, the transmitter’s date of ART initiation lay
completely before the recipients’ infection window (Supple-
mentary Figure 2B). Importantly, 16 of 17 had a documented
period of treatment interruption during the recipient’s infection
window. These therapy interruptions lasted between 42 to 859
days within the infection window of the recipient. The remain-
ing transmitter had no documented treatment interruption but
carried high-level resistance mutations (M184V and K103N)
and did not achieve viral suppression in the 6 years after treat-
ment initiation, including the recipient’s transmission window.
Overall, these results indicate that a substantial fraction of
chronic-phase transmission events—at least 17 of 121 (14%)
and up to 54 of 121 (45%)—occurred after ART initiation by
the transmitter. This observation underlines the important con-
tribution of treatment interruptions and the periods close to
ART initiation for onward HIV transmission.
DISCUSSION
In Switzerland, despite increasing treatment coverage and de-
creased time to ART initiation, the number of newly diagnosed
HIV infections remains stable [23]. Our study revealed 2 key
challenges for achieving a population level effect of TasP: recent
infections and HIV transmission during treatment interrup-
tions in patients with chronic infection.
We demonstrated that a substantial fraction of HIV transmis-
sions in the SHCS can be attributed to recently infected patients,
for whom the preventive effect of treatment is weaker, due
to underdiagnosis and lack of patient’s awareness of his sero-
positive status. In addition, immediate treatment of acute or re-
cent infection was recommended only recently [24]. Moreover,
our data show a strong effect of total VL on transmission in the
chronic phase, even after adjustment for time to initiation of
ART. This effect is partly due to transmission after ART initia-
tion, notably during treatment interruptions. This observation
implies that rapid administration of treatment, while the patient
is still in the early phase of infection, is necessary but not sufﬁ-
cient to prevent transmission (because transmission may also
occur after ART interruption in the chronic phase).
Our ﬁndings imply that TasP needs to be accompanied by in-
terventions to tackle treatment continuity, adherence, retention
in care, and, importantly, early diagnosis [25, 26]. A systematic
review has shown that the median proportion of patients inter-
rupting treatment was 23% for a median duration of 150 days
[27]. Furthermore, 54% of HIV-diagnosed patients in Europe
were late presenters—individuals who had a CD4 cell count
<350/μL or an AIDS-deﬁning illness within 6 months of HIV
diagnosis [28]. Cumulatively, our data imply that treatment in-
terruptions, whether structured or due to toxic effects, patient’s
wishes, or lack of adherence, are not only unfavorable for the
individual [29] but also bear public health consequences [26].
Our work further underlines the need for validated and con-
sensual thresholds for phylogeny-based detection of HIV trans-
mission. The observed positive correlation between the strictness
of the transmission pair selection criteria (higher bootstrap and
lower genetic distance) and the fraction of transmissions attribut-
ed to recent infections implies that too-strict selection criteria
overestimate the fraction of recent-phase transmission. Several
other studies that implemented strict genetic distance and boot-
strap thresholds (eg, 1.5% distance and 98% bootstrap) have
found recent infection as a predictor of membership in HIV
transmission clusters (reviewed in [17]). Our data suggest that
some of these results might have been affected by the strictness
of the chosen thresholds, which inadvertently favored selection
of recent transmission clusters over the chronic clusters.
This study has several limitations. One intrinsic challenge is
that neither the timing nor the order of transmission events are
strictly reﬂected in the pathogen phylogeny, which is also highly
dependent on the sampling density of the target population
[30]. However, the SHCS coverage of the Swiss HIV epidemic
was estimated to be high [12],with >10 000 genotypic resistance
tests done retrospectively using the SHCS biobank [11]. More-
over, 90 994 Los Alamos HIV-1 sequences were included to re-
duce the chances of random clustering.
Another limitation is that we were able to estimate the sero-
conversion date for only 29% of the cohort participants. This
resulted in selection toward the MSM risk group, possibly be-
cause of the high rate of HIV testing, a key criterion in our
estimation of seroconversion dates. We speculate that this selec-
tion toward MSM, combined with the high fraction of patients
that were diagnosed while still at the recent phase, led to an
overestimation of recent-phase transmission in our sample
compared with the general Swiss HIV-positive population.
Finally, in contrast to the chronic-phase total VL, an accurate
estimate of the total (AUC) recent-phase VL was not possible and
was not incorporated into our statistical models, because most
patients were enrolled in the cohort at variable times in relation
to the acute-phase viremic peak. Despite these limitations, our
work highlights the high fraction of recent-phase transmission
and transmission during therapy interruptions, two key challeng-
es for curbing HIV incidence with TasP.
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Supplementary Data
Supplementary materials are available at http://cid.oxfordjournals.org.
Consisting of data provided by the author to beneﬁt the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
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Research in context 
When administrated fast enough – before 72 hours since exposure – highly active antiretroviral 
therapy can prevent the establishment of HIV infection. HIV post-exposure prophylaxis (PEP) after 
sexual exposure has been prescribed in resource-rich countries for almost two decades. However, it 
remains unclear whether the prescription practices reflect the risk of HIV transmission. In other words, 
it is not clear whether PEP is prescribed when the transmission risk is high and withhold when the risk 
is negligible. This issue is especially pertinent, as most PEP prescriptions take place in emergency room 
settings by physicians without specialized training in estimating HIV transmission risk. 
 To address this gap, we conducted a systematic evaluation of the adequacy of PEP prescription 
for all persons presenting at the emergency room of the Zurich University Hospital after consensual sex 
from 2007 to 2013. We first defined an epidemiology-based risk assessment algorithm, which 
incorporated the major risk factors for HIV transmission, including unprotected sex, HIV status of the 
source partner and high-risk transmission groups. Each visit was assessed with respect to the risk of HIV 
transmission and the actual PEP prescription decision, i.e. whether PEP was prescribed or not. We found 
that HIV PEP after a sexual incident was correctly prescribed in the majority of all visits (74%); 
however, in 10% it was not prescribed while indicated, and in 12% it was prescribed while no HIV 
transmission risk was evident. Both, patient demand or refusal and physician incorrect interpretation of 
the risk situation contributed to risk discordant decisions. In a multivariable analysis, the presence of the 
source partner (i.e. the partner with whom the sexual act took place) increased the odds of correctly 
withholding unnecessary PEP. We speculate that the findings presented in this work might have simple 
practical implications; in particular, emergency doctors may benefit from a PEP-related specialized HIV 
transmission risk recognition training. 
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EPIDEMIOLOGY
Prescription of Postexposure Prophylaxis for HIV-1 in the
Emergency Room: Correct Transmission Risk Assessment
Remains Challenging
Alex Marzel, MSc,*† Henriette Heinrich, MD,‡§ Lukas Schilliger, MSc,‡ Jan S. Fehr, MD,*
Huldrych F. Günthard, MD,*† Roger Kouyos, PhD,*† and Silvana K. Rampini, MD‡
Background: Limited data are available about the accuracy of
postexposure prophylaxis (PEP) prescription in the emergency
rooms. Here, we evaluated PEP prescription decision making with
respect to the risk of sexual HIV transmission and the exposed
person’s fear vis-à-vis HIV.
Methods: Using a risk assessment algorithm, we retrospectively
evaluated the adequacy of PEP prescription for all persons presenting at
the emergency room of the University Hospital Zurich after consensual
sex from 2007 to 2013. We used logistic regression to identify factors
that correlate with risk-concordant and risk-discordant decisions.
Results: We documented 975 persons with a total of 1051 visits for
PEP: 83% were men, 71% were Swiss, and 37% were men who have
sex with men. In 74% of visits, the decisions were concordant with
the risk evaluation algorithm (22% discordant, 4% unknown). In
61% (644/1051) PEP was prescribed; however, in 12% (76/644) the
prescriptions were without indication of HIV transmission risk and
were attributed to the exposed person’s request. Importantly, in 10%
(101/1051) of all visits, there were potential risks but PEP was not
prescribed, either because of physician’s decision or exposed
person’s refusal. The presence of the source partner strongly
correlated with appropriately withholding PEP (adjusted odds ratio
for giving PEP 0.05; 95% conﬁdence interval: 0.03 to 0.08).
Conclusions: We found that 22% of PEP decisions were risk
discordant because of exposed person’s request, incorrect estimation
of the sexual transmission risk by the physician, or exposed person’s
refusal to accept PEP. Emergency physicians may beneﬁt from
specialized risk assessment training and patients from education in
HIV transmission risk awareness.
Key Words: postexposure prophylaxis, sexual risk, emergency
room, decision making, HIV transmission, patient demand
(J Acquir Immune Deﬁc Syndr 2017;74:359–366)
INTRODUCTION
Preventing HIV transmission is a major public health
challenge.1 Combined antiretroviral therapy (cART) is a valu-
able tool in this effort, either as preexposure (PrEP)2 or
postexposure prophylaxis (PEP).3 PEP is highly effective in
nonhuman primates in reducing the risk of simian immuno-
deﬁciency virus transmission by 77%–95%.4 The main
factors determining its effectiveness are the lag time between
exposure and start of cART and its duration of intake.4,5 In
humans, PEP with Zidovudine alone reduced the risk of HIV
transmission by 80% after occupational exposure.6 In 1997,
the Swiss Federal Ofﬁce of Public Health (FOPH) recom-
mended PEP after an HIV sexual risk exposure.7
After the introduction of cART by end of the 1990s, it
was controversial whether PEP should be prescribed in non-
occupational (sexual) contacts.8–10 Today, according to the
European AIDS Clinical Society guideline11 and the FOPH
guideline updated in 2006,12 PEP is primarily recommended
for persons having unprotected sex (ie, anal, vaginal, or
receptive oral sex with ejaculation) with a viremic HIV-
positive partner or a partner with unknown serostatus but with
the presence of HIV risk factors [ie, men who have sex with
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men (MSM), sex workers, intravenous drug users (IDU), or
persons from a country with a high HIV prevalence]. PEP is
not recommended for persons having unprotected sex with an
HIV-infected partner on successful cART. In all other
situations with unprotected sex, individual risk should be
evaluated. The internal guidelines from the University Hospital
Zurich (USZ), relevant to the analyzed period, were largely
derived from the FOPH guideline but left a lot of room for
subjective risk evaluation by the physician, stating that:
PEP should be prescribed in the following
situations: unprotected vaginal, anal, or oral
receptive intercourse with an HIV-positive part-
ner or during menstruation. PEP should not be
prescribed in cases of unprotected intercourse
with a partner with unknown HIV status. In this
case, fears and needs of the exposed person
should be taken into account. Neither categorical
nonprescription nor uncritical prescription can
be encouraged.
Previous studies have already shown that the decision to
use PEP is inﬂuenced by the experience of the physician in
charge,10 the emergency room (ER) setting,8 and the exposed
person’s request.10 Notwithstanding, people taking PEP
frequently suffer from side effects that result in poor
adherence, and as a result, only 65%–78% ﬁnish the 4-week
PEP regimen.13,14 Thus, the physician in charge must weigh
the pros and cons of PEP carefully in each case.
Here we systematically assessed PEP decision making
and factors that inﬂuence PEP decision making in daily
practice in a large ER of a tertiary care hospital. Identifying
these factors would be a major step in optimizing decision
making. We retrospectively evaluated all persons seeking
advice on PEP at the ER of the USZ between 2007
and 2013. We then reviewed whether the decision making
was in agreement with a risk assessment algorithm for
PEP prescription. In particular, we collected data on the
demographic factors of the persons, the kind of sexual risk
taken, the experience of the ER physician, and eventually
the person’s request and correlated these data with the
evaluated decisions.
METHODS
Ethics
The study was approved by the Institutional Review
Board of the USZ (KEK-ZH-Nr. 2013-0006).
Study Design
We identiﬁed, in a retrospective and cross-sectional
manner, all persons admitted to the ER of the USZ seeking
advice for HIV PEP in 2007–2013 by screening all electronic
charts from that period for the following keywords: post-
exposure prophylaxis, PEP, risk, exposure, sexual inter-
course, and sex. Nonconsensual sex and occupational HIV
exposure were excluded from the analysis. This ER has
;17,000 general internal medicine consultations per year.
Demographic Data and Sexual History
We collected the following data from the identiﬁed
electronic charts for each exposed person: (1) demographic data,
(2) a detailed sexual history, including type of sexual intercourse
[ie, insertive, receptive, versatile (insertive and receptive), anal,
vaginal, oral, smear of body ﬂuids on healthy or wounded skin
or mucous membranes, hand/feet to genitals contact, condom
use, condom dysfunction], hours since exposure, or additional
risk factors for HIV transmission (ie, menstruation, ejaculation,
and sexually transmitted infections), and (3) the result from the
HIV screening test at presentation. Based on the retrospective
nature of the study, it was not possible to deﬁne oral sex with or
without sperm exchange; thus, we considered unprotected oral
sex as a risk situation. By default, every person seeking PEP at
the ER should be tested for HIV on the spot. This screening was
done with the fourth generation HIV antigen/antibody (Ag/Ab)
combo screening test (Abbot, Wiesbaden, Germany), and its
result should be available by 4 hours at the latest. Furthermore,
for each source partner, we collected the gender, the risk group
(ie, MSM, sex worker, from endemic country, IDU), last known
HIV status, and the result of the HIV screening test performed at
the ER if he presented together with the exposed person. If the
presenting source partner was already known to be HIV positive,
we extracted the last documented viral load value from his/her
electronic chart. If no viral load was available, we requested an
HIV-1 RNA viral load (HIV-1 Test, version 2.0; Roche,
Branchburg). Eventually, we collected data on whether PEP
was prescribed, the postgraduate education of the physician in
charge, and the rational for the decision.
Risk Assessment Algorithm for PEP
Decision Making
To assess the adequacy of PEP decision making, we
developed an epidemiology-based risk assessment algorithm
taking into account known risk factors for HIV transmission
(Fig. 1). A time lag of .72 hours between sexual exposure
and ER visit renders PEP inefﬁcient, and in these cases, PEP
was not indicated. Next, we ascertained the HIV status of the
source partner, either by a negative HIV test done within the
past 3 months or otherwise the result of an on-the-spot HIV
test. In the case of HIV infection but an HIV RNA copy
number ,50/mL within the last 3 months or at presentation,
we considered PEP as not indicated. The 3-month cutoff for
having an HIV RNA below the detection limit is based on the
3-month intervals we see the HIV patients in our outpatient
clinic, which is the standard of care. If the HIV status of the
source partner was unknown, we classiﬁed the incident as low
HIV transmission risk, and PEP was not indicated unless the
source partner belonged to a high-risk group (Fig. 1).
We used this algorithm to categorize the PEP decisions
as concordant (ie, “prescribed-and-indicated” or “not-pre-
scribed-and-not-indicated”) or discordant (“prescribed-while-
not-indicated” or “not-prescribed-while-indicated”).
Statistical Analyses
Bivariate P values for categorical variables were
calculated using x2 test and Fisher exact test, and for
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numerical variables, a Mann–Whitney U test was used. We
used logistic regression to estimate correlating factors with
prescribing or not prescribing PEP, stratiﬁed by concordant
and discordant decisions (2 models). Statistical analysis was
performed with R (version 3.2.3, http://cran.r-project.org).
RESULTS
Demographic Data of the Exposed Persons
Between 2007 and 2013, 975 persons visited the ER
1051 times to get PEP: 911/975 (93%) presented once and 64/
975 (6.5%) presented repeatedly with 1 person presenting 7
times and a median interval of 1.7 years [interquartile range
(IQR) 0.76–2.68] between the ﬁrst and the last visit. MSM
were overrepresented among those with more than one visit
[37/64 (57%) vs. 315/911 (35%), Fisher exact test P, 0.001].
The number of visits remained stable over time with a median
of 149 visits per year (IQR 133–162) (Fig. 2). The median age
at ﬁrst visit was 31 years (IQR 26–38). Out of all visits, 872/
1051 (83%) exposed were men, 746/1051 (71%) were Swiss,
61/1051 (5.8%) were German, 42/1051 (4%) were Italian, and
202/1051 (19.2%) were from various countries. In 393/1051
(37.4%) visits, sexual contact between men was documented.
A large proportion of all PEP visits (43%, 451/1051) were
on weekends (Table 1); 376/1051 (36%) visits were between
noon and 6:00 PM and only 181/1051 (17%) were between
midnight and 6:00 AM The median self-reported time lag
between sexual intercourse and the ER visit was 20 hours (IQR
10–42), with 165/981 (17%) presenting after 48 hours and 46/981
(4.7%) after 72 hours (for 70 visits time since exposure was
missing). MSM presented sooner after exposure than non-MSM
[median 16 hours (IQR 5–32) vs. 24 hours (IQR 12–48), Mann–
Whitney P , 0.0001] and also presented more on weekends
[47% (185/393) vs. 40% (266/658), Fisher exact test P = 0.04].
In 4/1051 (0.4%) visits, the exposed person turned out
to be HIV positive already at presentation.
Condom Use and Type of Sexual Intercourse
The exposed persons reported condomless sex in 527/1051
(50.1%) visits, condom breakage or slippage (condom dysfunc-
tion) in 433/1051 (41.2%) visits, and protected sex in 23/1051
(2.2%) visits. In 68/1051 (6.5%) visits, data were missing. MSM
had mainly anal sex with 320/393 (81%) incidents. The anal sex
was receptive in 120/320 (37%) visits, insertive in 84/320 (26%),
versatile in 15/320 (5%), and data were missing in 101/320
(32%) visits. Heterosexual men and women had mainly vaginal
intercourse with 387/448 (86%) and 153/176 (86%), respectively.
Demographic Data of the Source Partners
The source partner belonged to a group at high risk of
being HIV infected in 670/1051 (63.7%) visits. More
FIGURE 1. HIV transmission risk assessment
algorithm used for the revision of PEP pre-
scribed in the ER. All presentations after
unprotected sexual intercourse (ie, condom-
less sex or condom dysfunction) were retro-
spectively evaluated using this risk assessment
algorithm.
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speciﬁcally, 401/1051 (38%) were MSM, 256/1051 (24%)
were sex workers, 46/1051 (4.3%) were from an HIV endemic
region, and 11/1051 (1%) were IDU. The source partner
belonged to more than one risk group in 41/1051 (4%) visits.
In 20% (211/1051) of the visits, the source partner did
not belong to a risk group and has not presented, and his/her
HIV status was unknown. This represents the fraction of low-
risk presentations.
Source partners accompanied the exposed person in 170/
1051 (16%) of the visits. However, we observed a decline in
source partner presentation from 23% (27/114) in 2007 to
11.8% (15/129) in 2013 (P for trend = 0.042). Women were
twice as likely to present with the source partner than men
[27.9% (50/179) vs. 13.8% (120/872), Fisher exact test, P ,
0.001]. The source partner was HIV infected in 131/1051 (12%)
of the visits as self-reported or documented in his/her chart at
the USZ. Out of those, for 60 (60/131, 45%), we could retrieve
a viral load value, 23 were documented and within last 3 months
of presentation (others were either self-reported or more than 3
months old). In 65% (39/60), the viral load was suppressed
(,50 copies per milliliter), and for the rest, the median viral
load was 3500 (IQR 456–10,000) copies per milliliter.
We did not observe an increase in sexual intercourse
with HIV-infected source partners over time (P for trend 0.48).
Revision of the PEP Decision Making
PEP was prescribed in 644/1051 (61%) visits overall
(Table 1). The PEP decision making of the physician in
charge was in accord with the risk assessment algorithm in
779/1051 (74%) visits (ie, 485 prescribed-and-indicated and
294 not-prescribed-and-not-indicated) (Fig. 3). In 226/1051
(22%) visits, the decision making was discordant [ie, 125/226
(55%) prescribed-while-not-indicated and 101/226 (45%)
not-prescribed-while-indicated] (see Table 1, Supplemental
Digital Content, http://links.lww.com/QAI/A956).
The main reason for prescribing PEP when it was not
indicated was the person’s request in a low-risk situation in
76/125 (61%) visits. Although women made up only 78/644
(12%) of all prescribed PEPs, they were overrepresented with
27/76 (35%) in the category prescribed-while-not-indicated
because of their request (Fisher exact test P , 0.0001). The
remaining 49/125 (39%) PEPs prescribed in the category
prescribed-while-not-indicated were explained by an incorrect
interpretation of the sexual risk situation by physicians.
Notably, in 485/644 (75%) visits, PEP was prescribed
concordantly to the risk assessment algorithm.
Overall, there were 586 putative risk situations where
PEP was indicated [ie, 485 prescribed-and-indicated (concor-
dant) plus 101 not-prescribed-while-indicated (discordant)]
(Fig. 3). In these 101/586 (17%) risk situations, PEP was not
prescribed because of exposed person’s refusal (31/101, 31%),
the physicians not following the recommendation to give PEP
within the lag time of 72 hours between the sexual incident
and presentation (9/101, 9%), and the physician’s incorrect
interpretation of the sexual risk for HIV transmission (61/101,
60%). Notably, 20/61 (33%) sexual contacts were oral, and
oral sex has a lower HIV transmission risk than vaginal or anal
sex, especially if there is no exchange of sperm or blood. In 2/
20 (10%) oral sex incidents, the source partners were HIV
infected and one had 104 HIV RNA copies per milliliter in the
blood. Infectious disease (ID) specialists took the decisions in
10/20 (50%) of these oral sex–only incidents, which is
signiﬁcantly more often than their overall involvement in
decision making [179/1051 (17%), Fisher exact test P ,
0.001]. Notwithstanding, in 41/61 incidents, a high risk for
HIV transmission existed. Considering a total of 407 visits in
which no PEP was prescribed, these 41/407 (10%) missed
opportunities represent a considerable number in the context
of HIV prevention. Finally, visits in which contact with a sex
worker took place were signiﬁcantly overrepresented in this
category of not-prescribed-while-indicated (43.6%, 44/101 vs.
22.3%, 212/950, Fisher exact test P , 0.001).
We have not observed a change in the fraction of
discordant decisions with time (Fig. 2). In the remaining 46/
1051 (4%) visits, the data were too incomplete to categorize
the decision making. The main missing variables were sex of
the source partner (hence it was not clear if the exposed
person belonged to the MSM risk group), condom use, and
time since exposure or combination of those.
FIGURE 2. PEP visits to the ER of USZ
by year and according to the cate-
gories defined by the risk assessment
algorithm. The annual number of
visits is shown on the x axis. P for
trend 0.55. Forty-six visits with
unknown category were excluded
from the y axis for clarity.
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Factors Correlating With PEP
Decision Making
First, we used multivariable logistic regression to deﬁne
factors that correlate with concordant decisions. Repeated visits
to the ER for PEP [odds ratio (OR) 2.78; 95% conﬁdence
interval (CI): 1.54 to 5.03] and PEP decision making by ID
specialists (OR 1.85; 95% CI: 1.09 to 3.12) were associated
with concordant decisions on PEP prescription (ie, prescribed-
and-indicated) and attendance of the source partner (OR 0.05;
95% CI: 0.03 to 0.08) and female sex (OR 0.16; 95% CI: 0.10
to 0.27) with concordant decisions on nonprescription (ie, not-
prescribed-and-not-indicated) (Table 2).
TABLE 1. Demographic Data and Sexual History Divided by PEP Prescription Outcome
Overall Not-prescribed Prescribed P
N 1051 407 644
Age, median (IQR) 32.0 (26.0–38.0) 30.0 (26.0–37.0) 32.0 (27.0–38.0) 0.006
Sex, female, n (%) 179 (17.0) 101 (24.8) 78 (12.1) ,0.001
Swiss nationality, n (%) 746 (71.0) 278 (68.3) 468 (72.7) 0.147
MSM, n (%) 393 (37.4) 106 (26.0) 287 (44.6) ,0.001
.1 PEP visit, n (%) 140 (13.3) 38 (9.3) 102 (15.8) 0.003
Weekend, n (%) 451 (42.9) 175 (43.0) 276 (42.9) 1.000
Hours since exposure, median (IQR) 20.0 (10.0–42.0) 24.0 (10.0–49.0) 18.0 (10.0–38.0) ,0.001
Day time, n (%) 0.009
Midnight–06:00 AM 181 (17.2) 74 (18.2) 107 (16.6)
06:00 AM–noon 182 (17.3) 51 (12.5) 131 (20.3)
Noon–06:00 PM 376 (35.8) 148 (36.4) 228 (35.4)
06:00 PM–midnight 312 (29.7) 134 (32.9) 178 (27.6)
Year, n (%) 0.317
2007 114 (10.8) 48 (11.8) 66 (10.2)
2008 137 (13.0) 50 (12.3) 87 (13.5)
2009 168 (16.0) 72 (17.7) 96 (14.9)
2010 156 (14.8) 57 (14.0) 99 (15.4)
2011 198 (18.8) 64 (15.7) 134 (20.8)
2012 149 (14.2) 64 (15.7) 85 (13.2)
2013 129 (12.3) 52 (12.8) 77 (12.0)
Condom, n (%) 0.001
Condom dysfunction 433 (41.2) 170 (41.8) 263 (40.8)
Condomless sex 527 (50.1) 192 (47.2) 335 (52.0)
With condom 23 (2.2) 18 (4.4) 5 (0.8)
Unknown 68 (6.5) 27 (6.6) 41 (6.4)
Type of intercourse, n (%)
Anal 359 (34.2) 84 (20.6) 275 (42.7) ,0.001
Vaginal 543 (51.7) 244 (60.0) 299 (46.4) ,0.001
Oral 157 (14.9) 73 (17.9) 84 (13.0) 0.038
Only oral 94 (8.9) 52 (12.8) 42 (6.5) 0.001
Source partner risk group, n (%)
MSM 401 (38.2) 107 (26.3) 294 (45.7) ,0.001
Sex worker* 256 (24.4) 74 (18.2) 182 (28.3) ,0.001
Endemic country 46 (4.4) 13 (3.2) 33 (5.1) 0.182
Intravenous drug user (IDU) 11 (1.0) 2 (0.5) 9 (1.4) 0.274
HIV status of the source partner, n (%) ,0.001
Negative 175 (16.7) 140 (34.4) 35 (5.4)
Positive 131 (12.5) 16 (3.9) 115 (17.9)
Unknown 745 (70.9) 251 (61.7) 494 (76.7)
Source partner presented the same day, n (%) 170 (16.2) 138 (33.9) 32 (5.0) ,0.001
Deciding physician, n (%) 0.062
Resident in internal medicine 849 (80.8) 343 (84.3) 506 (78.6)
ID specialist 179 (17.0) 58 (14.3) 121 (18.8)
Internal medicine specialist 23 (2.2) 6 (1.5) 17 (2.6)
*Sex work in Switzerland is legal and regulated.
†P values for categorical variables were calculated using x2 test; for age and hours since exposure, a Mann–Whitney U test was used.
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In a second model, we used multivariable analysis to
describe factors that might lead to discordant decisions.
Female sex (OR 11.38; 95% CI: 4.10 to 31.6) and visits to
the ER between 06:00 AM and noon (OR 2.92; 95% CI: 1.01
to 8.42) were associated with discordant decisions (ie,
prescribed-while-not-indicated). Decision making by ID
specialists as opposed to residents in internal medicine was
associated with the decision category not-prescribed-while-
indicated (OR 0. 38; 95% CI: 0.18 to 0. 81). This association
became nonsigniﬁcant when the oral sex–only visits were
excluded (OR 0.47; 95% CI: 0.20 to 1.07).
DISCUSSION
Accurately estimating the risk of HIV transmission
after consensual sex and determining the necessity of PEP
prescription are challenges for the ER physicians.8 Here we
retrospectively examined the accuracy of PEP prescriptions
using a feasible risk assessment algorithm based on epide-
miological HIV transmission risk and identiﬁed factors that
correlate with risk-concordant decision making. Our main
ﬁndings were that (1) the ER physician estimated the sexual
risk for HIV transmission correctly in most visits (74%);
however, in 10% of visits, PEP was not prescribed despite
a risk situation. Furthermore, 12% of all PEP prescriptions
were based on the exposed person’s request rather than an
appropriate indication. (2) Repeated visits and ID expert
opinion were factors associated with correct prescription of
PEPs, whereas consultation in the morning and female sex
were associated with equivocal PEP prescriptions. (3) The
presence of the source partner resulted in correctly
withholding PEP.
Our risk assessment algorithm is in-line with the latest
EACS and FOPH guidelines and was used to retrospectively
deﬁne HIV transmission risk and prescription indications.
The internal USZ guidelines, relevant to the analyzed period,
did not specify the risk groups, hence giving leeway to the
clinician in charge and requesting a detailed knowledge about
HIV transmission risk. In addition, it was stated that the
subjective fears and concerns of the exposed person should be
taken into account, meaning that some PEPs were prescribed
on demand in low-risk situations. Here, our aim was to
estimate the objective risk of HIV transmission in each
situation and to deﬁne factors correlating with correct and
incorrect PEP prescriptions, not to describe the rate of
adherence to internal guidelines.
We found that 12% of all PEPs were prescribed based
on exposed person’s request (prescribed-while-not-indicated).
This might be because of inadequate counseling by the ER
physician, limited knowledge of HIV transmission risk
among them, or exposed person’s demand because of fear
of contracting HIV. Notably, patient request and uncertainty
by the physicians affect drug prescription habits.15,16 More
women fell into this category; it can be hypothesized that
women may be more concerned about HIV or simply look for
maximum protection.17 In addition, the gender of the
physician in charge may inﬂuence the decision making, an
issue not examined here.18–21
In 17% of the sexual incidents with a given risk for HIV
transmission, PEP was not prescribed (not-prescribed-while-
indicated). This was because of exposed person’s refusal (n =
31) and physician’s decision (n = 70). We speculate that
balancing the actual risk of acquiring HIV against the potential
side effects of PEP led to its refusal.13,14 A word of caution
must be added about the rather high number of physician
decisions against PEP prescription: oral intercourse is a low-
risk situation with an estimated HIV transmission rate of ,4/
10,000 incidents as opposed to insertive anal intercourse with
11/10,000.22–24 We did not include such subtle distinctions in
our risk assessment algorithm as ER physicians were not
speciﬁcally trained to integrate the detailed sexual history into
the assessment of the HIV transmission risk. In addition,
FIGURE 3. Flowchart of the study
and the categories of PEP decisions.
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sexual history may be unreliable, and the notes in the charts
are sometimes rudimentary, thus rendering them not useful for
retrospective risk assessment. Finally, the local recommenda-
tions did not differentiate between sexual risks taken. That is
why the ER physicians and, in particular, ID specialists might
have advised against PEP after taking into account a low-risk
situation (oral sex only), and this may explain the relatively
high number of discordant decisions.
The presence of the source partner in the ER signif-
icantly improved the odds of concordant decision making.
The immediate HIV testing of both sexual partners certainly
deﬁnes the transmission risk in a best way. Importantly,
current HIV tests are very sensitive and detect antigen and
antibodies,25 making it unlikely that an acute HIV infection is
missed. Thus, persons seeking advice for PEP should be
encouraged to present with their source partner22 when
receiving information about PEP.
Remarkably, the number of visits to our ER for PEP
remained stable over the observation period. This can be
explained by the interplay of the following factors. On the one
hand, more risk behavior as the result of “the Swiss
Statement” in 2008 that “HIV-positive persons on ART with
undetectable viral loads and no other sexually transmitted
infections may engage in condomless sex while in a stable
relationship”.26–28 On the other hand, concern of an HIV
infection may be less, leading to a smaller probability of
demanding PEP when risk behavior occurred. This is backed
up by recent studies showing an increase in unprotected sex in
HIV-infected heterosexuals and MSM in both occasional and
stable partnerships.29 Alternatively, persons who engage in
high-risk sexual activities and do not present to the ER may
be ignorant about PEP and its beneﬁt for reducing HIV
transmission.30 Indeed, knowledge of PEP was unexpectedly
low (48.7%) even among HIV-infected individuals overall in
the United Kingdom.31 In Switzerland, even the long-lasting
public health campaigns directed to HIV transmission pre-
vention do not promote PEP. However, prescriptions doubled
in a local gay health community center (www.mycheckpoint.
TABLE 2. Factors Correlating With PEP Decision Making
Dependent Variable: PEP Prescribed (Yes/No)
Risk-Concordant Decisions Risk-Discordant Decisions
Univariable, OR
(95% CI)
Multivariable, OR
(95% CI)
Univariable, OR
(95% CI)
Multivariable, OR
(95% CI)
Sex
Men (ref) 1 1
Women 0.14 (0.09 to 0.22)* 0.16 (0.10 to 0.27)* 11.18 (4.24 to 29.48)* 11.38 (4.10 to 31.59)*
Age 1.03 (1.01 to 1.05)* 1.02 (0.99 to 1.04) 0.97 (0.94 to 1.01) 0.98 (0.94 to 1.01)
Nationality
Non-Swiss (ref) 1 1
Swiss 1.30 (0.95 to 1.78) 1.01 (0.68 to 1.51) 1.04 (0.57 to 1.92) 1.65 (0.80 to 3.41)
More than one visit
No (ref) 1 1
Yes 2.42 (1.50 to 3.91)* 2.78 (1.54 to 5.03)* 0.72 (0.30 to 1.70) 0.68 (0.26 to 1.83)
Postgraduate education of the
physician in charge
Internal medicine resident (ref) 1 1
ID specialist 2.28 (1.46 to 3.56)* 1.85 (1.09 to 3.12)† 0.48 (0.25 to 0.92)† 0.38 (0.18 to 0.81)†
Internal medicine specialist 4.17 (0.93 to 18.81) 3.32 (0.64 to 17.12) 0.22 (0.02 to 2.20) 0.27 (0.02 to 2.83)
Source presented with the exposed
No (ref) 1 1
Yes 0.05 (0.03 to 0.09)* 0.05 (0.03 to 0.08)* 2.34 (0.72 to 7.58) 3.61 (0.92 to 14.12)
Presentation during weekend
No (ref) 1 1
Yes 0.96 (0.71 to 1.28) 1.23 (0.85 to 1.78) 1.13 (0.65 to 1.94) 1.02 (0.55 to 1.92)
Time of presentation
Midnight–06:00 AM (ref) 1 1
06:00 AM–noon 1.73 (1.04 to 2.90)† 1.65 (0.88 to 3.12) 1.76 (0.71 to 4.36) 2.92 (1.01 to 8.42)†
Noon–06:00 PM 0.98 (0.64 to 1.50) 0.94 (0.55 to 1.60) 1.33 (0.61 to 2.90) 1.77 (0.70 to 4.46)
06:00 PM–midnight 0.78 (0.51 to 1.21) 0.78 (0.45 to 1.35) 1.25 (0.56 to 2.78) 1.44 (0.56 to 3.68)
Year 1.03 (0.95 to 1.11) 0.93 (0.84 to 1.03) 0.92 (0.79 to 1.06) 0.94 (0.79 to 1.11)
Multivariable analysis using logistic regression of factors associated with prescription of PEP or not (binary dependent variable). Two separate models are shown, within the risk-
concordant decisions (left) and within the risk-discordant decisions (right). Note that risk behavior was not included as a predictor because it is a major component of the outcome (used
to classify decisions as justiﬁed or not).
*P , 0.01. All shown variables were included in the multivariable model.
†P , 0.05.
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ch/en/zh, Bruggmann P, MD, written personal communica-
tion 06.01.2016) in the corresponding period. For some
fraction of these, the prescribed PEP might have been
obtained because of a claimed but nonexistent risk situation
with the intention, on the recipient’s side, to use it as PrEP.
We found that only 6.5% of all persons repetitively
showed up at the ER for PEP. This number is substantially
lower than the 20% reported in previous studies32–35 and,
thus, suggests that PEP is unlikely to promote higher sexual
risk behavior, which is consistent with a report by Martin
et al.36 However, persons with high-risk sexual behavior,
presenting repetitively for PEP, most likely would be the ideal
candidates for HIV PrEP.
In summary, PEP decision making was adequate in the
majority of visits; however, in every ﬁfth visit, it was wrong.
To beneﬁt most from PEP, we see the need for further
improvement in PEP decision making and counseling. Thus,
ER physicians may beneﬁt from a specialized risk assessment
training that might incorporate the use of risk assessment
algorithms. On the exposed person’s side, future public health
campaigns could increase PEP awareness alongside with
knowledge about the risk situations that justify presentation.
A special emphasis can be made on the beneﬁts of pre-
sentation together with the source partner.
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CHAPTER III 
 
“Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships” 
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phylogenetic trees, and analyzed the data using various statistical tools, plots, and methods. AM 
wrote the R package with contribution of TT. AM and RDK wrote the first manuscript draft 
and the final version.  
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Research in context 
In this work, we propose and validate an interdisciplinary computational data mining 
approach for the detection of steady transmission and serosorting HIV infected couples using 
shared clinic visit dates. The ability to characterize these pairs is a long-lasting methodological 
challenge, which if solved, will assist targeted prevention of HIV transmission and 
identification of scarce pairs for biological research, when a biobank is available. This can help 
to address pertinent research questions on within-pair quasi-species exchange, transmitted drug 
resistance and viral recombination on the biological level and targeted prevention on the public 
health level. Moreover, the proposed method can serve as an additional confirmation criterion 
for increasingly used phylogenetically linked transmission pairs.  
Currently, the stable transmission and serosorting pairs that can be detected with our 
method are in very high demand both for biological and epidemiological research. Moreover, 
in addition to research questions that are centered around HIV biology and epidemiology, the 
detected pairs can shed light on within pair transmission of other common STIs (i.e. syphilis). 
Importantly, our method has a potential for broader application by users, beyond the HIV field. 
It is applicable to any type of observational epidemiological data containing visit dates.  Almost 
all epidemiological studies ignore the social network underlying their study population and 
must therefore, by necessity, assume that this population is composed of independent 
individuals. Our method allows to recover some of the strongest links in these networks, which 
will enable to study key questions that cannot be addressed in the classical “independent 
individuals” paradigm (e.g. infectious diseases transmission, risk clustering, etc.).   
We implemented the proposed method demonstrating its usefulness and applicability 
using the Swiss HIV Cohort Study as a showcase. Implementing the proposed concept allowed 
us to gain new insights about an epidemiologically relevant subpopulation of steady HIV 
positive transmission and serosorting couples of mixed ethnicity with large within-pair age gaps 
(and the man being older and white). These pairs were validated by three independent criteria: 
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an extensive phylogenetic tree, self-reported steady HIV positive partnership, and HIV risk 
group affiliation. 
With 39 cohorts of HIV infected individuals, from Europe alone, and large US cohorts 
(i.e. MACS) alongside with large consortiums (i.e. IeDEA), we speculate that this simple 
method might have application opportunities beyond the Swiss HIV Cohort Study. 
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Mining for pairs: shared clinic visit dates identify steady
HIV-positive partnerships
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Objectives
Here we examined the hypothesis that some stable HIV-infected partnerships can be found in
cohort studies, as the patients frequently attend the clinic visits together.
Methods
Using mathematical approximations and shuffling to derive the probabilities of sharing a given
number of visits by chance, we identified and validated couples that may represent either
transmission pairs or serosorting couples in a stable relationship.
Results
We analysed 434 432 visits for 16 139 Swiss HIV Cohort Study patients from 1990 to 2014. For
89 pairs, the number of shared visits exceeded the number expected. Of these, 33 transmission
pairs were confirmed on the basis of three criteria: an extensive phylogenetic tree, a self-reported
steady HIV-positive partnership, and risk group affiliation. Notably, 12 of the validated
transmission pairs (36%; 12 of 33) were of a mixed ethnicity with a large median age gap
[17.5 years; interquartile range (IQR) 11.8!22 years] and these patients harboured HIV-1 of
predominantly non-B subtypes, suggesting imported infections.
Conclusions
In the context of the surge in research interest in HIV transmission pairs, this simple method
widens the horizons of research on within-pair quasi-species exchange, transmitted drug resistance
and viral recombination at the biological level and targeted prevention at the public health level.
Keywords: cohort studies, data mining, epidemiology, HIV, phylogeny, transmission
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Introduction
Identifying and characterizing steady - as opposed to
occasional - HIV transmission pairs is a key challenge in
HIV epidemiology and prevention, especially in light of
data that suggest that steady partners are an increasing
source of HIV infection with increasing age among men
who have sex with men (MSM) [1,2].
In this work, we proposed and validated a new
approach for identifying steady HIV transmission pairs
and steady serosorting couples, that is, HIV-positive indi-
viduals who are not infected by the same viral variant
but prefer other HIV-positive individuals as sexual part-
ners. We examine the simple hypothesis that some steady
Correspondence: Professor Roger Kouyos, Division of Infectious Diseases
and Hospital Epidemiology, University Hospital Zurich, University of
Zurich, R€amistrasse 100, CH-8091 Z€urich, Switzerland. Tel: +41 44 255
36 10; fax: +41 44 255 32 91; e-mail: roger.kouyos@uzh.ch
*See Appendix.
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partners can be identified in longitudinal cohorts, because
they attend the follow-up and the laboratory visits
together. This is likely to be reflected in the number of
shared follow-up visits, with a frequency that is unlikely
to be attributed to chance.
Identifying and characterizing HIV-positive steady
transmission pairs has the potential to shed light on their
demographic and epidemiological features, which are not
likely to change after they become seroconcordant.
Knowing these characteristics can facilitate targeted pre-
vention of HIV transmission. Moreover, identification of
steady HIV-positive pairs that engage in unprotected sex,
given a still high prevalence of late treatment initiation
and treatment interruptions [3,4], can widen the horizons
of research on within-pair quasi-species exchange, trans-
mitted drug resistance and viral recombination [5]. In
addition to transmission pairs, the proposed method can
identify steady serosorting couples. Detailed longitudinal
data on these pairs are very scarce.
We used the Swiss HIV Cohort Study (SHCS) as a
showcase for the applicability of our method as the SHCS
is renowned for its breadth and depth of demographic
and molecular data as well as for its high coverage of the
HIV-positive population in Switzerland [6]. However,
with 39 cohorts of HIV-infected individuals from Europe
alone [7], and large ongoing US cohorts [8], this method
is expected to have ample application opportunities.
Implementing the proposed concept allowed us to iden-
tify an epidemiologically relevant subpopulation of steady
HIV-positive transmission pairs and serosorting couples of
mixed ethnicity with large age gaps. Importantly, at the
meta-level, our study demonstrates how a detailed,
prospective, and de-identified data set can be used - if pub-
licly available and in the wrong hands - to obtain sensitive
information at the level of individual patients.
Methods
Study population: the Swiss HIV Cohort Study and
the drug resistance database (SHCS-DRDB)
The SHCS is a large, prospective, multicentred, interdisci-
plinary study established in 1988. It is highly representa-
tive of the HIV epidemic in Switzerland, with an estimated
coverage of at least 45% of all HIV-infected individuals,
69% of all AIDS patients in Switzerland and 72% of all
individuals treated with antiretroviral therapy (ART) [6,9].
During the bi-annual follow-up visits, clinical and
demographical data are collected for each participant
using the study questionnaire, which includes a question
about being in a steady partnership with another
HIV-positive individual (without asking about the identity
of the partner). In addition, the standard of care requires
monitoring of viral load (since 1996) and CD4 count,
every 3 months. In practice, every second visit is a com-
bined cohort follow-up and laboratory monitoring visit;
thus, on average, a patient is expected to have a total of
at least four visits per year. Ideally, the visit dates are
chosen by the patients without restrictions. The drug
resistance database contains HIV-1 polymerase (pol) se-
quences for ~60% of all patients ever included in the
cohort and ~85% of patients enrolled after 1996 [10]. The
cohort database is de-identified.
Identification of steady transmission pairs and
serosorting couples using shared follow-up visits
Our method is based on the simple intuition that pairs of
patients who share a larger number of visits than expected
by chance are more likely to represent pairs who coordi-
nate their visits to the clinics, which might reflect being
either steady transmission pairs or serosorting couples. In
its simplest version, this algorithm would use the number
of shared visit dates within a couple as the test statistic.
The threshold number of shared visits that can be expected
by chance is determined by randomly shuffling cohort vis-
its across individuals and counting the number of random
visit collisions (a further explanation is given below). Pairs
exceeding that threshold are flagged as candidate pairs for
further evaluation and validation.
Below, we present a slight addition to this algorithm
which also adjusts for the length of follow-up.
Briefly, for each patient who consistently visited only
one of the seven SHCS study centres, all the shared visits
with the other eligible patients from the same centre were
extracted. To remove a potential bias stemming from a
nonrandom choice of visit dates as a consequence of a
wish to consistently visit a certain physician, we counted
for each physician the median interval between the dates
he/she sees patients. Visits of physicians who saw
patients infrequently were excluded if a median time
interval between the dates on which they saw SHCS
patients exceeded 7 days. As these physicians have a
large time span between visits, several patients might
choose the days these physicians work and share large
numbers of visits without actually being a pair.
Adjustment for the total number of visits per pair by
a penalty term
The chances of two unrelated cohort members sharing a
visit increase with the overall number of visits of each
member of the pair. To account for this, we adjusted the
number of shared visits per pair using the following
© 2017 British HIV Association HIV Medicine (2017)
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intuition: visits occur typically each quarter and a quarter
has approximately 75 eligible days for visits. If we make
the simplifying assumption that all visits for an individ-
ual with the lower number of visits within a pair fall
within quarters where the other individual also has a visit
and that the visits are distributed uniformly and indepen-
dently across the 75 eligible dates of each quarter (this
parameter should be tailored to each cohort; see Support-
ing Information S1 for sensitivity analysis with a 30-day
window), then the probability of obtaining S shared visit
dates per randomly chosen pair can be approximated as:
psharedðS;Ta;TbÞ¼ minðTa;TbÞS
! "
1
75
! "S
1! 1
75
! "minðTa;TbÞ!S
;
(1)
where Ta and Tb are the total number of visits made by
patients a and b, respectively, and S is the number of shared
visits. pshared can now be used to identify pairs of patients
whose number of shared visits is very unlikely to occur by
chance (by determining a threshold and considering all
pairs with pshared below this threshold as potential transmis-
sion or serosorting pairs; see the Bonferroni-corrected
method below) and takes into account the effect of unequal
visit numbers on the probability of sharing visits. As our
main concern is false positives (artificially low pshared) and
the last factor is expected to be large, we assume that:
~psharedðS; Ta; TbÞ ¼ minðTa; TbÞS
! "
1
75
! "S
: (2)
Finally, we consider instead of ~pshared the equivalent
quantity S0 (Eqn. 3). Equivalence here means that select-
ing potential stable transmission and serosorting pairs as
those whose ~pshared is lower than a threshold ~pthr yields
the same pairs as selecting those pairs whose S0 is above
a threshold S0thr , where S
0
thr ¼ !logð~pthrÞ= logð75Þ:
S0 ¼ ! logð~psharedÞ
logð75Þ ¼ S !
log
minðTa; TbÞ
S
! "# $
logð75Þ (3)
S0 can be interpreted as an effective (adjusted) number
of shared visits penalized by the term:
log
minðTa; TbÞ
S
! "# $
logð75Þ (4)
This accounts for the varying background probability
of shared visits as reflected in the varying length of fol-
low-up. Note that min(Ta,Tb) ensures a differential pen-
alty such that if S = min(Ta,Tb) the penalty is zero and
the larger the min(Ta,Tb) ! S the larger the penalty,
reflecting the intuition that if all the visits of one member
of the pair are shared with the other [hence S = min(Ta,
Tb)], then there is a higher probability that such a pair is
related (and hence should not be penalized).
Determining the threshold for the number of shared
visits using shuffling
As a consequence of the multiple comparisons problem
(3 029 261 pairs were analysed) and strongly simplifying
assumptions about the uniform distribution of visits, the
above expressions cannot be used to directly derive threshold
values for the effective number of shared visits S0. Hence, we
used the following shuffling strategy to derive the null distri-
bution. For each of the seven study centres, the visits were
shuffled within each quarter (such that the original distribu-
tion of the number of visits per individual was preserved) and
the number of randomly collided shared visits per pair was
counted and penalized using Eqn. 3. In other words, the
observed visit dates from a given quarter were randomly
reassigned between the patients who attended during this
quarter (see Supporting Information S1 for shuffling within a
30-day window). The shuffling procedure was replicated 100
times and allowed us to estimate the background number of
shared visits that are expected to occur by chance for each
centre (Fig. 1). From these shuffled data sets, we estimated
the fraction of pairs that were expected to be falsely identi-
fied in our data set as transmission/serosorting pairs for a
given threshold S0thr , denoted FFP(S
0
thr ), as the maximum
number of pairs with (S0shuffled % S0thr)/(S0unshuffled % S0thr). We
then chose the lowest threshold S0thr such that the fraction
FFP(S0thr ) is < 1% for further analysis.
Alternative method: determining the threshold for the
number of shared visits using Bonferroni correction
An alternative and less computationally demanding
approach for the detection of possible steady pairs would
be calculating the probability of sharing a given number of
visits (pshared) using Equation 1, and then determining the
selection cut-off using Bonferroni correction [11] for mul-
tiple comparisons [Type I error alpha (0.01)]/[number of
pairs that shared at least one visit (3 029 261)]. Pairs with
pshared below the threshold were flagged for further evalua-
tion. We implemented both approaches (shuffling and Bon-
ferroni correction) and compared their performances.
Phylogenetic tree and genetic distances
We used phylogenetic linkage as a key criterion for the val-
idation of the putative steady transmission pairs that were
detected using this method. A total of 19 893 partial HIV-1
pol sequences from 10 970 SHCS cohort participants (years
1989–2015) were pooled with 116 408 background, non-
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Swiss HIV-1 pol sequences from the Los Alamos database
for a large phylogenetic tree constructed using FASTTREE
[12]. See Supporting Information S1 for technical details.
Ethics
Ethical approval of the SHCS and written informed con-
sent from all participants were obtained.
Statistical analysis
Statistical analysis was performed using R (v 3.2.3)
[13,14] with some functions written in C++ to improve
performance [15].
R package
An R package named svisits was constructed to facilitate
easy application (available at https://github.com/alex
marzel/svisits). A short vignette that demonstrates the pack-
age application can be found in Supporting Information S2.
A data set with visit dates that were simulated (to protect
our patients’ privacy; see Discussion) using the empirical
distributions in the SHCS is embedded in the package.
Results
Data description
We analysed data for 16 139 SHCS patients, accounting
for a total of 434 432 visits from 1990 to 2014. A total
of 3 029 261 pairs of patients who attended the same
clinic on the same day at least once were identified
across all seven centres. For those pairs, the number of
unadjusted shared visits per pair ranged between 1 and
72, with a median of 1 (IQR: 1–2). This indicates that
sharing more than one visit with another patient was
rare. Following the shuffling and the correction penalty,
Fig. 1 Shuffling simulations for the determination of the background probability of sharing a follow-up visit in seven Swiss HIV Cohort Study
(SHCS) centres (labelled a–g). Each simulation is depicted by a blue line; the thresholds (S 0thr) used are shown on the x-axis and the minimal
false positive fraction on the y-axis. The 1% theoretical false positive threshold is depicted by the horizontal red dashed line. The lowest
threshold that is below the 1% cut-off for each centre is indicated by an arrow.
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the 1% false-positive thresholds for each centre ranged
from 5 to 6 effective shared visits per pair (Fig. 1),
depending on the centre.
Method validation
In line with our assumption, the number of eligible days
for a visit did not change substantially during the follow-
up time, with a median of 62 (IQR: 55–65) days per quar-
ter. In 192 out of 3 029 261 pairs, the number of
adjusted shared visits exceeded the established thresholds
S0thr; these pairs were selected for further evaluation. Two
pairs comprised of heterosexual women were excluded as
implausible transmission pairs. The remaining pairs were
validated as potential transmission pairs using three crite-
ria: (i) monophyletic clustering on the extensive (136 301
tips) phylogenetic tree and a maximal genetic distance of
2.5% between sequences; (ii) a self-report of having an
HIV-positive steady partner by both members of the pair
during the period between the first and the last shared
visits with the other member (question introduced in the
SHCS questionnaire in the year 2000); (iii) belonging to
the same HIV transmission risk group (MSM, heterosexual
or injecting drug use).
Of the identified pairs, 89 had available data for all
three validation criteria. Of these, 50 clustered on the
phylogeny and were below the genetic distance cut-off.
Thirty-three pairs (33 of 89; 37%) were confirmed using
all three criteria (Fig. 2). The median pairwise genetic dis-
tance of the viruses from these 33 pairs was low, 0.5%
(IQR: 0.15–0.98%), supporting the conclusion that these
were HIV transmission pairs [16,17]. Additionally, the
Shimodaira!Hasegawa local node support values for
the most recent common ancestor (MRCA) node between
the two pair members were also high, with a median of
97% (IQR: 92–99%), suggesting a high phylogenetic cer-
tainty of the monophyletic clusters.
Eight pairs were not linked by the phylogeny but were
risk group concordant and declared having an HIV-positive
steady partner. These pairs, who did not share a genetically
similar clone of the virus (median genetic distance 8.5%;
IQR: 3.5–10%) but had many shared visits (median 13; IQR:
8–23; adjusted), might represent not transmission but
steady serosorting couples (Fig. 2); however, these pairs
require stricter validation (Supporting Information S1).
Fourteen of 89 (15.7%) pairs were discrepant by all three
criteria and can be attributed to a residual nonrandom clus-
tering of visit dates which was not efficiently accounted for
by shuffling as a consequence of latent nonrandom visiting
patterns.
Importantly, the 33 pairs validated by all three criteria
had a significantly higher median number of effective
shared visits in comparison to pairs that were not vali-
dated by any of the criteria; 16 versus 6, respectively
(Wilcoxon P < 0.0001; P for trend = 0.044), which sup-
ports our basic concept that a high number of effective
shared visits is indicative of a putative transmission pair
(Fig. 3, top). Moreover, we also noticed that the pairs that
were validated by all criteria had a significantly lower
median number of total visits per pair (Ta + Tb) than
unvalidated pairs (64 versus 153, respectively; Wilcoxon
P < 0.0001; P for trend = 0.047; Fig. 3, bottom). This
indicates that the latter pairs were probably false positive
because of the overall very high number of visits per
pair, despite the adjustment for the total follow-up time
per pair (which is effective but not perfect).
Finally, we explored whether there was a negative
association between the effective (penalized) and unad-
justed number of shared visits and the minimal genetic
distance within each pair, among the 89 pairs eligible for
validation. For the adjusted visits, the Spearman’s rho
was !0.35 (P < 0.0001), while the association for unad-
justed visits was weaker and nonsignificant, !0.17
Fig. 2 Flow chart and Venn diagram (bottom) demonstrating the
validation of 75 putative pairs detected using shared cohort follow-
up visit dates. Red numbers indicate putative transmission (n = 33)
and serosorting (n = 8) pairs.
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(P = 0.11), further supporting both our basic assumption
concerning the correlation between the number of shared
visits and being a possible transmission pair (i.e. more
shared visits, the closer are the viruses) and the necessity
of penalizing the total follow-up time per pair.
As an alternative, faster set-up, applying the Bonfer-
roni-corrected threshold provided qualitatively equivalent
results with a total yield of 271 candidate pairs (Fig. 4).
The overlap between the two approaches was high: 192
pairs. Validation analysis revealed the same 33 transmis-
sion pairs (validated by all three criteria) as found using
the shuffling, plus three additional pairs - adding face
validity to our study - as well as the same eight serosort-
ing pairs plus one. However, this approach had a slightly
higher false-positive rate; of the 132 of 271 pairs that
had available data for validation, 23% (31 of 132) were
not validated by any of the three criteria as compared
with 16% false positives using the shuffling (not signifi-
cant; P = 0.16) Chi-squared test.
Characterization of steady transmission pairs
Following the detection and the validation of the 33
potential steady transmission pairs, we went on to char-
acterize their main features. Twenty-six pairs (79%; 26 of
33) were heterosexual and seven pairs were MSM.
In 15 pairs both members were of white ethnicity, five
pairs were concordantly of black ethnicity and one pair
was concordantly Asian. Twelve pairs (36%; 12 of 33)
were of mixed ethnicity; ten were white!Asian (eight
were heterosexual, with the man always being white, and
two were MSM pairs). The two remaining inter-ethnic
pairs consisted of a white man and a Latino woman. Pair-
wise comparisons showed that white!Asian pairs had a
significantly higher mean age gap in comparison to
white!white and black!black pairs [19 years versus
6.7 years (P = 0.002) and 5.6 years (P = 0.025), respec-
tively; Tukey and Kramer (Nemenyi) test [18]; Fig. 5].
Among the ten white!Asian couples, eight had virus
of subtype CRF01_AE, one virus of subtype 02_AG, and
one virus of subtype B, while among the white!white
pairs, the majority (73%; 11 of 15) had virus of subtype
B (Fisher’s exact test; P = 0.002).
Next, we examined whether these steady pairs used
condoms during the period between the first and last
shared visits. We found that 27 of 33 (82%) reported
condomless sex with a steady partner during the
assumed steady partnership period. Notably, seven births
were recorded by seven different women. In six of these
seven cases, the man declared that he had fathered a
child during the corresponding periods, which further
adds to the validity of our definition of the pairs as
steady, as it is well documented in sociological research
that childbearing decreases the probability of union dis-
solution [19].
Discussion
We have presented an epidemiological data mining
approach to identify putative transmission pairs or
serosorting couples based on shared visit dates in obser-
vational cohorts. There has been a growing use of HIV
Fig. 3 Relationship between the number of validation criteria that were met by the putative steady partnerships (x-axis) and the effective
number of shared visits per pair (y-axis, top), as well as the joint number of visits made by both pair members (y-axis, bottom).
© 2017 British HIV Association HIV Medicine (2017)
6 A Marzel et al.
64
resistance test sequences for epidemiological linkage of
transmission pairs, which has led to important insights
into key questions in HIV epidemiology [3,17,20–22].
However, it is also clear that phylogenetic linkage alone
cannot prove transmission [23–25]. This is mainly
because the validity of the phylogenetic clustering is
highly dependent on the sampling density of the target
population [24]. Our approach has the advantage of
detecting putative transmission pairs first based on an
aberrant number of shared visits, then validating them
Fig. 4 Probabilities of the observed number of shared visits for each pair with at least one shared visit, as determined by Equation 1, stratified
by Swiss HIV Cohort Study (SHCS) centre (labelled a–g; x-axis); values are –log10 transformed. The horizontal red line shows the Bonferroni-
corrected alpha (3.301135e-09); pairs below this threshold (i.e. above the line) were chosen for further evaluation as possible steady transmis-
sion pairs or serosorting couples. Green circles designate the pairs flagged by the shuffling method.
Fig. 5 Beanplot showing the within-pair age differences (in years) between the five observed combinations of ethnicity of the 33 validated
steady transmission pairs. The dashed green line shows the pooled median of the entire sample.
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using phylogeny or other available criteria, hence without
putting the entire weight of evidence on the phylogeny.
As is often the case in data mining, the main useful-
ness of our method lies not in its predictive accuracy, but
in its ability to narrow the screened population from mil-
lions of possible combinations to several dozen candidate
pairs that are to be assessed in depth and validated, as
screening and validation of all the possible combinations
are otherwise impractical. Hence, the method is mainly
useful as an a priori filtering tool with a good input-
to-output ratio. By the same token, classical epidemiolog-
ical concepts such as positive predictive value and
receiver operating characteristic (ROC) are not applicable
to this problem, because the real structure of the trans-
mission chains is mostly unknown [23–25].
We refrain from arguing that pairs that share clinic
visits are representative of all HIV-positive steady pairs.
Yet, even if these pairs are selective, this does not nullify
the biological level insights that can be gained by using
their samples. As early treatment initiation is now univer-
sally recommended regardless of CD4 count [26], a
method for retrospective detection of transmission pairs
that is based on samples that have already been collected
and stored is timely.
We found eight heterosexual, mixed-ethnicity steady
transmission pairs with subtype CRF01_AE. This result is
in line with a recently published analysis of the global
dispersal patterns of this subtype which is prevalent in
Asia, predominantly in Thailand. Angelis et al. [27]
showed that Switzerland experienced at least 15 hetero-
sexually driven migration events of CRF01_AE, which is
larger than expected and the highest number in continen-
tal Europe. Our study suggests that steady, mixed-ethni-
city partnerships with a large age gap (with the man
being white and older) contribute to these introduction
events. This observation opens up a targeted prevention
opportunity.
Apart from epidemiological level insights, identifica-
tion of steady transmission and serosorting pairs can
widen the horizons of research at the biological level,
providing insights into problems that are otherwise
difficult to tackle; for example: (i) prospective viral
quasi-species exchange between the steady partnership
members (both transmission pairs and serosorting cou-
ples), given the fact that treatment interruption is still
prevalent [3]; (ii) exchange of transmitter-founder strains
and prospective viral diversification, and (iii) within-pair
transmission of drug resistance. In addition to research
questions centred around HIV biology and epidemiology,
the detected pairs can shed light on within-pair transmis-
sion of other common sexually transmitted infections
(e.g. syphilis) which are currently on the rise in the HIV-
positive population [28,29].
Our study also demonstrates how even de-identified
data, when aggregated longitudinally and in great detail,
can still be used to obtain information about individuals
and their health, sexual patterns and habits. In the era
of ‘big data’ and its increased - and as some argue
inevitable [30] - use in public health research, our study
emphasizes that greater effort should be made to protect
the privacy of the patients and that making anonymized
health data publicly available might lead to unexpected
consequences [31]. Similar privacy concerns, but in the
context of the deposition of anonymized sequencing
data sets, were raised by Gymrek et al. [32] who were
able to successfully identify personal genomes by
combining anonymized metadata with Y-chromosome
haplotypes.
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(Chairman of the Clinical and Laboratory Committee),
C. A. Fux, M. Gorgievski, H. G€unthard (President of the
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CHAPTER IV  
“The cumulative impact of harm reduction on the Swiss HIV epidemic: cohort study, 
mathematical model and phylogenetic analysis” 
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Research in context  
  In this paper, we integrate more than thirty-five years of data from high-quality 
sources to assess the population-level effectiveness of prevention measures against one of the 
key drivers of the global HIV epidemic:  
 HIV transmission among injecting-drug-users (IDUs) is the leading mode of 
transmission in Eastern Europe and Central Asia(1) and is recently re-emerging in the United 
States in the context of the growing heroin epidemic driven by overprescription of opioid 
painkillers (2–4).   In Russia, a staggering figure of 98,000 new HIV cases were reported in 
2015 alone, with 54% attributed to injecting drug use (5).  Despite the immense scope of the 
problem, in many countries harm reduction remains non-existent or even illegal and as a result, 
an increasing number of opioid-dependent people are denied evidence-based interventions (6).  
 Although the effectiveness of individual harm reduction interventions like needle and 
syringe exchange programs and opioid substitution therapy is well established, population-level 
estimates of the cumulative impact of harm reduction are absent.  
In this regard, Switzerland offers a unique experience. From the early eighties, 
Switzerland experienced one of the heaviest burdens of drug addiction (mainly Heroin and 
Cocaine) in Europe which manifested in the emergence of large open drug scenes and 
subsequently in an HIV outbreak. After adapting an extensive harm reduction package, 
transmission of HIV among IDUs in Switzerland almost ceased. To date, a quantitative 
evaluation of the cumulative impact of the implemented harm reduction measures has not been 
performed. 
 In this work, we combine a mathematical model with the data from the Swiss HIV Cohort 
Study (SHCS), the SHCS drug-resistance sequence database, national epidemiological data and 
data from previous works to demonstrate that overall, harm reduction prevented 15,903 HIV 
cases, 1980-2015. In addition, using a phylogenetic analysis, we demonstrated that the benefits 
of harm reduction extend beyond the population of injecting-drug-users, with 2,540 averted 
spillover infections from injecting-drug-users to the general population. These results highlight, 
based on the Swiss experience, the pivotal role of harm reduction, for the successful curbing of 
HIV transmission among IDUs and prevention of repercussions for the general population.  
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The Cumulative Impact of Harm Reduction on the Swiss 
HIV Epidemic: Cohort Study, Mathematical Model, and 
Phylogenetic Analysis
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Matthias Hoffmann,9 Jürg Böni,2 Sabine Yerly,7 Thomas Klimkait,10 Matthieu Perreau,11 Huldrych F. Günthard,1,2 Roger D. Kouyos1,2; and the Swiss HIV Cohort Study
1Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland; 2Institute of Medical Virology, University of Zurich, Switzerland; 3Arud 
Centres for Addiction Medicine Zürich, Switzerland; 4Clinic for Infectious Diseases, Bern University Hospital, Switzerland; 5Division of Infectious Diseases and Hospital Epidemiology, University 
Hospital Basel, University Basel, Switzerland; 6Division of Infectious Diseases, Regional Hospital Lugano, Switzerland; 7Laboratory of Virology and Division of Infectious Diseases, Geneva 
University Hospital, Switzerland; 8Service of Infectious Diseases, Lausanne University Hospital, Switzerland; 9Division of Infectious Diseases, Cantonal Hospital St. Gallen, Switzerland; 10Molecular 
Virology, Department Biomedicine—Petersplatz, University of Basel, Switzerland; 11University of Lausanne, Switzerland
Background. Human immunodeficiency virus (HIV) transmission among injecting drug users (IDUs) is increasing in the 
United States due to the recent opioid epidemic and is the leading mode of transmission in Eastern Europe.
Methods. To evaluate the overall impact of HIV harm reduction, we combined (1) data from the Swiss HIV Cohort Study and 
public sources with (2) a mathematical model expressed as a system of ordinary differential equations. The model reconstructs the 
national epidemic from the first case in 1980 until 2015. Phylogenetic cluster analysis of HIV-1 pol sequences was used to quantify 
the epidemic spillover from IDUs to the general population.
Results. Overall, harm reduction prevented 15 903 (range, 15 359–16 448) HIV infections among IDUs until the end of 2015, 
5446 acquired immune deficiency syndrome (AIDS) deaths (range, 5142–5752), and a peak HIV prevalence of 50.7%. Introduction 
of harm reduction 2 years earlier could have halved the epidemic, preventing 3161 (range, 822–5499) HIV infections and 1468 
(range, 609–2326) AIDS deaths. Suddenly discontinuing all harm reduction in 2005 would have resulted in outbreak re-emergence 
with 1351 (range, 779–1925) additional HIV cases. Without harm reduction, the estimated additional number of heterosexuals 
infected by HIV-positive IDUs is estimated to have been 2540 (range, 2453–2627), which is equivalent to the total national reported 
incidence among heterosexuals in the period of 2007 to 2015.
Conclusions. Our results suggest that a paramount, population-level impact occurred because of the harm reduction package, 
beyond factors that can be explained by a reduction in risk behavior and a decrease in the number of drug users over time.
Keywords: harm reduction; HIV; injecting drug use; needle and syringe exchange; opioids.
 
Human immunodeficiency virus (HIV) transmission via inject-
ing drug use remains one of the leading modes of transmis-
sion in Eastern Europe and many Asian countries (eg, China, 
Indonesia, Iran), and it is recently re-emerging in the United 
States as a result of the growing heroin epidemic, which is 
driven by overprescription of opioid analgesics [1–3].
Despite a large body of evidence on the effectiveness of harm 
reduction measures to halt the spread of HIV among people who 
inject drugs, there is still a large heterogeneity in the estimates 
[4]. These measures also remain politically controversial and 
are far from being universally implemented and accepted [5, 6]. 
As a result, the harm reduction coverage is still extremely low 
across the world and lags behind World Health Organization 
(WHO) targets [7].
From the early 1980s, Switzerland experienced one of the 
heaviest burdens of drug addiction (mainly heroin and cocaine) 
in Europe, which manifested in the emergence of large open 
drug scenes such as the “Platzspitz” (“Needle-Park”) in Zürich. 
This resulted in an outbreak of HIV, hepatitis B virus (HBV), 
and hepatitis C virus (HCV) infections in this risk group, and 
Switzerland had the highest acquired immune deficiency syn-
drome (AIDS) incidence rate in Europe in 1988 [8]. After a 
growing public outcry, and considering the failure of repressive 
measures as the main response tool, a new progressive drug pol-
icy was gradually implemented that was based on “four pillars”: 
prevention, therapy, harm reduction, and law enforcement [9].
The main harm reduction measures included the follow-
ing: (1) extensive needle-exchange programs, ie, on-site dis-
tribution at open drug scenes, pharmacies, and syringe 
vending machines; (2) supervised drug consumption rooms; 
(3) low-threshold methadone programs; and (4) since 1994, a 
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supervised, injectable medicinal heroin program. In parallel, 
a wide-reaching “STOP AIDS” campaign was launched with a 
tailored message for drug users, which emphasized the HIV risk 
in needle sharing [10]. Furthermore, HIV-infected current and 
former injecting drug users (IDUs) had broad access to anti-
retroviral drug treatment programs [11, 12].
From the public health perspective and particularly regarding 
HIV transmission, those efforts proved to be a phenomenal suc-
cess. Despite a relatively low cessation rate of drug use and des-
pite the fact that the prevalence of heroin addiction remained 
relatively stable [13], the transmission of HIV among IDUs in 
Switzerland dropped from a peak of 937 new cases in 1989 to a 
low of 2% (9 of 519) of all new infections in 2014, hence almost 
eliminating HIV transmission among IDUs.
To date, a quantitative evaluation of the cumulative impact of 
the implemented harm reduction measures has not been per-
formed. In this study, we combine a mathematical model with 
the data from the Swiss HIV Cohort Study (SHCS), the SHCS 
drug-resistance sequence database, national epidemiological 
data, and data from previous works to perform the following: 
(1) estimate the counterfactual HIV incidence and prevalence 
among IDUs in absence, or with delayed introduction, of the 
harm reduction measures; (2) examine the effect of discontin-
uing harm reduction measures when the HIV epidemic among 
IDUs appears as under control; and (3) estimate the cumulative 
effect of the implemented harm reduction measures on the spill-
over of the epidemic to the general population in Switzerland.
METHODS
Ethics
We obtained ethical approval from the SHCS and written 
informed consent from all participants.
Swiss HIV Cohort Study and the Drug Resistance Database
The SHCS is an ongoing prospective cohort of HIV-positive 
individuals. The study prospectively enrolled patients since 
1988, and some data were retrospectively ascertained until 
1981. During the biannual outpatient visits, comprehensive 
clinical and behavioral data are collected [14]. In addition, for 
more than 60% of the participants, partial pol sequences are 
available. The representativeness of the SHCS was estimated to 
be high, with good coverage of marginalized and hard-to-reach 
populations, and is particularly good for subtype B, which is the 
predominant subtype in Switzerland [15].
Mathematical Model
We constructed a compartmental, deterministic transmis-
sion model represented as a nonlinear system of 32 ordinary 
differential equations (Figure 1). The model reconstructs the 
epidemic from the first introduced HIV case into the IDUs pop-
ulation in 1980 and is numerically solved until 2015. The mod-
eled population corresponds to all heroin users in Switzerland. 
The model is divided into 3 meta-strata that represent a typical 
progression of an addiction course: (1) “non-injectors” repre-
sent people who smoke or snort heroin; (2) “active injectors” 
represent populations at risk of infection with HIV by sharing 
injection paraphernalia; and (3) “past-injectors” represent peo-
ple covered by harm reduction that are still addicted to opioids, 
but do not contribute to the infectious pool anymore, since they 
switched to snorting/smoking or are in a methadone or super-
vised heroin program and permanently ceased injecting in a 
setting that facilitates transmission. The active injectors and the 
past-injectors are stratified into HIV susceptible and infected. 
All infected IDUs start in the undiagnosed compartment and 
can be diagnosed either in recent, chronic, or AIDS stage, with 
different rates. Since 1996, diagnosed individuals can transit 
to a combined antiretroviral treatment (cART) treated stage, 
with rates that depend on the disease stage and are increasing 
with calendar year to reflect transition to immediate treatment. 
Those rates were estimated from the SHCS based on CD4 
counts as a proxy for disease stage (Supplementary Table  3). 
Except for past-injectors, which are covered by harm reduction 
by definition, each compartment is mirrored by a parallel harm 
reduction-covered strata to which individuals transit with an 
average rate that represents the harm reduction recruitment 
rate. Because the different harm reduction layers were overlap-
ping in time (see Supplementary Figure 1), we do not model the 
separate effect of each measure (methadone, needle exchange, 
supervised injectable heroin, etc), but we use a harm reduc-
tion “package” [7] that was introduced in 1988, which means 
being covered by any of the harm reduction measures versus 
being missed by all of them. The exception to this pooled con-
sideration of harm reduction is the restricted methadone pro-
gram, because this was the main available measure before the 
introduction of the package, which allowed us to disentangle 
its effect. We assumed that IDUs covered by harm reduction 
had lower HIV transmission coefficient. This transmission rate, 
the harm reduction package recruitment rate, and other model 
parameters were determined by fitting the model using negative 
log-likelihood-distributed error to the annual number of new 
HIV cases and AIDS deaths in IDUs that were reported to the 
Swiss Federal Office of Public Health. See the Supplementary 
Data for a detailed description of the model, parametrization, 
and sensitivity analysis.
Phylogenetic Analysis
A large maximum likelihood phylogenetic tree with 19 604 Swiss 
sequences and 90 994 non-Swiss background sequences was 
constructed as previously described [16]. Introduction events 
into the general (heterosexual) population that originated from 
IDUs were detected by extracting all clusters that comprised 
only Swiss sequences and had at least 1 IDU and 1 heterosexual 
individual. For each IDU, the tree nodes were traversed back 
until the cluster either contained another IDU individual or a 
risk group that is other than an IDU or heterosexual, then the 
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largest previous cluster was returned. This way, our analysis 
estimated not only the spillover population but also the further 
transmission of HIV within the heterosexual population caused 
by that spillover population. See the Supplementary Data for 
a detailed description of cluster analysis and the spillover 
calculation.
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Figure 1. Graphical representation of the mathematical model. I, infected; S, susceptible; T, treated with cART (since 1996).
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Analysis Tools
Statistical analysis was performed with R (version 3.2.3). The 
system of equations was solved using the package deSolve (ver-
sion 1.14); the package “ape” (version 4.1) was used for phyloge-
netic analysis.
RESULTS
Injecting Drug Users in the Swiss HIV Cohort Study
Between 1983 and 2016, 4806 IDUs were enrolled in the SHCS, 
3311 of those were most likely infected with HIV through shar-
ing infected paraphernalia, and the remaining 1495 might have 
been infected via sharing or via sexual route.
The number of newly enrolled IDUs decreased with time from 
553 newly registered in 1990, to 17 in 2016 (P for trend <.0001; 
Figure 2), hence accurately reflecting the drop of HIV incidence 
among IDUs in Switzerland [17]. Most IDUs were men (65.7%, 3157 
of 4806; Supplementary Table 1) and were without university edu-
cation (99.1%, 4761 of 4806). Both time to cART and subsequently 
the fraction of IDUs with AIDS-defining illness have decreased with 
time (P for trend .048), with almost immediate treatment initiation 
in 2010–2016, and 15.9% (11 of 69) of IDUs with AIDS-defining 
illness, compared with 48.0% (1441 of 2999)  for IDUs that were 
diagnosed until 1990 (Fisher’s exact test, P < .0001).
The period prevalence of HBV and HCV coinfections was 
high, with 78.3% (2312 of 2954; 1862 not tested) and 94.6% (2728 
of 2883; 1923 not tested), respectively, for the entire period, and 
58.2% (39 of 67; 2 not tested) and 73.1% (49 of 67; 2 not tested) 
in the last 7 years. This high prevalence of HBV and HCV alludes 
to a high fraction of nonassortative needle sharing, as expected 
in an open drug scene and assumed in our model.
Model Performance
The proposed model exhibits a qualitatively good fit, both to the 
annual number of newly diagnosed HIV cases among IDUs in 
Switzerland and to the annual number of reported AIDS deaths 
(Figure 3a and b, respectively). The model also catches, for the 
most part, the assumed dynamic of the population of prob-
lematic heroin users in Switzerland, with a peak during early 
1990s and a subsequent gradual decline (Figure 3c). Finally, the 
model predicts HIV prevalence among IDUs in Switzerland, 
which falls in line with published estimates of approximately 
10% between 1993 to 2000 [18]. Human immunodeficiency 
virus prevalence and the number of heroin users were deliber-
ately not used for model fitting, to serve as an additional quality 
check for the prudence of our model; nevertheless, the dynam-
ics of those compartments is captured well by the model.
The Combined Effect of Harm Reduction Measures, No Harm Reduction, 
and Sudden Discontinuation
First, we examined the extreme—yet relevant to other coun-
tries—worst-case scenario of no harm reduction at all since 
1980, which required transferring the individuals on restricted 
methadone—that was available since late 1970s—to model 
compartments not covered by any harm reduction, from the 
start of the simulation. This resulted in 15 903 (range, 15 359–
16 448) additional infections until the end of 2015 (Figure 4a 
and Figure  5), 5446 new additional AIDS deaths (range, 
5142–5752) (Figure 4b), and a peak HIV prevalence of 50.7% 
(Figure 4c). Next, we examined whether a sudden discontinu-
ation of all harm reduction services, after several years of low 
incidence, will result in a renewed outbreak. Our model shows 
that suddenly discontinuing all harm reduction in the year 2000 
60
0
ID
U
1.
0
0.
8
0.
6
0.
4
0.
4
0.
0
Pr
op
or
tio
n
H
E
T
R
isk
 g
ro
up
M
SM
New registered (IDU)
a b
New AIDS cases (IDU)
50
0
40
0
30
0
N
 in
 th
e 
SH
C
S
20
0
10
0
0
1983 1985 1989 1992 1996
SHCS registration year
2000 2004 2008 20121987 1991 1995 1999
Years
2003 2007 2011 2015
Figure 2. (a) New registered injecting drug users (IDUs) and new acquired immune deficiency syndrome (AIDS) cases in the Swiss HIV Cohort Study (SHCS). (b) The fraction 
of IDUs (yellow) out of all newly registered patients in the Swiss HIV Cohort Study, by registration year.
75
Overall Impact of HIV Harm Reduction • OFID • 5
(10 years after the incidence peak) or 2005 would have resulted 
in outbreak re-emergence up to 2015 in both scenarios, with 
4965 (range, 3420–6511) and 1351 (range, 779–1925) additional 
HIV cases, respectively (Figure 4a and Figure 5). However, the 
re-emergence rate is twice as slow when harm reduction is 
discontinued in 2005 compared with 2000, with linear slopes 
of 20.2 (95% confidence interval [CI], 18.8–21.6) and 40.5 (95% 
CI, 39.6–41.3) new cases, respectively, for the first 5 years after 
discontinuation. Because of immediate cART in the recent 
years, discontinuation in 2005 would have had limited to no 
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effect on the number of AIDS deaths with 153 (range, 101–206) 
additional deaths (Figure 4b).
Delayed or Earlier Introduction
A delay of 2  years in the introduction of the harm reduc-
tion package, ie, 1990 instead of 1988, would have resulted in 
2325 (range, 1580–3071) additional HIV cases (Figure 4e and 
Figure 5) and 971 additional AIDS deaths (range, 724–1219) 
(Figure 4f). On the other hand, a 2 years earlier introduction 
(ie, 1986)  could have halved the epidemic, preventing 3161 
(range, 822–5499) HIV infections and 1468 (609–2326) AIDS 
deaths, with a peak HIV prevalence among IDUs that would 
have never exceeded 11.3 % (range, 8.5%–15.3%).
Only Restricted Methadone and No New Recruitment Since 2000
Next, we examined the effect of not introducing the extensive 
harm reduction package but continuing with high-thresh-
old methadone only, with the same recruitment rate as before 
1988 (~8.5% per year; Supplementary Data). This would have 
resulted in 11 462 additional HIV cases (range, 10 399–12 526) 
(Figure  4i and Figure  5) and 3190 (range, 2793–3588) add-
itional AIDS deaths (Figure  4j). It is notable that restricted 
methadone is still superior to the scenario with no harm reduc-
tion at all, with 4441 prevented cases and 2256 fewer deaths. 
Finally, we explored a less radical discontinuation scenario, in 
which individuals that are covered by harm reduction remain 
in the covered compartment (with the same dropout rate); 
however, since 2000, there is no new recruitment to the harm 
reduction covered compartments. This scenario emulates a 
harm reduction budget cut plot. This would have resulted in 
a slow re-emergence with 1616 additional HIV cases (range, 
938–2295) (Figure 4i) with no substantial increase in additional 
AIDS deaths (range, 114–235) (Figure 4j).
The Effect of Combined Antiretroviral Treatment 
Although, chronologically, the epidemic reached its peak and 
began to decline before cART introduction in 1996, we still 
observe a moderate protective effect of cART (the harm reduc-
tion-related parameters were not changed in this scenario), 
with 771 (range, 401–1142) new HIV cases prevented by cART 
alone until the end of 2015, and—as expected—an ample effect 
on AIDS deaths, with 1771 (range, 991–2552) prevented deaths 
(Figure 5 and Supplementary Figure 3).
Spillover to the General Population
The phylogeny contained 4235 sequences from 2399 SHCS 
IDUs, with 94.3% (2262 of 2399) harboring subtype B. Cluster 
analysis showed 499 heterosexuals clustered with IDU in Swiss-
only clusters, which were linked to 358 putative cross-risk-
group introduction events (Supplementary Figure 4) in which 
the phylogenetically closest IDU was male in 60.3% (216 of 
358) and female in 39.7% (142 of 358). In absence of any harm 
reduction (scenario a), the estimated additional number of het-
erosexuals whose infection originated from HIV-positive IDUs 
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is estimated to have been 2540 (range, 2453–2627) new infec-
tions, which is comparable to the total national HIV incidence 
among heterosexuals in the entire period from 2007 to 2015 
(n = 2476, Federal Office of Public Health [19–21]).
DISCUSSION
According to UNAIDS, in Eastern Europe and Central Asia, 51% 
of all newly diagnosed HIV is attributed to people who inject 
drugs [22]. However, only 7% to 15% of all IDUs in Eastern 
Europe have access to needle and syringe programs, whereas 
for opioid substitution treatment the coverage is approximately 
1% [3], and it remains illegal in Russia. Likewise, the Western-
Europe, North-America, and Australasia region combined have 
not yet reached the WHO middle-coverage target of 20% for 
needle and syringe programs [7].
Our model estimates that a very high prevalence of HIV 
(~50%) among IDUs would have occurred in the absence 
of harm reduction. More importantly, our model takes into 
account both the overall decrease in heroin consumption as 
well as the decreasing number of injectors. Thus, the high prev-
alence in the absence of harm reduction is predicted to have 
occurred despite those general trends of drug use. This coun-
terfactual estimate is also in line with historical seroprevalence 
data from socioeconomically comparable areas that had little to 
no harm reduction at that time. Frankfurt, Germany, had a large 
open drug scene, with HIV prevalence of 73.7% in 1994 [23], 
in Spain the prevalence was 63% in 1996 [24], and in northern 
Italy the prevalence was 49% in 1989 [25]. Some areas in the 
United States also exhibited high HIV prevalence, with 61% in 
New York [26] and 60% in New Haven, Connecticut [27], dur-
ing the early 1990s. In Eastern Europe, and especially in Russia, 
which exercises a repressive approach toward IDUs and repul-
sion of the harm reduction concept on the political level, a 37% 
prevalence was estimated in 2003 [3]. In Estonia, the rate was as 
high as 72% [3].
Considering the low incidence of HIV among IDUs in 
Switzerland in the recent years, there is a growing debate on 
whether the funds invested in harm reduction can be safely allo-
cated elsewhere. In 2016, the canton of Zürich decided to cut 4.5 
million Swiss Francs from the drug-addiction treatment pro-
grams until 2019 [28]. Our study shows that suddenly stopping 
harm reduction measures, even several years after the epidemic 
appears as under control, can lead to a new outbreak. This result 
is supported by a recent experience from Greece, a country with 
a historically low HIV incidence among IDUs (1.5% to 4.5% of 
all new infections during 2000–2010) [29]. In 2011, due to the 
fiscal crisis and severe austerity, the harm reduction measures 
were underperforming [30]. Until the first 8 months of 2013, 
1000 new HIV cases among IDUs have already been diagnosed 
[31]. After harm reduction—in form of needle and syringe 
exchange and opioid-substitution—was scaled up again, HIV 
incidence was reduced 5-fold within 1 year [32].
Our estimates show a moderate impact of cART on curb-
ing HIV transmission among IDU in Switzerland. This can be 
attributed to 2 factors: (1) cART was introduced in 1996 after the 
epidemic was already contained by the harm reduction meas-
ures, which started in part in 1988; and (2) the effect of cART 
is partly undermined by lower adherence among IDUs [33], 
which was also reflected in our model. However, as expected, 
cART prevented a large number of AIDS deaths among IDUs.
Our model has several benefits and can be adjusted for the 
following factors: (1) the decrease in the number of injectors 
with time; (2) the possible reduction in risk behavior even in 
people who are not reached by any harm reduction due to over-
all awareness of HIV [34]; and (3) the decrease in needle shar-
ing by IDUs who are aware of their HIV-seropositive status and 
are concerned of infecting others [35]. Because the extent of the 
relevance of those developments to the Swiss settings is uncer-
tain, we speculate that we might have underestimated the effect-
iveness of the combined harm reduction measures and that our 
estimates lay on the conservative side. This is further supported 
by the fact that, due to scarcity of data, we could not account 
for cocaine-only injectors; however, injectors of cocaine and 
heroin (“Speedball”) were accounted for in our model. In add-
ition, our model has the advantage of being applicable to the 
current opioid analgesics-driven HIV epidemic, because it 
accounts for the transition from a noninjecting to injecting 
drug administration mode.
Our model is limited because it does not differentiate 
between the different measures implemented, except for 
restricted methadone. However, in this work, we were a pri-
ori interested in cumulative estimates. Our model also only 
accounts for sexual transmission within but not between the 3 
meta-strata. Nonetheless, the contribution of sexual transmis-
sion is expected to be of secondary importance due to an 8-fold 
higher per-act transmission probability for needle sharing [36]. 
Finally, as it is often in modeling studies, the uncertainty ranges 
of our predictions might be underestimated.
Indeed, not all countries affected by an HIV epidemic among 
IDUs possess the resources that were available in Switzerland. 
However, the unit costs of harm reduction interventions are rel-
atively low and are estimated to be highly cost effective [7] and, 
in light of the results presented here, might even be cost saving. 
In addition, we demonstrated that the benefits of harm reduc-
tion extend beyond the population of IDUs, with thousands of 
averted spillover heterosexual infections. Similar studies are 
needed for the HCV epidemic, which affects this population 
even more severely than HIV.
CONCLUSIONS
In summary, our results highlight, based on the Swiss experi-
ence, the pivotal role of harm reduction for successful curb-
ing of HIV transmission among IDUs and prevention of grave 
repercussions for the general population.
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Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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	Research in context 
 One of the most pertinent issues concerning the HIV positive population is the dramatic 
increase in coinfections with sexually transmitted infections (STIs), in particular in Men-who-
have-Sex-with-Men (MSM) and hence there is high urgency for studies that help to optimize 
screening and prevention strategies.  
 In this work, we systematically describe the characteristics and risk factors of 
individuals with a sexually transmitted infection (STI) in a well-characterized cohort of mainly 
MSM with a prior diagnosis of primary HIV-1 infection. We prospectively collected the data 
from 214 individuals enrolled in both the Zurich Primary HIV Infection Study (ZPHI) and the 
Swiss HIV Cohort Study (SHCS).   
 The prospective and longitudinal study design allowed us to calculate prevalence and 
incidence rates of most common STIs (Gonorrhoea, Chlamydia, Syphilis etc.) and to test a 
variety of risk factors against having a STI. In our unique patient population, we found a very 
high STI prevalence (33%), mostly presenting asymptomatic, and identified three independent 
factors associated with a positive STI screen: i) anal intercourse, ii) reporting condomless sex, 
and iii) reporting any recent drug use. These results highlight the importance of a more frequent 
(3-monthly) screening in high-risk populations as identified in this study, and demonstrate the 
potential of relying on self-reported sexual risk behaviour and drug use data for screening 
prioritization
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High Rates of Subsequent Asymptomatic Sexually 
Transmitted Infections and Risky Sexual Behavior in 
Patients Initially Presenting With Primary Human 
Immunodeficiency Virus-1 Infection
Dominique L. Braun,1,2,a Alex Marzel,1,a Daniela Steffens,1 Peter W. Schreiber,1,2 Christina Grube,1 Alexandra U. Scherrer,1,2  
Roger D. Kouyos,1,2,a and Huldrych F. Günthard1,2,a; for the Swiss HIV Cohort Study
1Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and 2Institute of Medical Virology, University of Zurich, Switzerland
Background. Knowledge of the risk factors of individuals with an asymptomatic sexually transmitted infection (STI) is essential 
for implementation of targeted STI screening strategies.
Methods. Between June 2015 and January 2017, an STI screening was offered to all participants in the Zurich Primary human 
immunodeficiency virus (HIV)-1 Infection study. Patients were tested for gonorrhea, chlamydia, syphilis, and hepatitis C virus 
(HCV).
Results. Of 214 participants, 174 (81%) were screened at least once. Most patients were men who have sex with men (MSM) 
(87.4%). Presenting with a primary HIV infection was associated with higher odds for later risky sexual behavior, as compared with 
presenting in the chronic phase (odds ratio [OR], 5.58; 95% confidence interval [CI], 3.68–8.8). In total, 79 STIs were detected, 
reflecting a high period prevalence of 33.3% (58 of 174 patients). Sixty-six percent of patients (52 of 79) were asymptomatic. Most 
common STIs were chlamydia (50.6%; 40 of 79 patients), gonorrhea (25.3%; 20 of 79), and syphilis (19%; 15 of 79). In a multivaria-
ble model, engaging in insertive (OR, 6.48; 95% CI, 1.14–36.76) or both insertive and receptive (4.61; 1.01–20.96) anal intercourse, 
STI symptoms (3.4; 1.68–6.89), and condomless sex (2.06; 1.14–3.74) were positively correlated with a positive screening result. The 
hazard of an incident STI increased with the presence of STI symptoms (hazard ratio, 3.03; 95% CI, 1.17–7.84) and any recent drug 
use (2.63; 1–6.9).
Conclusions. A trimonthly STI screening including asymptomatic individuals should be considered in this population, particu-
larly in MSM who report sexual risk behavior.
Keywords. primary HIV-1 infection; sexually transmitted infection; sexually transmitted disease; asymptomatic; screening. 
Rates of sexually transmitted infections (STIs) are rising in men 
who have sex with men (MSM) and individuals with human 
immunodeficiency virus (HIV) infection [1–5]. Patients with 
a primary HIV infection treated with early antiretroviral ther-
apy (ART) represent a highly sexually active population and 
contribute substantially to this epidemic [6, 7]. Recognizing 
the high prevalence of STIs in the HIV-infected and HIV-
uninfected MSM population, the Centers for Disease Control 
and Prevention recommends routine laboratory screening for 
common STIs (ie, syphilis, gonorrhea, chlamydia) at least annu-
ally for sexually active MSM and a more frequent STI screening 
(ie, at 3–6-month intervals) for MSM who have multiple or 
anonymous partners [2].
During recent years it has been recognized that STIs com-
monly present as asymptomatic, predominantly affect MSM, 
and may occur in multiple anatomic sites [4, 8–12]. An inten-
sive 3-site screening (ie, rectal, pharyngeal, urethral) is there-
fore needed to detect asymptomatic STIs [13] appropriately. 
The rationale to direct efforts into diagnosing and treating 
asymptomatic STIs include (1) the identification of trans-
mitter pools and the reduction of onward transmission, (2) 
the prevention of disseminated infection, (3) the identifica-
tion of other STIs through partner notification, and (4) the 
prevention of the emergence of resistance as the oropharyn-
geal niche provides an enabling environment for horizontal 
transfer of genetic material from commensal Neisseria sp. 
and other bacterial species to Neisseria gonorrhoeae (20) [14]. 
A  recently published mathematical model [15] showed that 
the introduction of a routine STI screening every 6 months 
could reduce the incidence of Chlamydia trachomatis and 
HIV infection by 15% and 4%, respectively. However, 3-site 
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screening at 3–6-month intervals is both time and cost con-
suming [16].
Given the high burden of STIs, especially in HIV-infected 
MSM, and the challenges to identify them accurately, better 
knowledge of the characteristics and risk factors of patients with 
STIs, specifically asymptomatic STIs, is crucial to better guiding 
healthcare providers on whom to screen. In this regard, data are 
particularly scarce concerning HIV-infected individuals whose 
initial diagnosis was of acute or recent infection. Understanding 
the risk profile and behavioral attitudes associated with STI 
acquisition could help identify individuals in need of regular 
and intensified STI screening. Here we report on the charac-
teristics of 214 HIV-infected predominantly MSM enrolled in 
the Zurich Primary HIV-Infection (ZPHI) study and the risk 
factors associated with STI detection in this population.
METHODS
Study Population
All patients had a documented primary HIV infection and 
are enrolled in the ZPHI, an open-label, nonrandomized, 
observational, single-center study (ClinicalTrials.gov, ID 
NCT00537966) [17]. The ethics committee of the Canton of 
Zurich approved the study protocol, and written informed 
consent was obtained from all patients. Acute or recent pri-
mary HIV infection was confirmed in all patients, as pub-
lished elsewhere [17–19]. Acute HIV infection was defined as 
acute retroviral syndrome (ARS), negative or indeterminate 
HIV line immunoassay results in the presence of positive 
p24-antigen, and/or detectable HIV-1 RNA, or as a docu-
mented seroconversion with or without symptoms during the 
past 90 days. Recent infection was defined as possible ARS, 
positive HIV Line Immunoassay results, detectable HIV-RNA, 
and a negative HIV glycoprotein 120 avidity or detuned assay 
result, or as a documented acute HIV-1 infection but with re-
ferral to our center >90 but <180 days after the presumed date 
of infection.
All patients considered in this study are also participants 
in the Swiss HIV Cohort Study (SHCS) (www.shcs.ch) [20]. 
The SHCS is a prospective cohort with ongoing enrollment for 
HIV-infected individuals in Switzerland that started in 1988. 
Clinical, laboratory, and sociodemographic information is 
collected every 6 months, including information about sexual 
behavior. In addition, detailed treatment history is kept for all 
patients.
Data Collection
Between 1 June 2015 and 31 January 2017 we offered regular 
STI screenings to all patients from the ZPHI study who had 
a clinical visit. Patients had to be screened at least once to be 
included in the analysis. They were then also asked to complete 
a behavioral questionnaire that assessed the sexual behavior and 
symptoms related to a possible STI in the preceding 3 months 
(Supplementary Material). From June 2015 to June 2016, we 
performed separate polymerase chain reaction (PCR) tests for 
each anatomic site to determine the sites of infection. To reduce 
costs, the sampling procedure was simplified to a pooled STI 
screening from July 2016 to January 2017.
Laboratory Tests
Swabs obtained from the urethra, rectum and pharynx were 
tested by PCR for C. trachomatis and N. gonorrhoeae. Blood 
was tested for syphilis by Treponema-pallidum-Particle-
agglutination (TPPA), and VDRL and/or rapid plasma reagin 
tests were done in the event of a positive TPPA result. Patients 
were also tested yearly for anti–hepatitis C virus (HCV) im-
munoglobulin G. In patients presenting with elevated trans-
aminase levels, with >50 U/L as the upper limit of a normal 
value, blood samples were also tested for hepatitis C by PCR. 
For detailed testing information, see Supplemetary box 1. For 
specific treatment see Supplemetary box 2.
Statistical Analysis
Statistical analysis was performed using R software, version 
3.3.2. Bivariate P values were calculated using the Fisher exact 
test for categorical variables and the Wilcoxon test for con-
tinuous variables. Bivariate P values were adjusted for multi-
ple comparisons using the Benjamini-Hochberg procedure. 
For multivariable analysis, with the outcome of STI diagnosis 
during any of the screening visits, a generalized linear mixed 
model logistic regression was used with a per-patient random 
intercept. Apart from age at diagnosis and CD4 cell count, 
which were included a priori, variables that were significant 
in the bivariate analysis (Benjamini-Hochberg P < .05) were 
included in the multivariable model, if not strongly collinear 
with another independent variable. Square root transformation 
was performed on the CD4 cell counts to fulfill model assump-
tions [21]. The Cox proportional hazard model was used for the 
prospective subsample with a negative baseline, with the same 
selection strategy for variables.
RESULTS
Visits, Patients, and Period Prevalence of STI
During the study period, 623 follow-up visits from 214 patients 
occurred with a median of 3 visits per patient (range, 1–4 visits); 174 
of 214 patients (81%) agreed to be screened at least once, accounting 
for 334 visits (Figure 1) with a valid STI screening. In total, 79 STIs 
were detected in 58 patients during 71 visits, reflecting a high period 
prevalence of 33.3% (58 of 174; 95% confidence interval [CI], 26.4%-
40.9%). Even if it is assumed that all 40 untested patients had no 
STIs, this would still imply a high period prevalence of 27.1% (58 of 
214; 21.3%-33.6%). In 8 visits, >1 STI was detected in the same pa-
tient. The most prevalent reported reason for the 40 patients’ study 
nonparticipation was a reported belief that their risky behavior was 
insufficient to warrant screening (Figure 1).
85
 • CID 2017:XX (XX XXXX) • 3High Rates of STIs in Patients After PHI
The most common STIs were chlamydia (50.6%; 40 of 79), gon-
orrhea (25.3%; 20 of 79), and syphilis (19%; 15 of 79) (Table 1). The 
stage of syphilis infection included stage 1 (n = 7; 47%), stage 2 
(n = 3; 20%), early latent (n = 4; 27%), and neurosyphilis (n = 1; 
6%). A large fraction (of the detected STIs 65.8%; 52 of 79) were 
asymptomatic. For both chlamydia and gonorrhea, the rectum was 
the most prevalent anatomic site of infection, accounting for 62.5% 
(20 of 32; 8 unknown owing to pooled testing) and 53.3% (8 of 15; 
5 unknown owing to pooled testing), respectively (Supplementary 
Table S1). The 3 detected HCV infections were considered inci-
dent infections because all 3 individuals had a prior negative HCV 
antibody test recorded in the SHCS database, presented with 
recently elevated liver transaminase levels, and reported risky sex-
ual behavior and/or drug use in the preceding months.
HIV Diagnosis During Primary Infection and Subsequent Risky Sexual 
Behavior
First, we examined whether presentation with a documented 
primary HIV infection was associated with a higher rate of later 
risky sexual behavior, compared with HIV diagnosis during the 
chronic phase. We compared 169 MSM ZPHI patients who ini-
tially presented with documented primary HIV infection and 
were offered STI screening in this study with 5105 MSM from 
the SHCS without a documented primary HIV infection. The 
outcome variable was reported condomless sex with an occa-
sional partner at least once after diagnosis of HIV infection. 
After adjustment for age at diagnosis, year of diagnosis, and first 
CD4 cell count, diagnosis of a primary HIV infection was asso-
ciated with a 5-fold higher odds for later risky sexual behavior, 
compared with diagnosis during the chronic phase (adjusted 
odds ratio [OR], 5.58; 95% CI, 3.68–8.8) (Table 2).
Factors Correlating With STI Detection
Only 1 STI was detected in the heterosexual risk group, with 
the remaining 98.6% (70 of 71) of visits with an STI belonging 
Figure 1. Flow chart of the study. Abbreviation: ZPHI, Zurich Primary HIV-Infection.
Table 1. Sexually Transmitted Infections (STIs) Detected Stratified By 
Presence of STI Symptoms
Type of STI
STIs Detected, No. (%)
Total Symptomatic Asymptomatic
Chlamydia 40 (50.6) 11 (27.5) 29 (72.5)
Gonorrhea 20 (25.3) 6 (30) 14 (70)
Syphilis 15 (19) 9 (60) 6 (40)
Acute hepatitis C 3 (3.8) 0 (0) 3 (100)
HSV infectiona 1 (1.3) 1 (100) 0 (0)
Total 79 (100) 27 (34.2) 52 (65.8)
Abbreviations: HSV, herpes simplex virus; STI, sexually transmitted infection.
aAccidental finding; HSV was not screened for systematically. 
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to the MSM risk group. In a bivariate analysis, compared with 
visits without STI detection, detection of an STI during a visit 
was significantly associated with a more recent year of HIV 
diagnosis (median year, 2012 [interquartile range (IQR), 2009–
2014] vs 2010 [2007–2013]; P = .009) and hence with a shorter 
time since HIV diagnosis (median, 3.2 vs 5.3 years; P =  .006). 
STI detection was also correlated with having anal inter-
course (96% [68 of 71] vs 80% [21 of 263]; P =  .03), a higher 
number of sexual partners (median, 3 [IQR, 2–6.5) vs 2 [1–4]; 
P < .001), reports of condomless sex (59.2% [42 of 71] vs 33.8% 
[89 of 263]; P = .001) and reports of STI symptoms (33.8% [24 
of 71] vs 9.1% [24 of 263]; P < .001) (Table 3).
In a multivariable model restricted to MSM, the number of 
years since HIV diagnosis (OR, 0.87; 95% CI, .8–.96) and √CD4 
cell count (0.93; .87–.99) were negatively associated with the 
odds of having a positive STI test result (Figure 2A). On the other 
hand, engaging in insertive (OR, 6.48; 95% CI, 1.14–36.76) or 
both insertive and receptive (4.61; 1.01–20.96) anal intercourse 
in the last 3 months, reporting STI symptoms (3.4; 1.68–6.89,) 
and reporting condomless sex (2.06; 91.14–3.74) were all posi-
tively correlated with the odds for a positive screening result.
Incidence Rate and Survival Analysis
Seventy-three patients were screened more than once and had 
a first negative screening result, which served as a baseline for 
the incidence analysis. Overall, 21 patients had ≥1 incident 
STI during a total of 37.2 person-years, which corresponds 
to an incidence density rate of 56 (95% CI, 35–86.3) per 100 
person-years. When restricted to MSM only (93.2%; 68 of 
73), the incidence rate was 61.6 (95% CI, 38.2–94.2) per 100 
person-years.
In a bivariate analysis, incident STI was associated with a 
higher number of sexual partners (median, 3 [IQR, 2–6] vs 2 
[1–3.2l]; P = .041), reporting of STI symptoms (38.1% [8 of 21] 
vs 9.6% [5 of 52]; P = .05), and any drug use in the last 6 months 
(38.1% [8 of  21] vs 5.8% [3 of  52]; P =  .04) (Supplementary 
Table S2). In a multivariable Cox proportional hazard model 
restricted to MSM only, the hazard of an incident STI increased 
with the presence of STI symptoms (hazard ratio, 3.03; 95% 
CI, 1.17–7.84; P =  .02) and any recent drug use (2.63; 1–6.9: 
P = .049) (Figure 2B).
Finally, considering the above-mentioned finding that any 
recent drug use was associated with STI risk, we explored data 
about use of specific substances (Table 4). None of the examined 
MSM reported intravenous heroin or cocaine use. However, a 
strong bivariate association was found between incident STI 
and recent use of noninjectable cocaine, cannabis, and other 
noninjectable drugs (as a group), (adjusted P = .005, .01, and 
.006, respectively). More specifically, recent use of ecstasy or 
gamma-hydroxybutyric acid was significantly associated with 
an incident STI, with rates of 28.6% (6 of 21) versus 0 of 47 (P 
= .003), and 19% (4 of 21) versus 0 of 47 (P = .01), respectively.
DISCUSSION
In this prospective analysis of mainly Swiss MSM with a prior 
diagnosis of primary HIV infection treated with suppressive 
ART during the study, we found a very high period prevalence 
and incidence rate of STIs. In line with the literature, the ma-
jority of the detected STIs were asymptomatic, and the most 
affected anatomic site was the rectum [1, 4, 8, 9, 11, 13, 22–34]. 
We identified 3 independent factors predictive of a positive STI 
screening result: (1) engaging in insertive or both insertive and 
receptive anal intercourse, (2) reporting STI symptoms, and (3) 
reporting condomless sex.
The STI period prevalence of 33% and the incidence rate of 
61.6 per 100 person-years in our study is high compared with 
other studies in Western Europe. A study of HIV-infected MSM 
in the SHCS found an overall point STI prevalence of 20%, and 
another study from Germany reported a markedly lower STI 
prevalence of 15% in its MSM population [12, 23].
The very high prevalence in our study could be explained 
by several factors. First, individuals initially diagnosed with 
primary HIV infection might constitute per se a high-risk 
population as suggested by our analysis of rates of risky sexual 
behavior in patients with a diagnosis of primary versus chronic 
HIV infection. Second, individuals receiving suppressive ART 
are considered noninfectious for their sexual partners in terms 
of HIV, which might result in risk-compensation behavior and 
thus higher risk for contracting bacterial STIs and hepatitis 
C. In line with this assumption, a 2-fold increase in the syph-
ilis incidence was observed in the SHCS after 2008, the year the 
so-called Swiss statement was introduced, which declared that 
HIV-infected persons receiving effective HIV treatment are not 
Table 2. Standard Logistic Regression for Correlation Between 
Presentation With Primary Human Immunodeficiency Virus (HIV) Infection 
and Risky Sexual Behavior at Any Time Point After HIV Diagnosisa
Univariable Model Multivariable Model
OR (95% CI) P Value OR (95% CI) P Value
Age at HIV diagnosis 0.99 (.98–.99) <.001 0.98 (.98–.99) <.001
Year of HIV diagnosis 1.04 (1.04–1.05) <.001 1.04 (1.04–1.05) <.001
First CD4 cell count, 
cells/μL
 <200 (reference) 1 … 1 …
 200–500 1.73 (1.5–1.99) <.001 1.51 (1.3–1.75) <.001
 >500 1.82 (1.57–2.13) <.001 1.6 (1.36–1.87) <.001
HIV infection at 
presentation
 Chronic (reference) 1 … 1 …
 Primary HIV 7.9 (5.25–12.41) <.001 5.58 (3.68–8.8) <.001
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio.
aIn this analysis, 169 men who have sex with men (MSM) in the Zurich Primary HIV-Infection 
study, who initially presented with a primary HIV infection and were offered screening for 
sexually transmitted infection in this study were compared with 5105 MSM from the Swiss 
HIV Cohort study without a documented primary HIV infection. The outcome variable was 
defined as reporting condomless sex with occasional partner at least once after HIV diag-
nosis. All variables were included in the multivariable model.
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at risk of transmitting HIV through sexual contact [5, 35, 36]. 
The fact that 3 individuals were identified with acute HCV in-
fection reflects the current HCV epidemic affecting MSM, 
predominantly those coinfected with HIV, and it emphasizes the 
need for systematic HCV screening in the affected population 
[37].
Table 3. Association of Selected Factors With Any Sexually Transmitted Infection (STI) and Asymptomatic STI, Versus No STI
Factor Overall No STI Any STI P Valuea Asymptomatic STI P Valuea,b
Visits, No. 334 263 71 … 46 …
Age at STI diagnosis, me-
dian (IQR), y
33.8 (28.2–41.0) 33.8 (28.8–41.6) 33.2 (27.4–36.8) .28 33.2 (27.4–36.8) .39
Male sex, % 326 (97.6) 256 (97.3) 70 (98.6) 1 45 (97.8) 1
Time since HIV diagnosis, 
median (IQR), y
4.9 (2.3–7.9) 5.3 (2.7–8.2) 3.2 (1.5–6.5) .006 3.3 (1.8–6.4) .16
Year of HIV diagnosis year, 
median (IQR)
2010 (2007–2013) 2010 (2007–2013) 2012.0 (2009–2014) .009 2012 (2008–2013) .16
White ethnicity, % 311 (93.1) 248 (94.3) 63 (88.7) .19 41 (89.1) .36
Higher education, % 75 (22.5) 62 (23.6) 13 (18.3) .54 10 (21.7) .88
Risk group MSM, % 305 (91.3) 235 (89.4) 70 (98.6) .05 45 (97.8) .23
Stable partner, % 181 (54.2) 150 (57.0) 31 (43.7) .12 22 (47.8) .41
Sexual contact, % 321 (96.1) 250 (95.1) 71 (100.0) .14 46 (100.0) .39
Anal intercourse, % .03 .17
 No 55 (16.5) 52 (19.8) 3 (4.2) 2 (4.3)
 Receptive 50 (15.0) 37 (14.1) 13 (18.3) 7 (15.2)
 Insertive 33 (9.9) 26 (9.9) 7 (9.9) 6 (13.0)
 Both 196 (58.7) 148 (56.3) 48 (67.6) 31 (67.4)
Oral sex only, % 18 (5.4) 18 (6.8) 0 (0.0) .05 0 (0.0) .23
No. of sexual partners, me-
dian (IQR)
2.0 (1.0–4.8) 2.0 (1.0–4.0) 3.0 (2.0–6.5) <.001 3.5 (2.0–7.8) .004
Condomless sex, % 131 (39.2) 89 (33.8) 42 (59.2) .001 24 (52.2) .16
STI symptoms, % 48 (14.4) 24 (9.1) 24 (33.8) <.001 0 (0.0) .16
No. of symptoms, median 
(IQR)
0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–1.0) <.001 0.0 (0.0–0.0) .16
CD4 cell count at STI 
screen, median (IQR), 
cells/μL
696.0 (523.0–867.0) 707.0 (525.5–886.0) 605.5 (488.5–795.5) .09 602.0 (482.5–759.0) .17
CD4/CD8 cell count ratio, 
median (IQR)
1.2 (0.9–1.5) 1.2 (0.9–1.5) 1.1 (0.9–1.4) .14 1.0 (0.8–1.4) .23
Virally suppressed, % 308 (92.2) 244 (92.8) 64 (90.1) .54 42 (91.3) .88
History of syphilis, % 121 (36.9) 92 (35.5) 29 (42.0) .46 21 (46.7) .36
History of depression, % 99 (29.7) 81 (30.8) 18 (25.7) .54 12 (26.1) .73
Psychiatric history, % 82 (24.6) 71 (27.0) 11 (15.7) .12 7 (15.2) .23
Ever smoked, % 173 (52.6) 139 (53.7) 34 (48.6) .56 21 (45.7) .49
Any recent drug use, % 44 (13.2) 32 (12.2) 12 (17.1) .46 6 (13.0) .88
Binge drinking, % .54 .57
 Never 274 (84.8) 220 (85.9) 54 (80.6) 37 (80.4)
 Monthly or less 37 (11.5) 27 (10.5) 10 (14.9) 6 (13.0)
 Weekly or more 12 (3.7) 9 (3.5) 3 (4.5) 3 (6.5)
Housing, % .58 .88
 Alone 253 (84.9) 205 (85.8) 48 (81.4) 33 (82.5)
 With friends 37 (12.4) 27 (11.3) 10 (16.9) 6 (15.0)
 Other 8 (2.7) 7 (2.9) 1 (1.7) 1 (2.5)
Traveled to tropics, % 42 (12.6) 33 (12.5) 9 (12.9) >.99 8 (17.4) .49
Physical activity, % .12 .23
 Low 72 (21.6) 64 (24.3) 8 (11.4) 5 (10.9)
 Moderate 154 (46.2) 118 (44.9) 36 (51.4) 23 (50.0)
 High 107 (32.1) 81 (30.8) 26 (37.1) 18 (39.1)
BMI, median (IQR), kg/m2 23.5 (21.9–25.7) 23.7 (22.1–26.2) 22.7 (21.7–24.6) .07 23.2 (21.9–25.6) .49
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquartile range; MSM, men who have sex with men: STI, sexually transmitted infection.
aBenjamini-Hochberg adjustment for variables in the table. 
bCompared with no STI.
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In line with the literature, the majority (66%) of our patients 
with an STI did not report any symptoms at presentation and im-
mediately before STI testing. In recent years, a plethora of data 
have been published supporting the strategy to screen asymp-
tomatic sexually active individuals for STIs, especially in the 
MSM population [4, 8, 9, 11, 13, 23, 28, 30]. Because up to 90% of 
STIs are asymptomatic [23], a symptom-based testing approach 
would fail to both accurately detect STIs and interrupt the trans-
mission chain by prompt treatment. On the other hand, and 
as expected, symptoms were highly predictive of an STI in this 
high-risk population in the minority of cases in which they were 
reported.
In our multivariable model restricted to MSM, a longer time 
since HIV diagnosis and a higher √CD4 cell count were asso-
ciated with lower odds of a positive STI screening result. The 
negative—age-adjusted—association with the duration of HIV 
infection might indicate that individuals in whom HIV infec-
tion was diagnosed more recently have a higher sensitivity to 
safe-sex fatigue or a higher rate of STI treatment optimism [38] 
than those whose HIV infection was diagnosed in previous 
years. However, this hypothesis should be further investigated 
in future behavioral studies. The negative association of an STI 
with √CD4 cell count probably has no clinical significance be-
cause the median CD4 cell count even among patients with 
an STI was relatively high (605/μL). Moreover, a recent study 
with a large sample size did not find an association of √CD4 cell 
count with the hazard of contracting syphilis [5].
We found that engaging in anal intercourse, reporting con-
domless sex, and also reporting any recent drug use for inci-
dent STI, predicted a positive STI screening result. All of these 
variables are a proxy for risky sexual behavior and associated 
with a higher incidence of STIs in several studies [5, 13, 23, 30, 
34]. In line with the literature [13, 25], we found a strong asso-
ciation between incident STI and recent use of noninjectable 
Table 4. Incident Sexually Transmitted Infections By Self-Reported Drug 
Use in Past 6 Months (Men Who Have Sex With Men Only)
Self-Reported Drug 
Use
MSM, No. (%)
P Value
Adjusted 
P Valuea
Overall 
(n = 68)
No inci-
dent STI 
(n = 47)
Incident 
STI 
(n = 21)
Any recent drug use 10 (14.7) 2 (4.3) 8 (38.1) <.001 .003
Intravenous drug 
use
 Heroin 68 (100.0) 47 (100.0) 21 (100.0)
 Cocaine 68 (100.0) 47 (100.0) 21 (100.0)
 Other 1 (1.5) 0 (0.0) 1 (4.8) .31 .31
Noninjectable drug 
use
 Heroin 68 (100.0) 47 (100.0) 21 (100.0)
 Cocaine 5 (7.4) 0 (0.0) 5 (23.8) .002 .005
 Cannabis 4 (5.9) 0 (0.0) 4 (19.0) .007 .01
 Other 9 (13.2) 2 (4.3) 7 (33.3) .003 .006
Ecstasy 6 (8.8) 0 (0.0) 6 (28.6) <.001 .003
Gamma- 
hydroxybutyric 
acid 
4 (5.9) 0 (0.0) 4 (19.0) .007 .01
Poppers 6 (8.8) 2 (4.3) 4 (19.0) .07 .08
Abbreviations: MSM, men who have sex with men; STI, sexually transmitted infection.
aBenjamini-Hochberg adjustment for variables in the table.
Figure 2. A, Mixed model logistic regression for factors associated with a positive sexually transmitted infection (STI) screening (men who have sex with men [MSM] only). 
B, Cox Proportional hazard model for factors associated with incident STI (MSM only). Abbreviations: HIV, human immunodeficiency virus; STI, sexually transmitted infection.
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drugs, specifically noninjectable cocaine, psychotropic drugs, 
and cannabis. Although only 1 MSM reported intravenous drug 
use, we believe that some underreporting cannot be ruled out 
in our study population. Even though the use of certain drugs 
such as methamphetamine, mephedrone, and gamma-hy-
droxybutyrate/gamma-butyrolactone in combination with 
sex—often referred to as “chemsex”—was initially occurring 
predominantly in London [39], similar scenes have also set up 
in other European cities with an established gay culture, includ-
ing Switzerland [40]. Recently, local clusters of crystal meth-
amphetamine use in rural and urban areas in Switzerland have 
been reported [41].
Our study findings have several implications for clinical prac-
tice. First, a trimonthly STI screening can benefit MSM reporting 
sexually risky behavior and/or any recent drug use, regardless 
of symptoms. This is supported both by empirical data and by a 
modeling study of preexposure prophylaxis users showing that 
more intensive STI screening might substantially decrease the 
STI rate [42, 43]. Second, because most but not all diagnosed STIs 
affected the rectum, the STI screening should include all 3 ana-
tomic sites: rectum, pharynx, and urethra. A pooled STI screen-
ing is a promising way to reduce costs and promote acceptance of 
this approach by health insurers. Third, because the presence of 
symptoms was highly predictive for a positive STI screening result 
in our study, symptoms and signs compatible with an STI should 
trigger the prompt initiation of STI testing. Finally, consultations 
should be used to promote safer sex practices, because suppres-
sive ART does not replace condoms for protection from STIs in 
general. However, because all of our patients were counseled ac-
cordingly, the effect of additional counseling is questionable.
Our study has several strengths and limitations. One strength 
is that the prospective and longitudinal study design allowed us 
to calculate incidence rates. In addition, owing to the unique 
design of the SHCS and the ZPHI studies, we were able to test 
associations between STIs and a variety of risk and behav-
ioral factors. One limitation of the study is that, because of the 
change from a 3-site to a pooled screening approach, we could 
not assess the exact site of the infection during the whole study. 
However, this had no implication for the treatment of the STI or 
for identification of risk factors associated with STI prevalence 
and incidence.
In conclusion, we found a very high prevalence of asymp-
tomatic STIs in patients who initially presented with a primary 
HIV-1 infection, most of whom were treated with suppressive 
ART during the study. The significant associations of STIs with 
anal intercourse and the reporting of condomless sex or any re-
cent drug use could help identify a subgroup of high-risk MSM 
and prioritize screening and resource allocations.
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 Research in context 
 While current guidelines encourage the implementation of lifestyle changes before statin 
initiation for cardiovascular disease prevention, empirical data about the association of diet and 
exercise with total cholesterol in aging HIV positive individuals is absent.  
 To fill this gap, we interviewed 395 Swiss HIV Cohort participants older than 45 years old, 
using a validated Food-Frequency-Questionnaire and found that the combined consumption of 
refined/milled grains, meat, carbonated beverages and coffee exhibited positive association with 
total cholesterol. On the other hand, regular physical activity, exhibited a negative correlation. 
Importantly, forty percent of our sample reported very low level or absence of leisure physical 
activity. In summary, our data shows that physical activity can be substantially scaled up in this 
population. The reported dietary patterns carry an important prevention potential to achieve 
cardiovascular and other health benefits in HIV positive persons. 
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Dietary Patterns and Physical Activity Correlate With 
Total Cholesterol Independently of Lipid-Lowering Drugs 
and Antiretroviral Therapy in Aging People Living With 
Human Immunodeficiency Virus 
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Background. Hypercholesterolemia is a well established risk factor for coronary heart disease and is highly prevalent among 
human immunodeficiency virus (HIV)-positive persons. Antiretroviral therapy (ART) can both directly modify total cholesterol 
and have drug-drug interactions with statins. This makes investigating modifiable behavioral predictors of total cholesterol a perti-
nent task.
Methods. To explore the association between diet and physical activity with cross-sectionally measured total cholesterol, we 
administered a validated Food-Frequency-Questionnaire to participants of the Swiss HIV Cohort Study ≥45  years old. Linear 
mixed-effects models were applied to explore the associations between dietary patterns and physical activity with total cholesterol, 
after adjustment for clinical and demographic covariates.
Results. In total, 395 patients were included. Forty percent (158 of 395) had elevated total cholesterol (>5.2 mmol/L), and 41% 
(164 of 395) were not regularly physically active. In multivariable analysis, 2 factors were positively associated with total cholesterol; 
female sex (β = 0.562; 95% confidence interval [CI], 0.229–0.896) and the combined consumption of meat, refined/milled grains, 
carbonated beverages, and coffee (β = 0.243; 95% CI, 0.047–0.439). On the other hand, regular physical activity (β = −0.381; 95% 
CI, −0.626 to −0.136), lipid-lowering drugs (β = −0.443; 95% CI −0.691 to −0.196), ART containing tenofovir (β = −0.336; 95% CI 
−0.554 to −0.118), and black ethnicity (β = −0.967; 95% CI −1.524 to −0.410) exhibited a negative association.
Conclusions. We found independent associations between certain dietary patterns and physical activity with total cholesterol. 
Increasing physical activity might achieve cardiovascular and other health benefits in HIV-positive individuals. The clinical rele-
vance of the identified dietary patterns requires further investigation in prospective cohort studies and randomized controlled trials.
Keywords. aging; diet; HIV; physical activity; total cholesterol.
 
Although life expectancy in human immunodeficiency virus 
(HIV)-positive people on antiretroviral therapy (ART) has 
improved worldwide in recent years, it remains shorter in com-
parison with the general population [1].
Total cholesterol is a well established and low-cost marker 
of coronary heart disease (CHD), even across cultures [2]. 
A recent systematic review and meta-analysis showed that total 
cholesterol is a strong risk factor for CHD in the general pop-
ulation, with 1-mmol/L increase in total cholesterol associated 
with 20% higher risk of CHD in women and 24% in men [3].
Both HIV infection per se and its treatment may be asso-
ciated with high total cholesterol [4]. Certain ART agents are 
associated with a range of metabolic abnormalities—including 
HIV lipodystrophy, dyslipidemia, diabetes mellitus, and insulin 
resistance [5]—and contribute to the elevated risk of cardiovas-
cular disease (CVD) [6]. In addition, individuals who are HIV 
positive generally tend to have a higher rate of traditional risk 
factors for CVD such as smoking and hyperlipidemia [7].
Although statins can significantly reduce total choles-
terol, their use might present a challenge for HIV-positive 
patients due to drug-drug interactions with ART [8] and in 
light of the main treatment goal to achieve viral suppres-
sion, which often requires change of regimen. Moreover, 
older patients who are HIV positive have an elevated risk of 
polypharmacy [9].
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All this makes understanding the contribution of behavioral 
factors like dietary habits and physical activity a pertinent task 
which carries a possible prevention potential [10, 11], because 
both are modifiable risk factors. Although current guidelines 
encourage the implementation of lifestyle changes before statins 
initiation for CVD prevention [12], no empirical data about the 
association of diet and exercise with total cholesterol in aging 
HIV-positive individuals are available.
Therefore, the main aims of this study were as follows: (1) 
describe the predictors of total cholesterol in an aging HIV-
positive population living in a resource-rich setting; (2) describe 
the major dietary patterns of this population; (3) and examine 
whether behavioral determinants such as dietary patterns and 
physical activity independently correlate with total cholesterol 
after adjustment for highly active ART, lipid-lowering drugs, 
and other confounders.
METHODS
Swiss Human Immunodeficiency Virus Cohort Study
The Swiss HIV Cohort Study (SHCS) is a large, ongoing, mul-
ticenter cohort study of HIV-positive individuals with a pro-
spective recruitment since 1988 [13]. During the biannual 
outpatient visits, comprehensive clinical and behavioral data 
(including leisure physical activity) are collected. The patients 
described in this study are all enrolled in the SHCS nested 
project “Metabolism and Aging”, which includes participants 
≥45 years of age undergoing dual energy x-ray absorptiometry 
scan, neurocognitive testing, and in the 2 centers of Zurich and 
Geneva additionally coronary computed tomography scan. 
For this project, Metabolic and Aging study participants of 
the Zurich, Berne, and Geneva centers were enrolled. Ethical 
approval of the SHCS and written informed consent from all 
participants were obtained upon cohort enrollment.
Dietary Assessment
Information on diet was obtained by a short and validated 
Food-Frequency Questionnaire (FFQ). This qualitative FFQ 
was originally used in the large INTERHEART study conducted 
in 52 countries [14] and was administered thereafter in several 
other large international studies [15, 16]. In this questionnaire, 
participants are asked, “In the last 12 months, how often did 
you consume foods from each of the following categories?” 
A  list of 23 broad food categories is then presented, and the 
subject states the number of consumed items per month, week, 
or day. Because this FFQ was designed for use in international 
studies, it contains all of the main food groups, ie, dairy, meat, 
fish, fruits, and vegetables, and has been found to be applic-
able to different countries despite regional dietary differences 
[14]. Although we intentionally kept the original questionnaire 
intact to maintain its validity, we added a short supplementary 
part that gathered additional information about the following: 
(1) dietary supplements (vitamins, minerals, etc); (2) coffee 
and tea consumption; and (3) major dietary change in the last 
2 years. Data about alcohol consumption are regularly gathered 
in the SHCS. The FFQ interviews were conducted by phone by 
a trained staff and were collected using the REDCap electronic 
data capture tool [17] hosted at University Hospital Zürich.
Statistical Analysis
To assess the dietary patterns, first, all food items were con-
verted into daily consumption. Then, Ward error sum of 
squares hierarchical clustering method [18, 19] was used with 
1-Kendall’s tau correlation matrix as an input. Based on the 
classification output, the 4 largest and most general food clus-
ters were extracted, and for each person the sum of the con-
sumption frequency of food items that belong to each of the 4 
clusters was calculated separately. In other words, each person 
received 4 score variables (pattern I to pattern IV) that reflected 
the cumulative consumption frequency of the food items for 
each pattern.
Linear mixed-effects model with per center random intercept 
was used to assess the correlation between dietary patterns and 
total cholesterol. The closest available total cholesterol measure-
ment to the dietary assessment was used regardless of fasting 
state. Fasting state during the measurement was adjusted for 
in the multivariable models. Two multivariable models were 
explored: (1) the minimally adjusted model, only for age, sex, 
risk group, physical activity, ART, lipid-lowering drugs, and 
fasting state; and (2) the model that was adjusted for the covar-
iates in model I  plus additional demographical and clinical 
covariates (ethnicity, university education, living alone, smok-
ing, depression, diabetes, hypertension, number of years on 
ART, recent dietary change, multivitamin supplement, Omega 
3 supplement, protein powder supplement) (Figure 4). Because 
the cumulative consumption scores were skewed to the right, 
they were ln(x+1) transformed. Benjamini-Hochberg adjust-
ment for multiple testing was performed for the correlation 
matrix (Figure 2) but not for the multivariable analysis, due to 
limited power. Statistical analysis was performed with R (ver-
sion 3.3.2).
RESULTS
Patients
In total, from June 2016 until October 2017, of 539 eligible 
participants 395 (73.3%) were interviewed for the study, the 
remaining either refused to participate (n = 31, 5.8%), could not 
be reached on at least 5 different occasions (n = 111, 20.6%), or 
provided incomplete response (n = 2). The median age of the par-
ticipants was 55.7 years (interquartile range [IQR], 52.2–60.8), 
the majority were male (85.6%, 338 of 395), of white ethnicity 
(94.4%, 373 of 395), and belonged to the men-who-have-sex-
with-men (MSM) risk group (59%, 233 of 395) (Table 1). A total 
of 11.6% (46 of 395) were obese and 32.4% (128 of 395) were 
overweight. The median time on ART was 14.2 years (IQR, 8.8–
20.4), and the median most recent CD4 value was 648 cells/µL 
(IQR, 494.5–816.0). The vast majority of patients (95.9%, 379 
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of 395) were virally suppressed with HIV viral load below 50 
copies/mL.
Dietary Patterns
First, we aimed to explore which food groups correlate and 
cluster with each other. In other words, when patients con-
sume one food group, which other food groups they are likely 
to consume as well (positive association) or on the other hand 
to avoid (negative association). Hierarchical clustering ana-
lysis suggested 4 distinct metapatterns (Figure  1, Figure  2): 
(Pattern I) “Meat,” “Refined/ milled grains,” “Carbonated 
beverages,” “Coffee” - This pattern positively correlated with 
smoking, with 21.4% (22 of 103)  of smokers in the lowest 
quartile and 45.8% (44 of 96) of smokers in the highest quartile 
(Fisher’s exact test, P < .001) (Supplementary Table 1); (Pattern 
II) “Organ meats,” “Poultry,” “Fish/seafood,” “Alcohol” - 
Pattern II negatively correlated with female sex, with 26.7% 
(27 of 101) females in the lowest quartile and 8.2% (8 of 97) in 
the highest consumption quartile (Fisher’s exact test, P = .001) 
(Supplementary Table 2); (Pattern III) “Whole grains,” “Dairy 
products,” “Eggs,” “Leafy green vegetables,” “Other vegetables 
(raw),” “Other vegetables (cooked),” “Legumes/nuts/seeds,” 
“Potatoes, boiled/mashed,” “Pickled food,” “Fruits,” “Tea 
(Black/Green)” - Pattern III was positively associated with 
university education with 9.1% (9 of 99)  having university 
education in the lowest quartile versus 22.2% (22 of 99) in the 
highest (Fisher’s exact test, P = .018) and was negatively asso-
ciated with smoking with 45.5% (45 of 99) smokers in the low-
est quartile and 20.2% (20 of 99) in the highest consumption 
quartile (Fisher’s exact test, P < .001) (Supplementary Table 3); 
(Pattern IV) “Pizza,” “Deep fried foods,” “Salty snacks,” “Ice 
cream/pudding,” “Desserts/sweet snacks,” “Confectionary 
sugars/syrups,” “Fruit juice/drinks” - This pattern was nega-
tively associated with diabetes, hypertension, and lipid-low-
ering drugs (Fisher’s exact test, P  =  .016, .011, and .014, 
respectively), suggesting that patients diagnosed with these 
conditions tend to avoid junk food (Supplementary Table 4).
Noteworthy pairwise negative associations (Figure  2) were 
as follows: patients who consumed fruits more frequently 
consumed less frequently meat, refined/milled grains, and 
carbonated beverages. Coffee and tea were also negatively cor-
related (Kendall’s tau −0.19, adjusted P < .001), suggesting that 
when it comes to regular consumption, some patients tend to 
prefer either one or the other. Next, we explored separately 
the frequency of meat consumption; only 3.3% (13 of 395) of 
the participants reported to completely avoid meat and organ 
meats, and only 5 patients were lacto-ovo-vegetarian (1.3%, 5 
of 395) avoiding meat, organ meats, poultry, and fish.
Examining the total daily consumption frequency stratified 
by pattern (Figure 3) shows that the most frequently consumed 
pattern is the apparently healthier pattern III (mean = 6.5, stand-
ard deviation [sd] = 3.3), followed by pattern I  (mean = 4.6, 
sd =  3.1), pattern IV (mean =  1.8, sd =  1.1), and pattern II 
(mean = 0.7, sd = 0.4).
Physical Activity
Thirty-one percent (124 of 395) of the patients reported not 
to perform any leisure physical activity. Ten percent (40 of 
395)  reported physical activity frequency of 1 to 4 times a 
month, 21% (81 of 395) reported physical activity 1 to 2 times a 
week, and the largest group (38%, 150 of 395) reported physical 
activity 3 or more times per week.
Table 1. Patient Characteristics
Characteristics Overall
n 395
Age (median [IQR])  55.7 [52.2–60.8]
Sex, female (%)  57 (14.4)
Ethnicity (%)
 White  373 (94.4)
 Black  15 (3.8)
 Hispanic  7 (1.8)
Risk Group (%)
 Heterosexual  108 (27.3)
 Men who have sex with men  233 (59.0)
 Injecting drug users  24 (6.1)
 Other  30 (7.6)
University education, yes (%)  55 (13.9)
Living alone, yes (%)  162 (41.0)
Current smoking, yes (%)  126 (31.9)
BMI (%)
 Normal (≥18.5–25)  212 (53.7)
 Overweight (≥25–30)  128 (32.4)
 Obese (≥30)  46 (11.6)
 Underweight (<18.5)  9 (2.3)
Depression, yes (%)  59 (14.9)
Diabetes, yes (%)  23 (5.8)
Hypertension, yes (%)  135 (34.2)
Lipid-lowering drugs, yes (%)  98 (24.8)
Virally suppressed, yes (%)  379 (95.9)
CD4 (median [IQR]) 648.0 [494.5–816.0]
Years on ART (median [IQR])  14.2 [8.8–20.4]
On NRTI, yes (%)  320 (81.0)
On NTRTI, yes (%)  192 (48.6)
On NNRTI, yes (%)  117 (29.6)
On PI, yes (%)  107 (27.1)
On INTI, yes (%)  227 (57.5)
Physical activity (%)
 Never  124 (31.4)
 1–4 times a month  40 (10.1)
 1–2 times a week  81 (20.5)
 ≥3 times a week  150 (38.0)
Dietary Change in the Last 2 Years (%)
 No  360 (91.1)
 Became vegetarian  3 (0.8)
 Other change  32 (8.1)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; INTI, integrase inhibitor; 
IQR, interquartile range; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, 
nucleoside reverse-transcriptase inhibitor; NTRTI, nucleotide reverse-transcriptase inhibi-
tor; PI, protease inhibitor.
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Total Cholesterol
The median total cholesterol value was 5 mmol/L (sd = 1.1). 
Forty percent (158 of 395) of participants were above the cut-
off of 5.2 mmol/L, and 13.1% (51 of 395) were above the cutoff 
of 6.2 mmol/L (Supplementary Figure 1). Lipid-lowering drugs 
were prescribed in 24.8% of the participants (98 of 395).
Factors Associated With Total Cholesterol
Next, we examined the factors that correlate with total chol-
esterol. In the first multivariable model (Model I; Figure  4), 
physical activity at least 3 times a week compared with none 
(β = −0.274; 95% confidence interval [CI], −0.519 to −0.029), 
lipid-lowering drugs (β = −0.458; 95% CI, −0.703 to −0.212), 
ART including a nucleotide reverse-transcriptase inhibitor 
(NtRTI) (β = −0.344; 95% CI, −0.565 to −0.123), and intrave-
nous drug users (IDU) risk group (β = −0.705; 95% CI, −1.168 
to −0.242) were negatively correlated with total cholesterol. 
On the other hand, female sex (β =  0.487; 95% CI, 0.147 to 
0.827) and dietary pattern I (“Meat,” “Refined/ milled grains,” 
“Carbonated beverages,” “Coffee”)—but not the other 3 pat-
terns—positively correlated with total cholesterol (β =  0.276; 
95% CI, 0.082–0.471; P = .007).
After additionally adjusting for a wide range of demographic 
and clinical covariates (Model II; Figure 4), lipid-lowering drugs 
(β = −0.443; 95% CI, −0.691 to −0.196), NtRTI (β = −0.336; 95% 
CI, −0.554 to −0.118), and regular physical activity (β = −0.381; 
95% CI, −0.626 to −0.136) remained negatively correlated with 
total cholesterol, in addition to black ethnicity (β = −0.967; 95% 
CI, −1.524 to −0.410), IDU risk group (β =  −0.708; 95% CI, 
−1.175 to −0.241), living alone (β = −0.236; 95% CI, −0.436 to 
−0.035), and taking a multivitamin (β = −0.378; 95% CI, −0.730 
to −0.027). On the other hand, female sex (β = 0.562; 95% CI, 
0.229–0.896) and dietary pattern I (β = 0.243; 95% CI, 0.047–
0.439; P = .02) remained positively and significantly correlated 
with total cholesterol even after adjustment for the additional 
covariates in Model II.
Sensitivity Analysis
As a sensitivity analysis, we repeated the multivariable analysis 
(Model I excluding lipid-lowering drugs) separately for patients 
on and off lipid-lowering drugs (Supplementary Table 5). For 
patients on lipid-lowering drugs, frequent physical activity 
(β = −0.732; 95% CI, −1.166 to −0.232), NtRTI (β = −0.546; 95% 
CI, −0.980 to −0.076), and IDU risk group (β = −1.148; 95% CI, 
−2.023 to −0.278) negatively correlated with total cholesterol. 
None of the covariates, including dietary pattern I (β = 0.352; 
95% CI, −0.039 to 0.747; P = .115), significantly positively cor-
related with total cholesterol among patients on lipid-lowering 
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Figure 2. Correlation matrix of the examined food items. Squares with “X” are not statistically significant after adjustment for multiple testing.
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Figure 3. Boxplot of total daily consumption stratified by dietary patterns. Pattern I: meat, refined/milled grains, carbonated beverages, coffee. Pattern II: organ meats, poultry, 
fish/seafood, alcohol. Pattern III: whole grains, dairy products, eggs, leafy green vegetables, other vegetables (raw and cooked), legumes/nuts/seeds, potatoes, boiled/mashed, 
pickled food, fruits, tea (black/green). Pattern IV: pizza, deep fried foods, salty snacks, ice cream/pudding, desserts/sweet snacks, confectionary sugars/syrups, fruit juice/drinks.
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drugs; however, the limited statistical power of this subgroup 
analysis should be taken into account.
Among patients not on lipid-lowering drugs, none of the 
covariates were significantly negatively associated with total 
cholesterol. On the other hand, dietary pattern I  and female 
sex remained significantly positively correlated with total chol-
esterol in people not on lipid-lowering drugs (β = 0.234, 95% 
CI = 0.011–0.457, P = .047 and β = 0.574, 95% CI = 0.198–0.949, 
P = .004, respectively).
High-Density Lipoproteins and Triglycerides
Finally, to obtain a more complete picture on factors associated 
with dyslipidemia in general, we also explored the fully adjusted 
model with high-density lipoproteins (HDL) and triglycerides 
as outcomes. For HDL, age (β = 0.012; 95% CI, 0.006–0.019) 
and female sex (β = 0.474; 95% CI, 0.331–0.615) showed a posi-
tive association, whereas having hypertension (β = −0.132; 95% 
CI, −0.227 to −0.036) and ART regimen with protease inhibi-
tors (β = −0.121; 95% CI, −0.224 to −0.018) exhibited a negative 
correlation. None of the remaining variables, including physical 
activity and the examined 4 dietary patterns, showed any signif-
icant correlation. For triglycerides, diabetes (β = 0.730; 95% CI, 
0.144–1.367), hypertension (β = 0.371; 95% CI, 0.045–0.690), 
nonnucleoside reverse-transcriptase inhibitors (β = 0.480; 95% 
CI, 0.131–0.822), protease inhibitors (β = 0.695; 95% CI, 0.342–
1.038), and integrase inhibitors (β  =  0.589; 95% CI, 0.259–
0.891) showed positive association, whereas age (β =  −0.024; 
95% CI, −0.045 to −0.001), female sex (β =  −0.554; 95% CI, 
Age
Female sex, vs. Male
Risk group: MSM vs. HET
Risk group: IDU vs. HET
Risk group: Other vs. HET
On NRTI, yes vs. no
On NTRTI, yes vs. no
On NNRTI, yes vs. no
On PI, yes vs. no
On INTI, yes vs. no
Physical activity 1–4 times a month vs. none
Physical activity 1–2 times a week vs. none
Physical activity ≥3 times a week vs. none
Univariable Model I Model II
Lipid lowering drugs, yes vs. no
Dietary pattern I
Dietary pattern II
Dietary pattern III
Dietary pattern IV
Fasting cholesterol, yes vs. no
–1 –0.5 0
Coefficient
0.5 1
Figure 4. Factors that correlate with total cholesterol, univariable and 2 linear mixed-effect models. Model I was adjusted for all the covariates in the figure. Model II was 
adjusted for all covariates in the figure and additionally for ethnicity, university education, living alone, smoking, depression, diabetes, hypertension, number of years on 
antiretroviral therapy, recent dietary change, multivitamin supplement, Omega 3 supplement, protein powder supplement. Dietary patterns consumption frequencies were 
ln(x+1) transformed. Pattern I: meat, refined/milled grains, carbonated beverages, coffee. Pattern II: organ meats, poultry, fish/seafood, alcohol. Pattern III: whole grains, dairy 
products, eggs, leafy green vegetables, other vegetables (raw and cooked), legumes/nuts/seeds, potatoes, boiled/mashed, pickled food, fruits, tea (black/green). Pattern IV: 
pizza, deep fried foods, salty snacks, ice cream/pudding, desserts/sweet snacks, confectionary sugars/syrups, fruit juice/drinks. Abbreviations: ART, antiretroviral therapy; 
HET, heterosexual; IDU, injecting drug users; INTI, integrase inhibitor; MSM, men who have sex with men; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, 
nucleoside reverse-transcriptase inhibitor; NTRTI, nucleotide reverse-transcriptase inhibitor; PI, protease inhibitor.
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−1.009 to −0.047), MSM risk group (β  =  −0.455; 95% CI, 
−0.836 to −0.036), IDU risk group (β = −1.213; 95% CI, −1.886 
to −0.540), living alone (β = −0.332; 95% CI, −0.630 to −0.051), 
and physical activity of at least 3 times per week (β = −0.389; 
95% CI, −0.764 to −0.058) were negatively associated with tri-
glycerides. In contrast to physical activity, none of the dietary 
patterns exhibited a significant association with triglycerides in 
our fully adjusted model.
DISCUSSION
In this analysis of HIV-positive individuals ≥45 years old pre-
dominantly on suppressive ART, we found several factors that 
were independently correlated with total cholesterol: female sex 
and the frequency of combined consumption of meat, refined/
milled grains, carbonated beverages, and coffee (dietary pattern 
I) showed positive correlation. On the other hand, regular phys-
ical activity, lipid-lowering drugs, an ART regimen containing 
tenofovir, and black ethnicity exhibited a negative correlation. 
In the analysis restricted to patients not on lipid-lowering 
drugs, total cholesterol remained associated with dietary pat-
tern I  (meat, refined/milled grains, carbonated beverages, 
coffee), supporting current guidelines that encourage imple-
mentation of lifestyle and dietary changes before statin initi-
ation [12]. In participants on lipid-lowering drugs, there was 
an additional benefit of physical activity, beyond the effect of 
lipid-lowering drugs.
It has been previously shown that people living with HIV 
consume more saturated fat and cholesterol compared with 
HIV-negative individuals [20]. It was also demonstrated that 
tackling HIV dyslipidemia with diet is feasible [10]. In a system-
atic review and meta-analysis of the effects of dietary interven-
tion on HIV dyslipidemia, dietary intervention reduced total 
cholesterol by −0.36 mmol/L compared with placebo/control 
[21]. However, no study was performed on a predominantly 
aging HIV-positive population.
Several previous studies in the general population demon-
strated associations between individual food items that 
comprise pattern I in our study and total cholesterol or cardio-
vascular risk. In a prospective cohort study of 31 546 high-risk 
individuals from 40 countries, meat, poultry, and egg consump-
tion were independently correlated with composite outcome of 
cardiovascular death, nonfatal myocardial infarction, nonfa-
tal stroke, or hospitalization for congestive heart failure [15]. 
Although in our analysis meat indeed clustered in pattern I, 
poultry and eggs clustered in different patterns.
Our results are biologically plausible because most meat 
products contain saturated fat that increases cholesterol [22]. 
In addition, almost all meat products contain cholesterol by 
itself [23, 24]. Frequency of coffee consumption also clus-
tered with pattern I and is also supported by previous works. 
In a meta-analysis of 14 clinical trials, a dose-response relation 
between coffee consumption and both total cholesterol and 
low-density lipoprotein cholesterol was identified [25]. The 
effect was weak for filtered coffee; however, most of the coffee 
that is consumed in Switzerland is unfiltered.
The observation that pattern III that contained vegetables, 
legumes, and fruits positively correlated with higher education 
and negatively correlated with smoking is consistent with the 
well established association between education and health liter-
acy [26]. This might also suggest that patients with low educa-
tion could benefit most from dietary counseling.
The beneficial effect of regular exercise on cholesterol is well 
established. For example, in a randomized controlled trial from 
the UK, in which participants were asked to maintain their nor-
mal dietary habits, high-intensity exercise program for 24 weeks 
resulted in significant decreases in total cholesterol (mean 
change, −0.55 ± 0.81 mmol/L) [27]. Forty percent of our sam-
ple reported physical activity of 1 to 4 times a month or never, 
hence not meeting the World Health Organization (WHO) 
guidelines of 150 minutes of moderate-intensity aerobic phys-
ical activity throughout the week [28]. This suggests that there 
is considerable room for improvement in this area, especially 
because the benefits of physical activity extend beyond cardio-
vascular risk factors and also include prevention of dementia 
[29], depression, and anxiety [30]. Data about the benefits of 
physical activity for HIV dyslipidemia is scarce [31], especially 
in aging HIV-positive population.
The strengths of our study include the use of a popula-
tion-based cohort, the SHCS, with a large array of prospectively 
collected clinical and laboratory data, enabling us to adjust for 
many important clinical and demographic potential confound-
ers. Patients from 3 different study centers across Switzerland 
were included, hence increasing generalizability. Moreover, 
nutrition data were assessed by a well validated questionnaire 
used in large studies in the general population.
Our study also has limitations. Inherent to cross-sectional 
studies, there is a lack of temporality [32]. Due to the observa-
tional study design, and in light of the fact that there are many 
potential confounders associated with dietary patterns, physical 
activity and total cholesterol levels, we cannot rule-out residual 
confounding for which we could not account. Another limita-
tion is that the FFQ measured frequency but not quantity of 
consumption [15]. Finally, due to collinearity between food 
items within the same consumption pattern, it was not possi-
ble to examine the effect of single food items. Nevertheless, our 
results are in line with large cohort studies, randomized con-
trolled trials, and meta-analysis [15, 25, 27].
Future studies are needed to illuminate the effect of type of fat 
intake (saturated fat, monounsaturated fat, and polyunsaturated 
fat) on dyslipidemia and on the association between dietary 
patterns and hard endpoints such as cardiovascular morbidity 
and mortality. The most beneficial type of physical activity in 
terms of adherence and cardiovascular benefit for this popula-
tion is also yet to be determined.
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CONCLUSIONS
In summary, our cross-sectional study suggests that there are 
independent associations between certain dietary patterns and 
physical activity with total cholesterol. Physical activity should 
be substantially scaled up in this population to meet WHO 
guidelines and to achieve cardiovascular and other health ben-
efits. The reported dietary patterns pave the way for further 
investigations in prospective cohort studies and randomized 
controlled trials.
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 CONCLUSION 
 In 2016, for the first time, the total number of HIV cases in the WHO European Region 
surpassed two million. According to the latest WHO/ECDC report 153,407 people were newly 
diagnosed with HIV in 50 countries of the Region in 20151.  However, the epidemic drivers remain 
different in Western and in Eastern parts of Europe. In Western Europe, the epidemic is continued 
to be fueled by Men-who-have-Sex-with-Men. In this thesis, we could shed light on the importance 
of transmission during recent infection and after treatment interruption among Swiss MSM. We 
also critically characterized the prescription practices of Post-Exposure-Prophylaxis, which is 
commonly used by MSM, in a study that might improve future prevention.  In contrast to Western 
Europe, the main driver of transmission in Eastern Europe are people-who-inject-drugs. 
Astonishingly, the number of AIDS cases in this area increased by 80% in 10 years2. Since 
Switzerland experienced an epidemic of opioid addiction in the 1980s, we could gain insights that 
might be potentially relevant to HIV prevention in Eastern Europe as well, by demonstrating the 
essential role that harm reduction played in HIV containment both among injecting-drugs-users 
and the general population. This thesis did however not only concentrate on the prevention of HIV 
infection, but also on improving the health of people that already live with the virus. This was done 
on two main levels: (i) We showed high rates of asymptomatic STIs and risky sexual behavior in 
patients initially presenting with primary HIV-1 infection, found epidemiological risk factors for 
STIs, and suggested that screening might have to be intensified. (ii) We described nutrition and 
physical activity habits of aging people living with HIV and correlated this data with total 
cholesterol with the intention to facilitate prevention of coronary heart disease. 
 In summary, in this thesis, we intended to contribute to various aspects of HIV 
epidemiology and clinical practice, with a hope to improve prevention efforts and treatment. 
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Supplementary Text I 
For each SHCS participant a seroconversion date (infection date) was estimated based on 
the following hierarchical algorithm: 
(i) The top priority was given to the SHCS participants who were also members of the 
Zurich Primary HIV Infection Study (ZPHI). For these patients the estimated date 
of infection as defined in the ZPHI was used as the infection date (see [1, 2] for the 
definition of this date). 
(ii)  Provided the patient was not a member of the ZPHI (which was the case for 
98.4% of the SHCS participants) the next priority was given to the documented 
primary infection as recorded by the physicians in the SHCS. In this case, the date 
of primary infection diagnosis was used as seroconversion date. Primary infection 
diagnosis by the physicians in the SHCS was based on one of the following 
criteria: 1. Exposure to HIV within the last three months and clinical 
documentation or history of signs and/or symptoms suggestive of acute retroviral 
syndrome (such as acute febrile mononucleosis like syndrome with 
lymphadenopathy or rash or pharyngitis or aphthous ulceration or meningo 
encephalitis or myalgia or hepatitis) and a documented negative HIV antibody test 
within the last six months and detectable HIV-RNA in serum or plasma. 2. 
Detectable p24 Antigen or HIV-RNA and a negative or borderline HIV antibody 
test converting to reactive. 
(iii) If no data was available to fulfill conditions (i) and (ii) the midpoint date between 
the last HIV negative date and the earliest HIV positive date was calculated 
provided that this time interval did not exceed three years (to reduce 
misclassification bias). 
(iv) Finally, if there was no data available to fulfill conditions (i), (ii), (iii) but there 
was an available, therapy naïve, genotypic drug resistance test for the patient of 
interest, then the fraction of the ambiguous nucleotides in the earliest sequences 
was calculated. Previous work has shown that most HIV infections are established 
by a single virus which subsequently diversifies [3]. Based on this, Kouyos et al. 
[4] showed that the percentage of ambiguous nucleotides (i.e. other than A/T/G/C) 
in the genotypic resistance test sequences, positively correlates with the disease 
progression stage. Hence, based on previous studies we have chosen the cutoff of 
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0.5% for distinction between recent and chronic phase of the infection [4]. To 
reduce misclassification bias, this was done only for patients for whom the first 
CD4 count value was above 250 and the time interval between the first sequence 
and HIV diagnosis was lower than three years. In this case the time of HIV 
diagnosis was used as a proxy for the seroconversion date.  
 
Supplementary Text II 
Phylogenetic tree construction 
The phylogenetic maximum-likelihood Generalized Time-Reversible (GTR) model 
based tree was constructed with an overall of 110,598 HIV-1 nucleotide pol open-reading-
frame protease and reverse-transcriptase (RT) sequences. These were comprised of 19,604 
sequences from 10,970 different SHCS cohort participants and additional 90,994 sequences 
from the Los Alamos (http://www.hiv.lanl.gov/) database which were included to decrease the 
chances of a false-positive random clustering. All the available, non-Swiss, pol sequences 
(region: 2253-3870) with a minimal length of 900 bp as to September 2014 were retrieved. 
Redundant control sequences (different sequence id but an identical nucleotide composition) 
were deduplicated. For the SHCS patients only sequences with a minimum length of 250 bp 
for the protease gene and 500 bp for the RT gene were included.  
All the sequences were initially aligned to a HXB2 reference genome 
(http://www.ncbi.nlm.nih.gov/nuccore/K03455.1) using the MUSLCE [5]. Next, insertions 
relatively to HXB2 and resistance mutations according to Stanford: http://hivdb.stanford.edu/ 
and International AIDS Society https://www.iasusa.org/ lists were removed. In the following 
step, one hundred maximum-likelihood GTR-model-based bootstrapped trees were 
constructed using SEQBOOT[6] and FastTree[7]. Finally, node support values were 
generated based on 100 bootstrapped trees and the reference (non-bootstrapped alignment) 
tree using the “CompareToBootstrap” script. Following the tree construction, tips that 
corresponded to various pairwise minimal patristic genetic distance (1%, 1.5%, 2%, 2.5%) 
and the bootstrap (50% to 100% by increment of 2%, of the deepest node) thresholds were 
defined as potential transmission pairs and were extracted using custom scripts. The R 
package “APE” version 3.1 was implemented for tree exploration and analysis [8].  
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Supplementary Figure 1. Example of potential transmission events during recent (panel A) 
and chronic (panel B) HIV infection as represented on the phylogeny. The tips of the tree 
represent HIV sequences from different patients, SHCS patients are designated by A-D 
letters. The numbers at the tree nodes represent the bootstrap percent (red) for each node. Δt 
represents the time interval between the seroconversion dates of the pair members. The 
cophenetic genetic distance within pair A-B and C-D is 0.1% and 0.6%, respectively. 
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Supplementary Table 1. Logistic regression analysis for being chronic (>1 year since seroconversion, coded as 1) versus  recent (<=1 year since 
seroconversion, coded as 0) phylogenetically linked HIV transmitter. N=255 transmitters (complete cases, 144 chronic and 111 recent), Bootstrap 
50%, genetic distance 1.5%. Abbreviations: C.I, confidence interval; OR, odds ratio; ART, antiretroviral therapy; VL AUC, viral load area under 
the curve.  
 Bivariate OR (95% C.I) P-value Multivariable OR (95% C.I) P-value 
Age at infection 0.98 (0.95-1) 0.06 0.99 (0.96-1.02) 0.531 
Sex 
    
Male (Ref.) 
    
Female 1.13 (0.58-2.2) 0.721 1.46 (0.51-4.15) 0.48 
Risk group 
    
Men who have sex with men (Ref.) 
    
Heterosexuals 1.36 (0.77-2.37) 0.287 1 (0.36-2.73) 0.997 
Injection drug users 0.77 (0.36-1.64) 0.496 0.6 (0.18-2.03) 0.409 
Subtype 
    
Non-B (Ref.) 
    
B 1.18 (0.66-2.1) 0.574 0.98 (0.44-2.2) 0.959 
√CD4 counts a 1.03 (0.99-1.07) 0.216 0.94 (0.89-0.99) 0.024 
Transmission year 1.01 (0.96-1.05) 0.792 1.14 (1.06-1.24) 0.001 
Time to ART (years) 1.3 (1.16-1.46) <0.0001 1.22 (1.05-1.43) 0.01 
Chronic RNA VL AUC 2.22 (1.64-3.01) <0.0001 2.74 (1.77-4.26) <0.0001 
112
a At baseline before treatment 
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Supplementary Figure 2. Example of potential post-ART transmission in which the infection window of the recipient (red vertical lines, see 
methods for definitions) overlaps with the ART-start-date (dashed blue line) of the transmitter (A). The black lines depict the viral load 
measurements of a hypothetical transmitter. In this scenario, the transmission occurred either briefly before or after the initiation of ART. (B) The 
antiretroviral therapy was started before the lower bond of the infection window of the recipient (no overlap), hence in this scenario there is a high 
degree of certainty that the transmission occurred after ART was initiated by the transmitter.  
 
 
  
114
 References 
 
1. Braun DL, Kouyos R, Oberle C, et al. A novel Acute Retroviral Syndrome Severity Score 
predicts the key surrogate markers for HIV-1 disease progression. PloS one 2014; 9(12): 
e114111. 
2. Rieder P, Joos B, Scherrer AU, et al. Characterization of human immunodeficiency virus type 
1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of America 2011; 53(12): 
1271-9. 
3. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes 
associated with the progression of human immunodeficiency virus type 1 infection. Journal of 
virology 1999; 73(12): 10489-502. 
4. Kouyos RD, von Wyl V, Yerly S, et al. Ambiguous nucleotide calls from population-based 
sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of America 2011; 52(4): 
532-9. 
5. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. 
Nucleic Acids Research 2004; 32(5): 1792-7. 
6. Felsenstein J. PHYLIP (Phylogeny Inference Package) version 3.6. Distributed by the author. 
Department of Genome Sciences, University of Washington, Seattle, 2005. Eﬃciently Finding 
the Most Parsimonious Phylogenetic Tree 47. 
7. Price MN, Dehal PS, Arkin AP. FastTree: Computing Large Minimum Evolution Trees with 
Profiles instead of a Distance Matrix. Molecular Biology and Evolution 2009; 26(7): 1641-50. 
8. Paradis E, Claude J, Strimmer K. APE: analyses of phylogenetics and evolution in R 
language. Bioinformatics 2004; 20(2): 289-90. 
 
115
 Supplementary Material:  Chapter II:  “Prescription of Postexposure Prophylaxis for HIV-1 in 
the Emergency Room: Correct Transmission Risk Assessment Remains Challenging” 
 
 
   
  
116
1	
	
	
Supplementary Table 1. Demographic data and sexual history divided by PEP decision 
classification. 
	
 Overall Prescribed-
and-
indicated 
Prescribed-
while-not-
indicated 
Not-
prescribed-
and-not 
indicated 
Not-
prescribed-
while-
indicated 
 
P 
n 1051 485 125 294 101  
Age (median [IQR]) 32.0       
[26.0, 38.0] 
33.0            
[27.0, 38.0] 
31.0             
[25.0, 37.0] 
30.0            
[25.0, 36.0] 
32.0         
[26.0, 39.0] 
<0.001 
Sex, female (%) 179 (17.0) 31 (  6.4) 46 ( 36.8) 95 ( 32.3) 5 (  5.0) <0.001 
Swiss nationality (%) 746 (71.0) 349 ( 72.0) 95 ( 76.0) 195 ( 66.3) 76 ( 75.2) 0.125 
MSM  (%) 393 (37.4) 278 ( 57.3) 5 (  4.0) 56 ( 19.0) 48 ( 47.5) <0.001 
>1 PEP visit  (%) 140 (13.3) 86 ( 17.7) 11 (  8.8) 24 (  8.2) 12 ( 11.9) 0.001 
Weekend (%) 451 (42.9) 214 ( 44.1) 48 ( 38.4) 133 ( 45.2) 36 ( 35.6) 0.245 
Hours since exposure 
(median [IQR]) 
20.0       
[10.0, 42.0] 
18.0              
[9.0, 35.0] 
19.0             
[11.0, 43.5] 
24.0            
[10.0, 57.5] 
24.0         
[10.0, 48.0] 
<0.001 
Day time (%)      0.143 
   Midnight-6 AM 181 (17.2) 85 ( 17.5) 18 ( 14.4) 52 ( 17.7) 19 ( 18.8)  
   6 AM - Noon 182 (17.3) 102 ( 21.0) 25 ( 20.0) 36 ( 12.2) 15 ( 14.9)  
   Noon- 6 PM 376 (35.8) 170 ( 35.1) 44 ( 35.2) 106 ( 36.1) 35 ( 34.7)  
   6 PM- Midnight 312 (29.7) 128 ( 26.4) 38 ( 30.4) 100 ( 34.0) 32 ( 31.7)  
Year (%)      0.423 
   2007 114 (10.8) 50 ( 10.3) 14 ( 11.2) 39 ( 13.3) 8 (  7.9)  
   2008 137 (13.0) 63 ( 13.0) 20 ( 16.0) 34 ( 11.6) 15 ( 14.9)  
   2009 168 (16.0) 72 ( 14.8) 22 ( 17.6) 54 ( 18.4) 18 ( 17.8)  
   2010 156 (14.8) 79 ( 16.3) 19 ( 15.2) 45 ( 15.3) 12 ( 11.9)  
   2011 198 (18.8) 105 ( 21.6) 27 ( 21.6) 45 ( 15.3) 19 ( 18.8)  
   2012 149 (14.2) 70 ( 14.4) 11 (  8.8) 41 ( 13.9) 21 ( 20.8)  
   2013 129 (12.3) 46 (  9.5) 12 (  9.6) 36 ( 12.2) 8 (  7.9)  
Condom (%)      <0.001 
   Condom dysfunction 433 (41.2) 208 ( 42.9) 51 ( 40.8) 122 ( 41.5) 48 ( 47.5)  
   Condomless sex 527 (50.1) 263 ( 54.2) 59 ( 47.2) 138 ( 46.9) 51 ( 50.5)  
   With condom 23 ( 2.2) 1 (  0.2) 4 (  3.2) 18 (  6.1) 0 (  0.0)  
   Unknown 68 ( 6.5) 13 (  2.7) 11 (  8.8) 16 (  5.4) 2 (  2.0)  
Type of intercourse       
   Anal (%) 359 (34.2) 261 ( 53.8) 9 (  7.2) 53 ( 18.0) 30 ( 29.7) <0.001 
   Vaginal (%) 543 (51.7) 186 ( 38.4) 106 ( 84.8) 201 ( 68.4) 43 ( 42.6) <0.001 
   Oral (%) 157 (14.9) 68 ( 14.0) 14 ( 11.2) 43 ( 14.6) 28 ( 27.7) 0.002 
   Only oral (%) 94 ( 8.9) 34 (  7.0) 8 (  6.4) 29 (  9.9) 21 ( 20.8) <0.001 
Source partner risk group       
MSM  (%) 401 (38.2) 284 ( 58.6) 6 (  4.8) 56 ( 19.0) 49 ( 48.5) <0.001 
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Sex worker a  (%) 256 (24.4) 177 ( 36.5) 4 (  3.2) 29 (  9.9) 44 ( 43.6) <0.001 
Endemic country (%)  46 ( 4.4) 32 (  6.6) 0 (  0.0) 6 (  2.0) 7 (  6.9) 0.001 
Injecting-drug-user (IDU) 
(%) 
11 ( 1.0) 9 (  1.9) 0 (  0.0) 1 (  0.3) 1 (  1.0) 0.137 
HIV status of the source 
partner (%) 
     <0.001 
   Negative 175 (16.7) 16 (  3.3) 19 ( 15.2) 136 ( 46.3) 4 (  4.0)  
   Positive 131 (12.5) 109 ( 22.5) 4 (  3.2) 12 (  4.1) 4 (  4.0)  
   Unknown 745 (70.9) 360 ( 74.2) 102 ( 81.6) 146 ( 49.7) 93 ( 92.1)  
Source partner presented 
the same day (%) 
170 (16.2) 21 (  4.3) 11 (  8.8) 133 ( 45.2) 4 (  4.0) <0.001 
Deciding physician (%)      <0.001 
    Resident in internal 
medicine 
849 (80.8) 378 ( 77.9) 104 ( 83.2) 263 ( 89.5) 70 ( 69.3)  
   Infectious disease  
specialist 
179 (17.0) 95 ( 19.6) 20 ( 16.0) 29 (  9.9) 28 ( 27.7)  
   Internal medicine 
specialist 
23 ( 2.2) 12 (  2.5) 1 (  0.8) 2 (  0.7) 3 (  3.0)  
a Sex work in Switzerland is legal and regulated 
b P-values for categorical variables were calculated using chi-square test, for age and hours since exposure a	
Kruskal–Wallis test was used. 
c  Forty-six visits in which the decision could have not been classified due to missing data are included only in the 
Overall column. 
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steady HIV-positive partnerships” 
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Supplementary Text 1 
 
Phylogenetic tree and genetic distances 
We used phylogenetic linkage as a key criterion for the validation of the putative steady 
transmission pairs that were detected using this method. 19,893 partial HIV-1 pol sequences 
from 10,970 SHCS cohort participants (years range 1989 to 2015) were pooled with 116,408 
background, non-Swiss HIV-1 pol sequences from the Los Alamos (http://www.hiv.lanl.gov/) 
database.The sequences were aligned to a HIV-1 HXB2 [1] reference genome  using the 
MUSCLE [2]. Next, insertions relative to HIV-1 HXB2 and resistance mutations according to 
Stanford: http://hivdb.stanford.edu/ and International Antiviral Society-USA 
https://www.iasusa.org/ lists were removed. Finally, a phylogenetic tree was generated using 
FastTree [3] with the Generalized Time-Reversible (GTR) model. We also calculated tree 
independent pairwise sequence genetic distances using "TN93"[4] model with the R package 
“ape” [5]. As a cutoff for evaluation as a serosorting pair we chose a minimal genetic distance 
of at least 2.5% within a given pair [4, 6], to ensure adequate distance.   
 
Serosorting pairs characterization 
Eight pairs had a high number of effective shared visits (median 13, IQR 8-22), reported an 
HIV+ steady partner in the SHCS questionnaire, belonged to the same risk group, but were 
not linked as monophyletic on the phylogeny and showed a high (range 2.6%-13.4%) pairwise 
distance between the viral sequences. Hence, these pairs are not likely to be transmission pairs 
- as they have genetically distant viruses- but tenuous serosorting pairs (that require extensive 
external validation). Four of these pairs were MSM, three heterosexual and one of an 
HET/IDU risk group. In line with the observation for the steady transmission pairs, two of the 
MSM pairs were of a mixed ethnicity with White and Latino males, the age gaps being large 
as well (12 and 19 years). In five pairs the members had a discordant HIV subtype (two pairs 
with B/01_AE, B/C, F/B and F/Recombinant). All eight pairs reported unprotected sex with a 
steady partner at least once during the shared visits period, which might be one of the main 
motivations behind serosorting, but can also facilitate viral superinfection. 
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Sensitivity analysis of the main simplifying assumption 
A core assumption of the binomial model is that visit dates are independently and 
identically distributed within quarters. One potential source of violation stems from the fact 
that patients seen at the beginning of one quarter will probably not be seen at the end of the 
next quarter, and vice versa. Patients seen on the same day or nearby in time for one visit have 
an increased probability of sharing a date for their next visit (hence constituting a “cohort” 
within the cohort). The contribution of this effect to the false-positives was tested by 
narrowing the shuffling window from three months to one months (this value can be modified 
by the package user) with a corresponding increase of the probability of sharing a single visit 
(in this case to 1/30, hence increasing the penalty term). Doing so decreased the total yield to 
178 pairs with a corresponding decrease of the clearly false-positive to 10% (8/78) (See 
Supplementary Fig.1 for the Venn diagram) without losing any of the validated 33 
transmission pairs. Hence, the user can benefit from adjusting the model to fit the empirical 
visits scheduling patterns in the specific cohort analyzed. 
 
Supplementary Figure 1. Flowchart and Venn diagram (bottom) demonstrating the 
validation of 70 putative pairs detected using shared cohort follow-up visit dates. Red 
numbers indicate putative transmission (n=33) and serosorting pairs (n=9). 
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svisits: finding HIV transmission and serosorting pairs
using shared clinic visit dates
Alex Marzel, Teja Turk
This package helps to find some stable HIV-infected partnerships in cohort studies based on the assumption
that some patients frequently attend the clinical visits together. These pairs are useful for biological and
epidemiological research.
Package installation:
library(svisits)
set.seed(14051948)
The following paragraphs explain step-by-step how the svisits package can be used to find stable HIV-infected
partnerships. All the steps can be also performed with one function call, which is demonstrated below.
First let us load the database with visit dates in a long format (each row represents a visit of a particular
person) and transform it to the appropriate format. The following simulated dataset contains 20 transmission
pseudo pairs. The data were simulated based on the visits distribution in the SHCS.
data("simulated_data")
# prepare the database
db_dates <- prepare_db(your_database = simulated_data,
ids_column = "subject",
dates_column = "sim_dates")
head(db_dates)
## subject dates
## 1 1 1993-10-02
## 2 1 1993-12-24
## 3 1 1994-03-16
## 4 1 1994-05-27
## 5 1 1994-08-21
## 6 1 1994-11-06
Deconstruct the dates into 3 months periods:
# extract month, day and year of each clinic visit:
db_dates <- cbind(db_dates, month.day.year(db_dates$dates))
# deconstruct the dates into 3 months periods
periodMonths <- 3
db_dates <- cbind(db_dates,
fupdatePeriod=db_dates$year+round(floor((db_dates$month-1)/periodMonths)
*periodMonths/12,
digits=2))
Get unadjusted, observed shared visits. It can take some time.
unadjusted_observed_pairs <- get_observed_pairs(db_dates)
head(unadjusted_observed_pairs)
## allPairs
## 1000_1163 1000_1168 1000_1258 1000_1310 1000_1347 1000_1388
## 1 1 1 1 1 1
Descriptive statistics of shared visits for pairs that shared at least a single visit:
1
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summary(as.numeric(unadjusted_observed_pairs))
## Min. 1st Qu. Median Mean 3rd Qu. Max.
## 1.000 1.000 1.000 1.321 1.000 24.000
Prepare the ids:
ids_table <- table(db_dates$subject)
ids <- data.table(ids = as.character(names(ids_table)),
N_visits = as.character(as.numeric(ids_table)))
setkey(ids, "ids")
Chances that two unrelated cohort members share a visit are increasing with the overall number of visits of
each member of the pair. To account for this we have to adjust the number of shared visits S within each
pair. This will return the adjusted number of shared visits SÕ for the observed, unshu ed data
SÕ = S ≠
log
Ë!min(Ta,Tb)
S
"È
log [75] ,
where Ta and Tb denote the number of visits of each member of the pair. The adjusted number of visits is
under the column “Corrected”:
adjusted_observed <- adjust_visits(unadjusted_pairs = unadjusted_observed_pairs,
ids = ids,
prob = 1/75)
head(adjusted_observed)
## allPairs Freq id_1 id_2 N_visits.x N_visits.y Corrected
## 1 1_10 1 1 10 46 68 0.1132248
## 2 4_10 1 4 10 39 68 0.1514599
## 3 8_10 1 8 10 10 68 0.4666841
## 4 9_10 1 9 10 12 68 0.4244555
## 5 161_1000 1 161 1000 17 11 0.4446087
## 6 176_1000 1 176 1000 11 11 0.4446087
Threshold for the number of shared visits
Shu ing
Due to the multiple comparisons problem and strongly simplifying assumptions about the uniform distribution
of visits, the corrected number of shared visits is not an optimal test statistic. Instead, the visits are first
shu ed within each quarter (such that the original distribution of the number of visits per individual
is preserved) and the number of randomly collided shared visits per pair is counted and penalized using
“adjust_visits”. In other words, the observed visit dates from a given quarter are randomly re-assigned
between the patients that attended the clinic during this quarter.
Define the number of desired shu ing simulations (ideally > 100, but it will take some time) and run. It will
take some time to finish.
n_shuffl <- 10
Shuffling_simulation_output <- replicate(n_shuffl,
Shuffling_simulation(db_dates,
ids = ids,
adjusted_observed),
simplify=F)
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# inspect the false-positive thresholds
head(Shuffling_simulation_output)
## [[1]]
## [1] 0.9394822 0.7810526 0.3095238 0.0000000 0.0000000 0.0000000 0.0000000
## [8] 0.0000000
##
## [[2]]
## [1] 0.9434465 0.7515789 0.2857143 0.0000000 0.0000000 0.0000000 0.0000000
## [8] 0.0000000
##
## [[3]]
## [1] 0.9418979 0.6905263 0.1904762 0.0000000 0.0000000 0.0000000 0.0000000
## [8] 0.0000000
##
## [[4]]
## [1] 0.9389866 0.6673684 0.2619048 0.0000000 0.0000000 0.0000000 0.0000000
## [8] 0.0000000
##
## [[5]]
## [1] 0.9485258 0.6547368 0.1428571 0.0000000 0.0000000 0.0000000 0.0000000
## [8] 0.0000000
##
## [[6]]
## [1] 0.92758920 0.65263158 0.30952381 0.04761905 0.00000000 0.00000000
## [7] 0.00000000 0.00000000
Extract the False-Positive thresholds:
# Thresholds
for_thresholds <- do.call("rbind", Shuffling_simulation_output)
# Take max FP value for each position from all the simulations.
# One can also take mean or median insted of maximum
for_thresholds_max <- apply(X = for_thresholds,
MARGIN = 2,
max,na.rm = TRUE)
# find lowest threshold below alpha=0.01
Thresholds_lowest <- match(for_thresholds_max[for_thresholds_max<0.01][1],
for_thresholds_max)
Plot the simulations and the False-Positive threshold (indicated by an arrow):
max_threshold <- length(Shuffling_simulation_output[[1]])
plot(x=1:max_threshold,
y=unlist(Shuffling_simulation_output[[1]]),
xlab="Shared visits threshold", ylab="False Positive Fraction",
type="l", col="darkblue", yaxp=c(0.0,1,10), lwd=0.8, main="",
xaxp=c(1,12,11), cex.lab=1.3, cex.axis=1.4, cex.main=1.3, ylim=c(0,1))
arrows(x0 = Thresholds_lowest, x1=Thresholds_lowest,
y0=0.22, y1=0.07, cex=3, lwd=5)
invisible(lapply(X=1:n_shuffl,
function(X) {
lines(x=1:max_threshold, y=unlist(Shuffling_simulation_output[[X]]),
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col="darkblue", lwd=0.8 )
}))
lines(c(-100,100), 0.01*c(1,1), lty=3, col="red", lwd=3)
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## [1] 5
# This is the cutoff for the number of adjusted visits
Extract the pairs above the threshold:
select_shuffled <- adjusted_observed[which(adjusted_observed$Corrected>Thresholds_lowest),]
# We found the 20 pairs
length(select_shuffled[,1])
## [1] 20
Alternative (and much faster approach): Bonferroni correction
Predict the probabilities and than adjust for multiple testing using Bonferroni:
# alpha 0.01, one false-positive pair
Bonferroni_m_output <- Bonferroni_m(unadjusted_observed_pairs,
ids = ids,
prob = 1/75,
alpha =0.01)
length(Bonferroni_m_output[,1])
## [1] 21
# alpha 0.001, only 20 true pairs
Bonferroni_m_output <- Bonferroni_m(unadjusted_observed_pairs,
ids = ids,
4
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prob = 1/75,
alpha =0.001)
length(Bonferroni_m_output[,1])
## [1] 20
Summary: one-step-approach
The above pairs can be alternatively found with one function call:
library(svisits)
data("simulated_data")
set.seed(14051948)
# with shuffling and Bonferroni for alpha=0.01
pairs <- find_pairs(simulated_data,
ids_column = "subject",
dates_column = "sim_dates",
shuffling = TRUE,
n_shuffl = 10)
head(pairs$Shuffled_pairs)
## allPairs Freq id_1 id_2 N_visits.x N_visits.y Corrected
## 62746 328_1453 22 328 1453 38 44 16.48171
## 65536 1173_1468 24 1173 1468 70 77 14.10959
## 85836 482_1587 21 482 1587 77 66 11.96045
## 101885 1504_1696 17 1504 1696 44 37 11.55935
## 141792 72_1898 16 72 1898 33 39 11.16443
## 142396 793_1900 18 793 1900 44 37 12.53495
# show similarity
identical(select_shuffled, pairs$Shuffled_pairs)
## [1] TRUE
# with only Bonferroni for alpha=0.001
pairs_Bonferroni <- find_pairs(simulated_data,
ids_column = "subject",
dates_column = "sim_dates",
alpha = 0.001,
shuffling = FALSE)
head(pairs_Bonferroni$Bonferroni_pairs)
## allPairs Freq id_1 id_2 N_visits.x N_visits.y Prob_for_Bonferr
## 62746 328_1453 22 328 1453 38 44 1.005805e-31
## 65536 1173_1468 24 1173 1468 70 77 1.885820e-27
## 85836 482_1587 21 482 1587 77 66 2.046927e-23
## 101885 1504_1696 17 1504 1696 44 37 1.617750e-22
## 141792 72_1898 16 72 1898 33 39 9.266487e-22
## 142396 793_1900 18 793 1900 44 37 2.429054e-24
## BP ltp
## 62746 62746 30.99749
## 65536 65536 26.72450
## 85836 85836 22.68890
## 101885 101885 21.79109
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## 141792 141792 21.03308
## 142396 142396 23.61456
# show similarity
identical(Bonferroni_m_output, pairs_Bonferroni$Bonferroni_pairs)
## [1] TRUE
6
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 Supplementary Material:  Chapter IV “The cumulative impact of harm reduction on the Swiss 
HIV epidemic: cohort study, mathematical model and phylogenetic analysis” 
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SUPPLEMENTARY MATERIAL 
The cumulative impact of harm reduction on the Swiss HIV epidemic: cohort study, mathematical model and phylogenetic analysis 
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Supplementary Table 1. IDUs in the Swiss HIV Cohort Study, 1980-2016, by diagnosis period. 
   Overall [1980,1990) [1990,2000) [2000,2010) [2010,2016] P for 
trend 
Phylogeny 
n  4806 2999 1344 394 69 0.044 2399 
Sex Male 3157 (65.7) 1932 (64.4) 896 (66.7) 278 (70.6) 51 (73.9) 0.005 1548 (64.5) 
 Female 1649 (34.3) 1067 (35.6) 448 (33.3) 116 (29.4) 18 (26.1)  851 (35.5) 
Age at diagnosis 
(median [IQR]) 
 27.0 [23.0, 
31.0] 
25.0 [23.0, 
28.0] 
29.0 [25.0, 
33.0] 
32.0 [28.0, 
38.0] 
36.0 [31.0, 
47.0] 
0.002 27.0 [23.0, 
31.0] 
University 
education 
Yes 45 ( 0.9) 22 ( 0.7) 12 ( 0.9) 6 ( 1.5) 5 ( 7.2) 0.163 22 ( 0.9) 
 No 4761 (99.1) 2977 (99.3) 1332 (99.1) 388 (98.5) 64 (92.8)  2377 (99.1) 
Untreated CD4 
(median [IQR]) 
 379.0 
[190.0, 
600.0] 
370.0 [185.5, 
600.0] 
378.0 [186.0, 
600.0] 
406.5 [238.8, 
632.5] 
366.0 [182.0, 
535.5] 
0.883 420.0 
[240.0, 
640.0] 
Years to cART 
(median [IQR]) 
 9.2 [3.6, 
12.6] 
12.2 [10.6, 
15.2] 
5.1 [2.4, 7.9] 1.6 [0.2, 3.5] 0.2 [0.1, 0.8] 0.048 9.1 [3.8, 
12.6] 
All time AIDS Yes 2010 (41.8) 1441 (48.0) 485 (36.1) 73 (18.5) 11 (15.9) 0.032 837 (34.9) 
 No 2796 (58.2) 1558 (52.0) 859 (63.9) 321 (81.5) 58 (84.1)  1562 (65.1) 
HBV Ever 
positive 
2312 (78.3) 1249 (83.9) 807 (79.5) 217 (56.7) 39 (58.2) 0.087 1742 (78.2) 
 Negative 642 (21.7) 240 (16.1) 208 (20.5) 166 (43.3) 28 (41.8)  485 (21.8) 
HBV missing Yes 1852 (38.5) 1510 (50.4) 329 (24.5) 11 ( 2.8) 2 ( 2.9) 0.062 172 ( 7.2) 
 No 2954 (61.5) 1489 (49.6) 1015 (75.5) 383 (97.2) 67 (97.1)  2227 (92.8) 
HCV Ever 
positive 
2728 (94.6) 1364 (96.2) 948 (94.0) 367 (94.3) 49 (73.1) 0.184 2117 (94.8) 
 Negative 155 ( 5.4) 54 ( 3.8) 61 ( 6.0) 22 ( 5.7) 18 (26.9)  117 ( 5.2) 
HCV missing Yes 1923 (40.0) 1581 (52.7) 335 (24.9) 5 ( 1.3) 2 ( 2.9) 0.071 165 ( 6.9) 
 No 2883 (60.0) 1418 (47.3) 1009 (75.1) 389 (98.7) 67 (97.1)  2234 (93.1) 
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Supplementary Figure 1. Selected milestones of HIV epidemic among heroin users in Switzerland, 1981-2016. Sources: 
(1)(2)(3)(4)(5)(6). 
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Supplementary Figure 2. Supervised drug consumption room, Oerlikon, Zürich.  
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Supplementary Figure 3. Counterfactual scenario with no cART introduction. 
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Supplementary Figure 4. Subsection of the phylogenetic tree that demonstrates three introduction events into the heterosexual 
population (red). Multiple sequences from the same patients were dropped for clarity, hence each tip represents a different patient. 
Abbreviations: HET: heterosexual, IDU: Injecting-Drug-User. 
 
IDU:Female
IDU:Female
HET:Male
IDU:Female
IDU:Female
HET:Male
HET:Female
Foreign Sequence
IDU:Male
IDU:Male
IDU:Male
HET:Female
IDU:Male
135
 7 
 
 
Supplementary Table 2. Model parameters and assumptions. Model parameters were obtained either by model fitting to the reported 
number of HIV cases and AIDS deaths, from the Swiss HIV Cohort Study or were approximated based on available literature 
preferably from historically comparable settings. Sensitivity analysis was performed by varying key model parameters (see below).  
 
 
Parameter Description and 
assumptions 
Value (range) Source 
b(t) Estimated annual 
number of new 
problematic heroin 
users in Switzerland 
Vector of 36 values 1980 to 2015: 
 
1153, 1200, 1245, 1311, 1456, 1755, 2278, 3046, 
3947, 4683, 4892, 4468, 3687, 2929, 2379, 2028, 
1793, 1603, 1431, 1277, 1143, 1024, 917, 821, 736, 
659, 590, 529, 474, 424, 380, 341, 305,  
273, 245, 219 
 
Years 2010 to 2015 were extrapolated using  
Generalized additive model (GAM) with integrated 
smoothness estimation from the R “mgcv” package 
(version 1.8-17) 
 
Incidence of heroin 
use from (7)  
 was extrapolated until 
2015, 
Data for the Swiss 
population size was 
obtained from the  
Swiss Federal 
Statistical Office 
(8) 
f_iv Fraction of heroin 
users that start their 
heroin consumption 
via intravenous 
route  
0.27 (9) 
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v(t) 
 
Rate of transition 
from non-
intravenous 
heroin use to 
injecting 
 
 
v " = 12.08	*+ , " < 1990	( 12.08	*+)/2, " ≥ 1990 
 
We make this transition two times slower after 1990 to account for the 
assumption that due to the increasing awareness of the HIV epidemic and the 
high overdose rate many non-injectors might be reluctant to switch to the 
injecting drug administration mode.   
 
(10) 
(11) 
fr_iv Transition rate 
from being an 
active intravenous 
user to either non-
intravenous mode 
(smoking, 
snorting or 
methadone), or to 
a supervised 
injectable heroin.  
Although the exact rate is unknown, data from Europe shows that this 
transition was not uncommon. Griffiths et al. (1994) showed that, 16% of 
current chasers were previously injectors (11).  de la Fuente (1994) showed 
that fear of contracting HIV played an important role in this transition (12). 
We set this rate at  34.56	78 and only allow this transition from the harm 
reduction covered compartment. 
 
(11) 
(12) 
m_n Death rate and 
emigration,  
for non-
intravenous users, 
not on harm 
reduction 
 
  
 143	*+ 
 
Based on life expectancy of 75 (in 1980) and a mean age of heroin use 
initiation of 20, plus 0.5% emigration 
 
 
* the curve from (7) that describes the estimated annual number of heroin 
users in Switzerland,  serves as an external control for the combined impact of 
all the deaths, emigration and cessation rates (Figure 3 in the manuscript) 
(13) 
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m_n_h Death rate and 
emigration,  
for non-
intravenous users, 
 on harm 
reduction 
 
 148	*+ 
 
Based on life expectancy of 75 (in 1980) and a mean age of heroin use 
initiation of 20, plus 0.5% emigration 
 
We assume 10% lower rate on harm reduction 
 
* the curve from (7) that describes the estimated annual number of heroin 
users in Switzerland,  serves as an external control for the combined impact of 
all the deaths, emigration and cessation rates (Figure 3 in the manuscript) 
(13) 
m_s_i Death and 
emigration for 
susceptible, and 
infected in the 
recent, chronic or 
treated non-AIDS 
stages, 
intravenous users, 
not on harm 
reduction 
124		*+ 
 
Sordo et al. reported pooled all-cause mortality of 27.7-1y out of methadone, 
plus 0.5% emigration 
 
* the curve from (7) that describes the estimated annual number of heroin 
users in Switzerland,  serves as an external control for the combined impact of 
all the deaths, emigration and cessation rates (Figure 3 in the manuscript) 
(14) 
m_s_i_h Death and 
emigration for 
susceptible, 
recent stage, 
chronic or treated 
non-AIDS stage, 
covered by any 
harm reduction 
 148		*+ 
 
Sordo et al. reported pooled all-cause mortality rates of 88;37	on methadone. 
However, this is a recent estimate. Since it is implausible that the death rate of 
non-injectors was faster than that of the active injectors (m_n_h), we fix the 
rate 39;37 
 
 
* the curve from (7) that describes the estimated annual number of heroin 
(14) 
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users in Switzerland,  serves as an external control for the combined impact of 
all the deaths, emigration and cessation rates (Figure 3 in the manuscript) 
m_a Death rate from 
AIDS for 
untreated patients, 
we assume the 
same rate for 
people on and off 
harm reduction 
 11.6		*+ (15)  
m_at AIDS death rate 
on HAART. 
Assumption: for 
some patients in 
the AIDS stage, 
treatment might 
be administrated 
too late.  
 19.09		*+ Assumed, based on (16) 
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w Successful 
withdrawal rate 
not on any harm 
reduction (“cold 
turkey”). Here 
withdrawal means 
complete 
cessation of 
opioid use, 
including 
methadone and 
non-injection 
 150		*+ 
Nordt and Stohler estimated a cessation rate of 4%, however this estimate 
included emigration and death and was based on a methadone registry,  
we assume 2% unassisted withdrawal 
 
* the curve from (7) that describes the estimated annual number of heroin 
users in Switzerland,  serves as an external control for the combined impact of 
all the deaths, emigration and cessation rates (Figure 3 in the manuscript) 
(7)  
w_h Successful 
withdrawal rate 
on harm reduction 
Here withdrawal 
means complete 
cessation of 
opioid use, 
including 
methadone and 
non-injection 
133		*+ 
Nordt and Stohler estimated a cessation rate of 4%, however this estimate 
included emigration and death and was based on a methadone registry. 
 
The cessation rate is higher on harm reduction since oftentimes maintenance 
medication serves as a gateway for cessation (17).  
 
 
* the curve from (7) that describes the estimated annual number of heroin 
users in Switzerland,  serves as an external control for the combined impact of 
all the deaths, emigration and cessation rates (Figure 3 in the manuscript) 
(7,17) 
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r_c Transition rate 
from recent to 
chronic HIV 
infection stage 
1	0.5	*+ Definition of recent infection 
c_a Transition rate 
from chronic to 
AIDS HIV 
infection stage 
1	8	*+ (18) 
a(t) HIV diagnosis 
rate, not on harm 
reduction 
 a " = 0, " < 1985	 1	3.48	*+ , " ≥ 1985 
 
Time to diagnosis was estimated based on the SHCS data, by taking the time 
interval between the HIV positive date and the last known HIV negative date 
(and not the midpoint as in (19)). We assume that most SHCS patients were 
covered by harm reduction, and that that the diagnosis rate was 50% slower in 
compartments not covered by harm reduction 
 
 
SHCS 
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a_h(t) HIV diagnosis 
rate, covered by 
harm reduction 
 a_h " = 0, " < 1985	 1	1.74	*+ , " ≥ 1985 
 
Time to diagnosis was estimated based on the SHCS data, by taking the time 
interval between the HIV positive date and the last known HIV negative date 
(and not the midpoint as in (19)). We assume that all SHCS patients were 
covered by harm reduction, and that that the diagnosis rate was 50% times 
slower in compartments not covered by harm reduction 
 
 
 
SHCS 
g_R(t) HAART initiation 
rate,  
For IDU not on 
harm reduction, 
that are in a 
recent infection 
stage 
 g_R " = 0, " < 19960.131	 + 	0.038		 ∗ 	 (t − 17), " ≥ 1996 
 
 
Estimated based on SHCS data, using time to event analysis 
 with IDUs with a CD4 value of >500 close to diagnosis as a proxy for the 
recent infection phase (Supplementary Table 3) 
 
Since the clinical practice gradually transitioned toward immediate treatment 
(20), the rate increases linearly with a slope 0.038 per year which will enforce 
immediate treatment in 2015.  
 
Uhlmann et al. (21) reported a 62% increase in ART initiation among people 
on methadone as compared to non-methadone.  Hence, we assumed a 62% 
slower rate for the parallel non-harm reduction compartment. This does not 
apply to the AIDS stage, in which people will be treated regardless of their 
harm reduction coverage. 
 
SHCS 
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g_R_h (t) HAART initiation 
rate,  
For IDU on harm 
reduction, that are 
in a recent 
infection stage 
 g_R_h " = 0, " < 19960.131 + 	0.038	 ∗ (t − 17), " ≥ 1996 
 
Estimated based on SHCS data, using time to event analysis 
 with IDUs with a CD4 value of >500 close to diagnosis as a proxy for the 
recent infection phase (Supplementary Table 3) 
 
Since the clinical practice gradually transitioned toward immediate treatment 
(20) , the rate increases linearly with a slope 0.038 per year which will 
enforce immediate treatment in 2015. 
 
We assume that all the SHCS patients were covered by harm reduction, since 
it would be unlikely to participate in the cohort while bypassing all the harm 
reduction measures.  
 
Uhlmann et al. (21) reported a 62% increase in ART initiation among people 
on methadone as compared to non-methadone.  Hence, we assumed a 62% 
slower rate for the parallel non-harm reduction compartment. This does not 
apply to the AIDS stage, in which people will be treated regardless of their 
harm reduction coverage. 
 
 
SHCS 
g_C(t) HAART initiation 
rate,  
For IDU not on 
harm reduction, 
that are in a 
chronic infection 
stage 
 g_C " = 0, " < 19960.24	 + 	0.071		 ∗ 	 (t − 17), " ≥ 1996 
 
Estimated based on SHCS data, using time to event analysis 
 with IDUs with a CD4 values between 200 and 500, close to diagnosis, as a 
proxy for the chronic infection phase (Supplementary Table 3) 
 
Since the clinical practice gradually transitioned toward immediate treatment 
(20), the rate increases linearly with a slope 0.071 per year which will enforce 
SHCS 
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immediate treatment in 2015. 
 
We assume that all the SHCS patients were covered by harm reduction, since 
it would be unlikely to participate in the cohort while bypassing all the harm 
reduction measures.  
 
Uhlmann et al. (21) reported a 62% increase in ART initiation among people 
on methadone as compared to non-methadone.  Hence, we assumed a 62% 
slower rate for the parallel non-harm reduction compartment. This does not 
apply to the AIDS stage, in which people will be treated regardless of their 
harm reduction coverage. 
 
g_C_h (t) HAART initiation 
rate,  
For IDU on harm 
reduction, that are 
in a chronic 
infection stage 
 g_C_h	 " = 0, " < 19960.24	 + 	0.071		 ∗ 	 (t − 17), " ≥ 1996 
 
Estimated based on SHCS data, using time to event analysis 
 with IDUs with a CD4 values between 200 and 500, close to diagnosis, as a 
proxy for the chronic infection phase (Supplementary Table 3) 
 
Since the clinical practice gradually transitioned toward immediate treatment 
(20), the rate increases linearly with a slope 0.071 per year which will enforce 
immediate treatment in 2015. 
 
We assume that all the SHCS patients were covered by harm reduction, since 
it would be unlikely to participate in the cohort while bypassing all the harm 
reduction measures.  
 
 
Uhlmann et al. (21) reported a 62% increase in ART initiation among people 
on methadone as compared to non-methadone.  Hence, we assumed a 62% 
slower rate for the parallel non-harm reduction compartment. This does not 
apply to the AIDS stage, in which people will be treated regardless of their 
SHCS 
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harm reduction coverage. 
 
g_A(t) HAART initiation 
rate,  
For IDU not on 
harm reduction, 
that are in AIDS 
stage 
 g_A	 " = 0, " < 19960.55 + 	0.138		 ∗ 	 (t − 17), " ≥ 1996 
 
Estimated based on SHCS data, using time to event analysis 
 with IDUs with CD4 values below 200, close to diagnosis, as a proxy for the 
AIDS infection phase (Supplementary Table 3) 
Time to HAART was calculated as the time interval between the first CD4 
value <200 (after 1996) and HAART initiation 
 
Since the clinical practice gradually transitioned toward immediate treatment 
(20), the rate increases linearly with a slope 0.138 per year which will 
enforce immediate treatment in 2015. 
 
We assume that all the SHCS patients were covered by harm reduction, since 
it would be unlikely to participate in the cohort while bypassing all the harm 
reduction measures.  
 
SHCS 
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g_A_h(t) HAART initiation 
rate,  
For IDU on harm 
reduction, that are 
in AIDS stage 
 g_A_h " = 0, " < 19960.55 + 	0.138	 ∗ 	 (t − 17), " ≥ 1996 
 
Estimated based on SHCS data, using time to event analysis 
 with IDUs with CD4 values below 200, close to diagnosis, as a proxy for the 
AIDS infection phase (Supplementary Table 3) 
 
Since the clinical practice gradually switched toward immediate treatment 
(20), the rate increases linearly with a slope 0.138 per year which will 
enforce immediate treatment in 2015. 
 
We assume that all the SHCS patients were covered by harm reduction, since 
it would be unlikely to participate in the cohort while bypassing all the harm 
reduction measures.  
 
 
SHCS 
r HAART 
interruption and 
drug resistance, 
not on harm 
reduction 
 1	4.76	*+ 
 
Estimated using time-to-event analysis of the IDUs in the SHCS that initiated 
HAART. The time variable was calculated from HAART initiation date until 
the first two consecutive HIV RNA measurements above 500 copies/mL. For 
individuals without interruption/resistance the date was censored at the last 
available follow-up. 
 
The estimated rate was 
3	J.36	78 
 
Since Palepu et al. found that methadone maintenance therapy (MMT) 
was positively associated with adherence (AOR 1.52; 95% CI 1.16-2.00), the 
rate for the not-covered by harm reduction compartment was increased by 
 
SHCS 
(22)(21)(15) 
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52%.  
 
 
r_h HAART 
interruption and 
drug resistance, 
on harm reduction 
 
 
Estimated using time-to-event analysis of the IDUs in the SHCS that initiated 
HAART. The time variable was calculated from HAART initiation date until 
the first two consecutive HIV RNA measurements above 500 copies/mL. For 
individuals without interruption/resistance the date was censored at the last 
available follow-up. 
 
The estimated rate was 
3	J.36	78 
(21)(15) 
 
SHCS 
(23,24) 
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h(t) Annual rate of 
recruitment to any 
harm reduction  
 ℎ "= estimate	 see	below 	fit:	 1	11.7	*+ , " < h_t_startmodel	fit:	1.44	(95%	Y. Z	1.16 − 1.71)	, " ≥ h_t_start 
  
Before 1988, only restricted methadone was available,  
After 1988 needle exchange and extended methadone were added, 
later in 1994 a supervised injectable heroin as well.  
The rate before 1988 ( 3	33.J	78), was estimated by fitting the 
following ODE system to the reported restricted methadone data 
(1980-1987) 
 [\[] 	= b(t) + o·M - h·I - µ·I 
 [[^] = h · I	 − 	o · M - µ·M 
 
Where the compartment I represents IDU not on methadone, the 
compartment M IDU on methadone.  b(t) new heroin users, o 
methadone drop-out ( 3b.J4	78), h methadone recruitment (model fit) 
and µ death, emigration and cessation rates ( 3	56	78).  
with initial conditions: I = 3857, M = 733.  
See Supplementary Figure 5.  
 
For the 
number of 
patients on 
restricted 
Methadone 
(25) 
 
After 
h_t_start: 
model fit 
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h_hivp(t) Annual rate of 
recruitment to harm 
reduction, for 
diagnosed HIV 
positive individuals 
2 * h(t)  
 
 
Gervasoni et al. show that HIV positive individuals have two times 
higher odds for being on methadone as compared to HIV negative.  
(26) 
o Annual rate of loss to 
harm reduction 
package 
 
Hissoud et al  
(27) showed that the proportion of remaining on methadone 
treatment was 69% at 1 year and 45% at 3 years, hence, we use the 
drop-out rate: 
 13.76	*+ 
(27) 
h_t_start Year in which the 
intensive harm 
reduction package was 
introduced and started 
to take an effect 
1988 
 
Start of the “Zipp-Aids” Needle and syringe exchange 
interventions  
(25) 
(5,6) 
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ds 
Fraction of HIV 
diagnosed IDU that 
will still share 
injection paraphernalia 
 
 
0.32 
 
Wilson et al (28) showed that IDU that were aware of their HIV 
positive status had a three times lower odds to share needles as 
compared to HIV negative (odds ratio 0.32, 95% C.I 0.11-0.96). 
No reduction in risk behavior was found in HIV positive 
individuals that were unaware of their infection (odds ratio 1.14 
95% C.I 0.58-2.2) 
On harm reduction: we assume 50% lower fraction 
 
(28) 
π A multiplier that 
represents the fraction 
of the initial non-harm 
reduction transmission 
coefficient that will 
remain after reduction 
in risk behavior due to 
overall increase in 
HIV awareness.  
0.4 
 
van Ameijden (29) showed based on data from the Netherlands, 
that borrowing needles/syringes has decreased from 51% in 1986 
to 20% in 1992. This reduction was similar for people that 
attended methadone and needle exchange and for people that did 
not. We are not aware of this kind of evidence for Switzerland, 
nevertheless we set the value on 40% to obtain the adjusted effect 
of harm reduction.  
 
(29) 
c d  Transmission coefficient, not on 
harm reduction 
Dynamic rate 
 c d = ce, t ≤ 	1987K − (K − ce) ∙ i(;jk∙(];l)),			t > 1987 
 ce =	"+nopqrpprso	coefficient	viws+i	1987,	 wr""ix (1.25, 95% C.I 1.24-1.26), see below 
 c r= model fit 0.6 (95% 0.45-0.75) 
 
K = ce· π = the lower bound of the initial ce	, after adjusting for 
reduction of risk behavior that is independent of harm reduction, 
Model fit 
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just due to HIV awareness. 
 
The interpretation of ce:  
Using the common notation for the force of infection of sexually 
transmitted infections: 
 cy ∙ z ∙ Z{  
 ce	represents the per partnership transmission probability (cy) that 
combines both injecting paraphernalia sharing partnerships and 
sexual partnerships with other active injectors, multiplied by the 
combined sharing and sexual IDU partners change rate (c).  Hence, ce= cy ∙ z, and since both quantities are unknown, and mostly 
likely also changed with time, we fitted them as one.  
 c|(") Transmission 
coefficient, on harm 
reduction 
Dynamic rate, represented as a step-function.  
 c|(") = φ˙ce, " ≤ ℎ_"_p"n+"(φ5)˙ce, " > ℎ_"_p"n+" 
 φ is the fraction of the initial non-harm reduction transmission rate 
(ce)	that is remained also on harm reduction. Obtained from 
model fit 0.56 95% C.I. (0.54-0.57). Since more interventions are 
introduces gradually with time, this rate is reduced even more after 
the harm reduction package was introduced (1988). Reducing the c| exponentially after 1988 did not improved the fit.  
Model fit 
 
    
  
151
 23 
Supplementary Table 3. Mean time to HAART (in years) by disease stage as approximated by CD4 counts at baseline (for patients 
diagnosed before HAART introduction baseline was set to 1996), among IDUs in the Swiss HIV Cohort Study, by diagnosis period. 
The rates were estimated with parametric survival regression model using the Weibull distribution.  
 
 <2000 [2000,2005) [2005,2010) [2010,2016] 
Recent (CD4 > 500) 7.6 3.5 3.3 1.1 
Chronic (CD4 200-500) 4.1 1.9 1.8 0.6 
AIDS (CD4 <200) 1.8 0.8 0.8 0.3 
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Supplementary Figure 5. Reported number of IDU in methadone treatment 1980-1987 and the reduced model (See Supplementary 
Table 2, parameter h) fit, used to estimate the rate of recruitment to restricted methadone (up to 1987). Data was obtained from: (25) 
and (7). 
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The force of infection was modelled as: 
 
 
 !=		#(%)	∙ (),++, -,.,/ 	 	0	 12	∙	(3,++, -,.,/ 		 	0			#4(%)	∙ (),5,++, -,.,/ 	 	0	 (12/7)	∙	(3,5,++, -,.,/ 		 	8	9:	;<%=>?	=@A?<%9BC  
 
Iu – infected injectors -undiagnosed, Id – infected injectors- diagnosed  
R – recent stage, C – chronic stage, A – AIDS stage DC – fraction of HIV diagnosed that still share injection paraphernalia (see 
Supplementary Table 2) 
h- on harm reduction package 
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Model equations  
See Supplementary Table 4 for initial values and interpretation of the compartments.  
 
  # Non-injectors 
 
 
EFG1%   =   b(t)·(1-f_iv) + o · Nvh -  h(t) · Nv – v(t) · Nv - Nv · (m_n+w) 
 
  
EFGH1%   =  -o · Nvh +  h(t) · Nv - v(t) · Nvh - Nvh · (m_n_h+w_h) 
     
  # Susceptible 
 
  
EI1%	= b(t) · f_iv + v(t)  · Nv  + o · Sh -  h(t)· S -  ! · S - S · (m_s_i+w) 
 
  
EIH1% 	 =   v(t)  · Nvh  - o · Sh +  h(t)· S -  ! · Sh - Sh · (m_s_i_h+w_h) -fr_iv · Sh 
     
    # Infected undiagnosed 
 
 
1(_K_L	1% 	= ! · S + o · I_u_Rh - h(t)  · I_u_R -  r_c · I_u_R -  a(t) · I_u_R - I_u_R · (m_s_i+w) 
  1(_K_LM	1% 	= ! · Sh - o · I_u_Rh + h(t) · I_u_R -  r_c · I_u_Rh -  a_h(t) · I_u_Rh - I_u_Rh · (m_s_i_h+w_h) -fr_iv · I_u_Rh 
     1(_K_N	1% 	  = r_c · I_u_R + o · I_u_Ch - h(t)  · I_u_C -  c_a · I_u_C  - a(t) · I_u_C - I_u_C · (m_s_i+w) 
 1(_K_NM	1% 	= r_c · I_u_Rh - o · I_u_Ch + h(t) · I_u_C -  c_a · I_u_Ch  - a_h(t) · I_u_Ch - I_u_Ch · (m_s_i_h+w_h) -fr_iv · I_u_Ch 
     
 
1(_K_O		1% 	= c_a · I_u_C + o · I_u_Ah - h(t) · I_u_A -  a(t) · I_u_A -  I_u_A · (m_a + w)  
 1(_K_OM		1% 	 = c_a · I_u_Ch - o · I_u_Ah + h(t) · I_u_A - a_h(t) · I_u_Ah -  I_u_Ah · (m_a + w_h) -fr_iv · I_u_Ah 
     
 
    #  Diagnosed 
 	1(_1_L		1% 	  = a(t) · I_u_R + r · Tr_R + o · I_d_Rh - h_hivp(t) · I_d_R  - r_c · I_d_R  -  g_R(t) · I_d_R -  I_d_R · (m_s_i+w) 
 	1(_1_LM		1% 	 = a_h(t) · I_u_Rh + r_h · Tr_Rh - o · I_d_Rh + h_hivp(t) · I_d_R  - r_c · I_d_Rh  -  g_R_h(t) · I_d_Rh -  I_d_Rh · (m_s_i_h+w_h) -
fr_iv · I_d_Rh 
     
 
	1(_1_N		1% 	= r_c · I_d_R + a(t) · I_u_C + r · Tr_C + o · I_d_Ch -  h_hivp(t) · I_d_C  - c_a · I_d_C   - g_C(t) · I_d_C  - I_d_C · (m_s_i+w) 
 
 
	1(_1_NM		1% 	= r_c · I_d_Rh + a_h(t) · I_u_Ch + r_h · Tr_Ch - o · I_d_Ch +  h_hivp(t) · I_d_C  - c_a · I_d_Ch   - g_C_h(t) · I_d_Ch  - I_d_Ch · 
(m_s_i_h+w_h) -fr_iv · I_d_Ch 
     
 
 
	1(_1_O			1% 	= c_a · I_d_C +  a(t) · I_u_A  + r · Tr_A + o · I_d_Ah - h_hivp(t) · I_d_A  - g_A(t) · I_d_A -  I_d_A · (m_a +w) 
 
    
	1(_1_OM			1% 	= c_a · I_d_Ch + a_h(t)  · I_u_Ah  + r_h · Tr_Ah - o · I_d_Ah + h_hivp(t) · I_d_A  - g_A_h(t)  · I_d_Ah -  I_d_Ah · (m_a +w_h) 
-fr_iv · I_d_Ah  
     
   # Treated 
 
	1PB_L			1% 	=  g_R(t) · I_d_R +  o · Tr_Rh - h_hivp(t) · Tr_R - r · Tr_R  - Tr_R · (m_s_i+w)  
 	1PB_LM			1% 	 =  g_R_h(t)· I_d_Rh -  o · Tr_Rh + h_hivp(t) · Tr_R - r_h · Tr_Rh  - Tr_Rh · (m_s_i_h+w_h)-fr_iv · Tr_Rh  
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	1PB_N				1% 	 =  g_C(t) · I_d_C +  o · Tr_Ch - h_hivp(t) · Tr_C - r · Tr_C  - Tr_C · (m_s_i+w) 
 	1PB_NM				1% 	=  g_C_h(t) · I_d_Ch - o · Tr_Ch + h_hivp(t) · Tr_C - r_h · Tr_Ch  - Tr_Ch  ·  (m_s_i_h+w_h)-fr_iv · Tr_Ch 
     	1PB_O					1% 	 =  g_A(t) · I_d_A + o · Tr_Ah  - h_hivp(t) · Tr_A - r · Tr_A  - Tr_A ·  (m_at+ w)  
 
 
	1PB_OM					1% 	=  g_A_h(t) · I_d_Ah - o · Tr_Ah  + h_hivp(t) · Tr_A - r_h · Tr_Ah  - Tr_Ah · (m_at+ w_h)-fr_iv · Tr_Ah 
     
    # Past injectors 
 
 
	1Q>_R					1% 	 =   fr_iv · Sh - (m_s_i_h+w_h) · Pv_S 
     
   # inflow from undiagnosed 
 	1Q>_(KL						1% 	 = fr_iv · I_u_Rh - r_c · Pv_IuR -  a_h(t) · Pv_IuR  - (m_s_i_h+w_h) · Pv_IuR 
 
 
	1Q>_(KN						1% 	 = fr_iv · I_u_Ch + r_c · Pv_IuR- c_a · Pv_IuC  - a_h(t) · Pv_IuC  - (m_s_i_h+w_h) · Pv_IuC 
 
 
	1Q>_(KO						1% 	= fr_iv · I_u_Ah + c_a · Pv_IuC  -a_h(t) · Pv_IuA -  (m_a +w_h) · Pv_IuA 
     
    # inflow from diagnosed 
 
 
1Q>_(1L							1% 	= fr_iv · I_d_Rh + a_h(t) · Pv_IuR + r_h · Pv_T_R - r_c · Pv_IdR - g_R_h(t) · Pv_IdR - (m_s_i_h+w_h) · Pv_IdR 
 
  
1Q>_(1N							1% 	= fr_iv · I_d_Ch + a_h(t) · Pv_IuC + r_c · Pv_IdR + r_h · Pv_T_C - c_a · Pv_IdC - g_C_h(t) · Pv_IdC - (m_s_i_h+w_h) · 
Pv_IdC 
 
 
1Q>_(1O							1% 	= fr_iv · I_d_Ah + c_a · Pv_IdC + r_h · Pv_T_A +a_h(t) · Pv_IuA - g_A_h(t) · Pv_IdA - (m_a +w_h) · Pv_IdA 
     
# inflow from Treated 
 1Q>_P_L							1% 	  = fr_iv · Tr_Rh +  g_R_h(t) · Pv_IdR - r_h · Pv_T_R - Pv_T_R  ·  (m_s_i_h + w_h) 
 1Q>_P_N							1% 	= fr_iv · Tr_Ch +  g_C_h(t)  · Pv_IdC - r_h · Pv_T_C - Pv_T_C  ·  (m_s_i_h + w_h) 
 1Q>_P_O							1% 	 = fr_iv · Tr_Ah +  g_A_h(t)  · Pv_IdA - r_h · Pv_T_A - Pv_T_A  ·  (m_at+ w_h) 
     
     
# Not part of the ODE system: Counters for the output 
   # incidence - new diagnosed HIV 
    HIV_new_diagnosed=   (a(t) · I_u_R + a(t) · I_u_C + a(t)  · I_u_A +  a_h(t)  · I_u_Rh + a_h(t)  · I_u_Ch +a_h(t)  · I_u_Ah 
                           + a_h(t)  · Pv_IuR + a_h(t)  · Pv_IuC +a_h(t)  · Pv_IuA) 
    # new reported HIV deaths 
    Reported_AIDS_death= ( I_d_A · m_a + m_at · Tr_A + I_d_Ah · m_a +Tr_Ah · m_at 
                            + m_a · Pv_IdA + Pv_T_A · m_at ) 
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Supplementary Table 4. Initial values at 1980 (t=0) and interpretation of the compartments.  
 
Compartment Interpretation Initial value 
Nv Non-injectors, not on harm reduction 250 
Nvh Non-injectors, on harm reduction 0 
S Injectors, Susceptible, not on harm reduction 3099 
Sh Injectors, Susceptible, on harm reduction 650 
I_u_R Injectors, Infected, recent stage, undiagnosed, not on harm 
reduction 
1 – index case 
I_u_C Injectors, Infected, chronic stage, undiagnosed, not on harm 
reduction 
0 
I_u_A Injectors, Infected, AIDS stage, undiagnosed, not on harm 
reduction 
0 
I_u_Rh Injectors, Infected, recent stage, undiagnosed, on harm 
reduction 
0 
I_u_Ch Injectors, Infected, chronic stage, undiagnosed, on harm 
reduction 
0 
I_u_Ah Injectors, Infected, AIDS stage, undiagnosed, on harm 
reduction 
0 
I_d_R Injectors, Infected, recent stage, diagnosed, not on harm 
reduction 
0 
I_d_C Injectors, Infected, chronic stage, diagnosed, not on harm 
reduction 
0 
I_d_A Injectors, Infected, AIDS stage, diagnosed, not on harm 
reduction 
0 
I_d_Rh Injectors, Infected, recent stage, diagnosed, on harm 
reduction 
0 
I_d_Ch Injectors, Infected, chronic stage, diagnosed, on harm 
reduction 
0 
I_d_Ah Injectors, Infected, AIDS stage, diagnosed, on harm 
reduction 
0 
Tr_R Injectors, Treated, recent stage, not on harm reduction 0 
Tr_C Injectors, Treated, chronic stage, not on harm reduction 0 
Tr_A Injectors, Treated, AIDS stage, not on harm reduction 0 
Tr_Rh Injectors, Treated, recent stage, on harm reduction 0 
Tr_Ch Injectors, Treated, chronic stage, on harm reduction 0 
Tr_Ah Injectors, Treated, AIDS stage, on harm reduction 0 
Pv_S Past-injectors, Susceptible 0 
Pv_IuR Past-injectors, Infected, recent stage, undiagnosed, on harm 
reduction 
0 
Pv_IuC Past-injectors, Infected, chronic stage, undiagnosed, on 
harm reduction 
0 
Pv_IuA Past-injectors, Infected, AIDS stage, undiagnosed, on harm 
reduction 
0 
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Pv_IdR Past-injectors, Infected, recent stage, diagnosed, on harm 
reduction 
0 
Pv_IdC Past-injectors, Infected, chronic stage, diagnosed, on harm 
reduction 
0 
Pv_IdA Past-injectors, Infected, AIDS stage, diagnosed, on harm 
reduction 
0 
Pv_T_R Past-injectors, Treated, recent stage, on harm reduction 0 
Pv_T_C Past-injectors, Treated, chronic stage, on harm reduction 0 
Pv_T_A Past-injectors, Treated, AIDS stage, on harm reduction 0 
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Model fitting and sensitivity range 
 
 The model was fitted to the annual numbers of HIV diagnosed and AIDS deaths using 
negative log-likelihood-distributed error (see below), with the R function “optim” and the "L-
BFGS-B" method. The optimization converged. Supplementary Table 5 shows the parameters 
that were obtained from model fit. Confidence intervals were obtained from the Hessian, that 
was calculated with the package “numDeriv” (version 2016.8-1).  
 The sensitivity range was obtained by sampling 10,000 times from the parameter space 
within the confidence intervals using the uniform distribution. Next, for each combination, the 
model was simulated and the sum of the difference between the HIV incidence and AIDS deaths 
in the best-fit model and each random combination was calculated. The highest score represents 
the parameters combination that provides the highest deviation below the best-fit while the 
lowest score provides the highest deviation from above (See Figure 3 in the main manuscript). 
These two parameter sets were utilized to obtain the model sensitivity range (Supplementary 
Table 5).  We opted for this procedure to deal with relatively narrow confidence intervals 
obtained from the Hessian. 
 
Supplementary Table 5. Parameters that were obtained by model fitting and parameters 
combination used for sensitivity analysis. 
 Initial 
guess 
Lower 
bound 
Upper  
bound 
Best  
fit 
Lower 
95% C.I 
Upper 
95% C.I 
Lower 
sensitivity  
scenario 
Upper 
sensitivity  
scenario ST 0.25 0.05 0.6 0.548 0.421 0.675 0.674 0.434 
h 2 0.5 3 1.027 0.672 1.381 1.374 0.673 
SU 1.4 1 2 1.301 1.28 1.322 1.28 1.321 
V 0.8 0.01 0.9 0.568 0.524 0.613 0.53 0.608 
Meaning of the parameters: ST Rate of decline of non-harm reduction transmission rate after introduction of harm reduction package, h Annual rate of 
recruitment to any harm reduction after the introduction of harm reduction package, SU	 Initial epidemic transmission coefficient, V	The fraction of the 
initial non-harm reduction transmission coefficient (SU)	that remained intact also on harm reduction (because harm reduction is not 100% effective in 
preventing HIV).  
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Phylogenetic analysis to quantify the epidemic spillover to the general population  
 
 All clusters that were comprised only of Swiss sequences and had at least one IDU and 
one heterosexual individual were extracted. For each IDU, the nodes were traversed back until 
the cluster either contained another IDU individual or a risk group that is other than IDU or HET, 
then the largest previous cluster was returned (Supplementary Figure 4). Because of a very large 
prevalence gradient – as described in (30) -  of 20%-10% prevalence among IDU and less than 
0.5% prevalence among heterosexuals, the direction of transmission in a cluster was always 
assumed to be from IDU to heterosexuals. The number of heterosexuals that would have been 
infected in a scenario without harm reduction was calculated as:  
 8	9:	M?%?B9C?WK;XC	=@	%M?	?W%B;<%?1	<XKC%?BCF	YZ	[\]	Y^	_H`	_a`` 	 ∙  (Incidence in the scenario without harm reduction - Incidence in the best 
fit) 
 bcc7dcc	 	 ∙ 15,903 = 3,308 
 
 
An alternative way that uses all the IDU in the cohort in the denominator and accounts for sparse 
sampling of heterosexuals on the tree by a weighting factor w=0.65, produces a more 
conservative result (that is we reported in the main manuscript): 
 
F	YZ	H`_`aYe`fghie	j^	_H`	`f_ahk_`E	kige_`aeF	YZ	[\]	j^	_H`	kYHYa_ 	  ∙ lm ∙	 (Incidence in the scenario without harm reduction - Incidence in the 
best fit) 
 bccbnop	 ∙ lo.pr ∙	15,903 = 2,540 
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Supplementary Figure 6. Vending machines that offer sterile injection paraphernalia and condoms in Zürich, Switzerland. Left: new 
model (2017), Right: old model. The vending automates offer a package that contains: 2 x 1 ml syringes with filter, 2 needles (0.45 x 
12 mm), 2 x 0.5 g Ascorbin, 2 x 1,5 ml NaCl, 2 x Alcohol pads, 2 x dry pads. Another option is available for a set of larger (0.5 x 16 
mm) needles. A pack of six condoms is also offered. Price for all items: 2 Swiss Francs (~2 US dollars, as for May 2017).  Photos: 
Alex Marzel. 
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Supplementary Table 1. Detected STIs by anatomical site.  
 
 Chlamydia Gonorrhea 
Pharyngeal 5 (15.6%) 4 (26.7%) 
Rectal 20 (62.5%) 8 (53.3%) 
Genital 7 (21.9%) 3 (20%) 
Non-missing/Total 32/40 (80%) 15/20 (75%) 
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Supplementary Table 2. Association of selected factors with incident STI.    
 Overall No incident STI Incident STI p-value p-value 
(adjusted) §  
Number of patients 73 52 21   
Age at diagnosis (median [IQR]) 33.1 [28.2, 
40.3] 
32.8 [28.1, 40.9] 34.7 [29.3, 37.2] 0.724 1 
Sex ,  Male (%) 72 (98.6) 51 (98.1) 21 (100.0) 1 1 
Years since diagnosis (median 
[IQR]) 
5.4 [3.3, 
8.9] 
6.2 [3.8, 9.1] 3.4 [3.0, 6.1] 0.039 0.184 
Diagnosis year (median [IQR]) 2010.0 
[2007.0, 
2012.0] 
2009.0 [2007.0, 
2012.0] 
2012.0 [2010.0, 
2013.0] 
0.053 0.189 
Ethnicity ,  White (%) 70 (95.9) 50 (96.2) 20 ( 95.2) 1 1 
Higher education ,  Yes (%) 20 (27.4) 15 (28.8) 5 ( 23.8) 0.777 1 
Risk group ,  MSM (%) 68 (93.2) 47 (90.4) 21 (100.0) 0.313 0.729 
Stable partner ,  Yes (%) 36 (49.3) 27 (51.9) 9 ( 42.9) 0.607 1 
Sexual contact ,  Yes (%) 72 (98.6) 51 (98.1) 21 (100.0) 1 1 
Anal intercourse (%)    0.964 1 
   No 6 ( 8.2) 5 ( 9.6) 1 (  4.8)   
167
   Receptive 8 (11.0) 6 (11.5) 2 (  9.5)   
   Insertive 6 ( 8.2) 4 ( 7.7) 2 (  9.5)   
   Both 53 (72.6) 37 (71.2) 16 ( 76.2)   
Oral sex only ,  Yes (%) 1 ( 1.4) 1 ( 1.9) 0 (  0.0) 1 1 
Number of sexual partners 
(median [IQR]) 
2.0 [1.0, 
5.0] 
2.0 [1.0, 3.2] 3.0 [2.0, 6.0] 0.004 0.041 
Condomless sex ,  Yes (%) 37 (50.7) 25 (48.1) 12 ( 57.1) 0.607 1 
STI symptoms ,  Yes (%) 13 (17.8) 5 ( 9.6) 8 ( 38.1) 0.007 0.05 
Number of symptoms (median 
[IQR]) 
0.0 [0.0, 
0.0] 
0.0 [0.0, 0.0] 0.0 [0.0, 1.0] 0.003 0.041 
CD4 at STI screen  (median 
[IQR]) 
734.0 
[544.0, 
887.0] 
752.0 [540.8, 
893.2] 
715.0 [579.0, 
876.0] 
0.55 1 
CD4/CD8 ratio (median [IQR]) 1.2 [0.9, 
1.6] 
1.2 [0.9, 1.6] 1.1 [0.9, 1.6] 0.559 1 
Virally suppressed ,  Yes (%) 68 (93.2) 49 (94.2) 19 ( 90.5) 0.621 1 
History of Syphilis ,  Yes (%) 25 (34.2) 15 (28.8) 10 ( 47.6) 0.174 0.487 
History of depression ,  Yes (%) 25 (34.2) 18 (34.6) 7 ( 33.3) 1 1 
168
Psychiatric history ,  Yes (%) 21 (28.8) 16 (30.8) 5 ( 23.8) 0.776 1 
Ever smoked ,  Yes (%) 37 (51.4) 27 (52.9) 10 ( 47.6) 0.797 1 
Any recent drug use ,  Yes (%) 11 (15.1) 3 ( 5.8) 8 ( 38.1) 0.001 0.039 
Binge drinking (%)    0.054 0.189 
   Never 56 (80.0) 43 (86.0) 13 ( 65.0)   
   Monthly or less 8 (11.4) 3 ( 6.0) 5 ( 25.0)   
   Weekly or more 6 ( 8.6) 4 ( 8.0) 2 ( 10.0)   
Housing (%)    0.261 0.663 
   Alone 57 (83.8) 44 (86.3) 13 ( 76.5)   
   Friends 9 (13.2) 5 ( 9.8) 4 ( 23.5)   
   Other 2 ( 2.9) 2 ( 3.9) 0 (  0.0)   
Traveled to tropics ,  Yes (%) 9 (12.3) 7 (13.5) 2 (  9.5) 1 1 
Physical activity (%)    0.113 0.351 
   Low 19 (26.0) 17 (32.7) 2 (  9.5)   
   Moderate 33 (45.2) 21 (40.4) 12 ( 57.1)   
   High 21 (28.8) 14 (26.9) 7 ( 33.3)   
BMI (median [IQR]) 23.5 [21.8, 24.7 [22.6, 27.0] 22.7 [21.6, 23.4] 0.018 0.101 
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25.7] 
§ - Benjamini-Hochberg adjustment 
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Supplementary 3. Risk behaviour questionnaire  
 
STI-screening is offered to all participants every three months. STI-testing is done by PCR test for 
chlamydia and gonorrhea from the rectum, pharynx, and the urethra in a pooled analysis, and for 
syphilis by serology, and for hepatitis C virus in case of elevated liver enzymes by anti-HCV-antibodies. 
All questions refer to the last 3 months prior to the STI-screening: 
- Sexual contacts? yes ☐ no ☐ 
 
- Closed partnership? yes ☐ no ☐ 
 
- Condom use?    With exclusive partner    yes ☐  no ☐ 
With occasional partner   yes ☐  no ☐ 
- Mode of sexual contact:   ☐ oral sex 
☐ anal intercourse    insertive☐   receptive☐ 
☐ vaginal intercourse 
- Number of sex partners: _____  
 
- Symptoms/signs of STI? yes ☐  no ☐ 
 
- Throat:  ☐Redness  
Patient ID 
Date: I__I__I__I__I__I__I__I__I 
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☐Pain 
☐Ulcera/lesions  
☐Enlarged lymph nodes in the neck region  
- Vagina/Penis:   ☐Redness 
☐Pain 
☐Ulcera/lesions 
☐Discharge 
☐Enlarged lymph nodes in the inguinal region 
- Anal:    ☐Redness 
☐Pain 
☐Discharge Ulcera/lesions 
☐Ulcera/lesions 
The specimens can be obtained self-collected by the participant, or by the physician 
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Supplementary 4. Diagnosis of STI 
Swabs obtained from the urethra, rectum and pharynx were tested by polymerase chain 
reaction for Chlamydia trachomatis and Neisseria gonorrhoeae (COBAS TaqMan 4800 CT Test v2.0, 
Roche Diagnostics, Rotkreuz, Switzerland); tests that were positive for C. trachomatis were further 
examined and typed for Lymphogranuloma venereum (LGV) strains (inhouse duplex real-time rapid PCR 
C. trachomatis variant L1-L3 and L2b-specific PCR, Institute for Clinical Microbiology, University of Basel 
Switzerland). For the pooled screening, a combined specimen was obtained with a single swab first from 
the pharynx, followed by the same swab from the rectum, and an additional swab from the urethra. All 
swabs were then put together in a single tube for the pooled PCR testing. Patients with a diagnosed STI 
were informed by phone from the treating physician and received antibiotic treatment, where 
appropriate, at the outpatient clinic. 
The non-treponemal test contained either Venereal Diseases Research Laboratory (VDRL) or 
Rapid plasma reagin (RPR) titers; and the treponemal branch included TPPA. Blood was tested for 
syphilis by TPPA (SERODIA®-TPPA, Fujirebio, Tokyo, Japan). If TPPA yielded a positive result, testing with 
VDRL and/or RPR was added. Patients with both tests negative and seroconversion of both tests were 
considered as incident cases. Positive TPPA and increasing VDRL/RPR by 4-fold were also considered as 
incident cases (reinfection). Positive TPPA and negative VDRL/RPR were considered as previously 
positive tests. For positive cases, a history of sexual exposure and a clinical exam was performed. 
VDRL/RPR positive and TPPA negative were repeated and if TPPA remained negative, considered to be 
false positive cases (however, there was none of this cases in our study). 
Patients were also tested yearly for anti HCV IgG (ARCHITECT Anti-HCV assay, Abbott, 
Wiesbaden, Germany). In patients presenting with elevated transaminases, considering >50 U/l as the 
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upper limit of a normal value, blood was additionally tested for Hepatitis C by PCR (COBAS® 
AmpliPrep/COBAS® TaqMan® HCV Test, v2.0, analytical sensitivity 15 IU/mL).  
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Supplementary 5. Treatment of STI 
Patients with a diagnosed STI were informed by phone from treating physician and received antibiotic 
treatment, where appropriate, at the outpatient clinic. Uncomplicated chlamydial infection was treated 
with azithromycin 1 g as a single dose or doxycycline 100 mg twice daily for seven days, LGV doxycycline 
100 mg twice daily for 21 days or azithromycin 1 g as a single dose repeated every week for three weeks. 
Gonorrhea was treated with ceftriaxone 250 mg by intramuscular injection in combination with 
azithromycin 1 g as a single dose orally. Early syphilis without signs of central nervous system 
involvement was treated with a single dose of 2.4 million unit’s long-acting benzathine penicillin G (BPG) 
by intramuscular injection. Partner management was discussed at the same visit and concomitant sex 
partners were informed by the patient if possible.  
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SUPPLEMENTARY MATERIAL 
 
Supplementary Figure 1. Distribution of total cholesterol values (as Kernel Density). 
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  2 
Supplementary Table 1. Demographic and clinical covariates by quartiles of dietary pattern I 
(meat, refined/milled grains, carbonated beverages, coffee).  
 Quartile I Quartile II Quartile III Quartile IV P 
   n=103   n= 97    n=99    n=96  
Age (median [IQR])  56.8 [54.0, 62.3] 
 55.0 [51.6, 
59.7] 
 54.8 [52.1, 
60.3] 
 55.2 [51.8, 
59.8] 0.055 
Sex, female (%)    26 (25.2)     11 (11.3)     11 (11.1)      9 ( 9.4)  0.004 
Ethnicity (%)                0.126 
   White    94 (91.3)     92 (94.8)     94 (94.9)     93 (96.9)   
   Black     8 ( 7.8)      4 ( 4.1)      3 ( 3.0)      0 ( 0.0)   
   Hispanic     1 ( 1.0)      1 ( 1.0)      2 ( 2.0)      3 ( 3.1)   
Risk group (%)                0.022 
   Heterosexual    38 (36.9)     20 (20.6)     20 (20.2)     30 (31.2)   
   Men-who-have-Sex-with-Men    45 (43.7)     68 (70.1)     65 (65.7)     55 (57.3)   
   Injecting drug users     9 ( 8.7)      4 ( 4.1)      5 ( 5.1)      6 ( 6.2)   
   Other    11 (10.7)      5 ( 5.2)      9 ( 9.1)      5 ( 5.2)   
University education, yes (%)    15 (14.6)     11 (11.3)     16 (16.2)     13 (13.5)  0.801 
Dwelling alone ,yes (%)    41 (39.8)     45 (46.4)     41 (41.4)     35 (36.5)  0.562 
Current smoking, yes (%)    22 (21.4)     29 (29.9)     31 (31.3)     44 (45.8)  0.003 
BMI (%)                0.745 
   Normal (>=18.5 - 25)    53 (51.5)     51 (52.6)     52 (52.5)     56 (58.3)   
   Overweight (>=25 - 30)    37 (35.9)     34 (35.1)     32 (32.3)     25 (26.0)   
   Obese (>=30)     9 ( 8.7)     10 (10.3)     14 (14.1)     13 (13.5)   
   Underweight (<18.5)     4 ( 3.9)      2 ( 2.1)      1 ( 1.0)      2 ( 2.1)   
Depression, yes (%)    19 (18.4)     13 (13.4)     14 (14.1)     13 (13.5)  0.711 
Diabetes, yes (%)     7 ( 6.8)      5 ( 5.2)      4 ( 4.0)      7 ( 7.3)  0.751 
Hypertension, yes (%)    44 (42.7)     29 (29.9)     33 (33.3)     29 (30.2)  0.184 
Lipid lowering drugs, yes (%)    22 (21.4)     28 (28.9)     17 (17.2)     31 (32.3)  0.058 
Virally suppressed, yes (%)   100 (97.1)     91 (93.8)     97 (98.0)     91 (94.8)  0.413 
CD4 (median [IQR]) 
657.0 
[536.5, 
862.0] 
660.0 
[503.0, 
803.0] 
624.0 
[454.0, 
804.5] 
628.5 
[488.8, 
805.0] 
0.814 
Years on ART (median [IQR])  13.9 [8.7, 20.5] 
 14.9 [8.0, 
20.2] 
 14.2 [9.0, 
20.5] 
 14.3 [8.9, 
20.4] 0.979 
On NRTI, yes (%)    91 (88.3)     76 (78.4)     70 (70.7)     83 (86.5)  0.005 
On NTRTI, yes (%)    46 (44.7)     40 (41.2)     44 (44.4)     62 (64.6)  0.004 
On NNRTI, yes (%)    27 (26.2)     29 (29.9)     30 (30.3)     31 (32.3)  0.819 
On PI, yes (%)    23 (22.3)     24 (24.7)     23 (23.2)     37 (38.5)  0.036 
On INTI, yes (%)    61 (59.2)     54 (55.7)     60 (60.6)     52 (54.2)  0.781 
Physical activity (%)                0.718 
   Never    30 (29.1)     32 (33.0)     28 (28.3)     34 (35.4)   
   1-4 times a month     8 ( 7.8)     10 (10.3)     13 (13.1)      9 ( 9.4)   
   1-2 times a week    26 (25.2)     18 (18.6)     23 (23.2)     14 (14.6)   
   >=3 times a week    39 (37.9)     37 (38.1)     35 (35.4)     39 (40.6)   
Dietary change in the last two 
years (%)                0.291 
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 Quartile I Quartile II Quartile III Quartile IV P 
   No    89 (86.4)     92 (94.8)     93 (93.9)     86 (89.6)   
   Became vegetarian     2 ( 1.9)      0 ( 0.0)      0 ( 0.0)      1 ( 1.0)   
   Other change    12 (11.7)      5 ( 5.2)      6 ( 6.1)      9 ( 9.4)   
 
P-values represents chi-square test for categorical variables, ANOVA for numeric normal and 
Kruskal-Wallis Rank Sum Test for non-normally distributed.  
 
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; INTI, integrase inhibitor; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase 
inhibitor; NTRTI, nucleotide reverse transcriptase inhibitor; PI, protease inhibitor. 
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Supplementary Table 2. Demographic and clinical covariates by quartiles of dietary pattern II 
(organ meats, poultry, fish/seafood, alcohol).  
 
 Quartile I Quartile II Quartile III Quartile IV p 
   n=101    n=99    n=98   n= 97  
Age (median [IQR])  56.2 [52.9, 63.2] 
 56.2 [53.0, 
60.3] 
 54.3 [51.3, 
59.7] 
 55.3 [51.8, 
59.9] 0.123 
Sex, female (%)    27 ( 26.7)     13 (13.1)      9 ( 9.2)      8 ( 8.2)  0.001 
Ethnicity (%)                0.096 
   White   101 (100.0)     94 (94.9)     90 (91.8)     88 (90.7)   
   Black     0 (  0.0)      3 ( 3.0)      5 ( 5.1)      7 ( 7.2)   
   Hispanic     0 (  0.0)      2 ( 2.0)      3 ( 3.1)      2 ( 2.1)   
Risk group (%)                0.129 
   Heterosexual    38 ( 37.6)     23 (23.2)     21 (21.4)     26 (26.8)   
   Men-who-have-Sex-with-
Men    45 ( 44.6)     63 (63.6)     64 (65.3)     61 (62.9)   
   Injecting drug users     8 (  7.9)      7 ( 7.1)      6 ( 6.1)      3 ( 3.1)   
   Other    10 (  9.9)      6 ( 6.1)      7 ( 7.1)      7 ( 7.2)   
University education, yes (%)    11 ( 10.9)      8 ( 8.1)     20 (20.4)     16 (16.5)  0.056 
Dwelling alone ,yes (%)    52 ( 51.5)     41 (41.4)     37 (37.8)     32 (33.0)  0.055 
Current smoking, yes (%)    36 ( 35.6)     28 (28.3)     25 (25.5)     37 (38.1)  0.185 
BMI (%)                0.167 
   Normal (>=18.5 - 25)    60 ( 59.4)     53 (53.5)     50 (51.0)     49 (50.5)   
   Overweight (>=25 - 30)    26 ( 25.7)     32 (32.3)     36 (36.7)     34 (35.1)   
   Obese (>=30)     9 (  8.9)     13 (13.1)     12 (12.2)     12 (12.4)   
   Underweight (<18.5)     6 (  5.9)      1 ( 1.0)      0 ( 0.0)      2 ( 2.1)   
Depression, yes (%)    20 ( 19.8)     16 (16.2)     11 (11.2)     12 (12.4)  0.313 
Diabetes, yes (%)     7 (  6.9)      3 ( 3.0)      8 ( 8.2)      5 ( 5.2)  0.442 
Hypertension, yes (%)    37 ( 36.6)     29 (29.3)     38 (38.8)     31 (32.0)  0.484 
Lipid lowering drugs, yes (%)    30 ( 29.7)     26 (26.3)     25 (25.5)     17 (17.5)  0.241 
Virally suppressed, yes (%)    98 ( 97.0)     96 (97.0)     95 (96.9)     90 (92.8)  0.345 
CD4 (median [IQR]) 666.0 [538.0, 841.0] 
653.0 [529.0, 
796.0] 
609.5 [473.8, 
804.5] 
615.0 [428.0, 
817.0] 0.142 
Years on ART (median [IQR])  15.9 [10.0, 20.5] 
 15.5 [9.0, 
20.5] 
 12.8 [8.0, 
19.8] 
 13.6 [8.4, 
20.2] 0.255 
On NRTI, yes (%)    86 ( 85.1)     72 (72.7)     79 (80.6)     83 (85.6)  0.077 
On NTRTI, yes (%)    45 ( 44.6)     47 (47.5)     43 (43.9)     57 (58.8)  0.133 
On NNRTI, yes (%)    33 ( 32.7)     31 (31.3)     28 (28.6)     25 (25.8)  0.722 
On PI, yes (%)    33 ( 32.7)     28 (28.3)     20 (20.4)     26 (26.8)  0.274 
On INTI, yes (%)    56 ( 55.4)     59 (59.6)     64 (65.3)     48 (49.5)  0.148 
Physical activity (%)                0.003 
   Never    39 ( 38.6)     24 (24.2)     28 (28.6)     33 (34.0)   
   1-4 times a month    13 ( 12.9)     12 (12.1)      3 ( 3.1)     12 (12.4)   
   1-2 times a week    13 ( 12.9)     32 (32.3)     19 (19.4)     17 (17.5)   
   >=3 times a week    36 ( 35.6)     31 (31.3)     48 (49.0)     35 (36.1)   
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 Quartile I Quartile II Quartile III Quartile IV p 
Dietary change in the last two 
years (%)                0.375 
   No    87 ( 86.1)     93 (93.9)     90 (91.8)     90 (92.8)   
   Became vegetarian     2 (  2.0)      0 ( 0.0)      1 ( 1.0)      0 ( 0.0)   
   Other change    12 ( 11.9)      6 ( 6.1)      7 ( 7.1)      7 ( 7.2)   
 
 
P-values represents chi-square test for categorical variables, ANOVA for numeric normal and 
Kruskal-Wallis Rank Sum Test for non-normally distributed.  
 
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; INTI, integrase inhibitor; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase 
inhibitor; NTRTI, nucleotide reverse transcriptase inhibitor; PI, protease inhibitor. 
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Supplementary Table 3. Demographic and clinical covariates by quartiles of dietary pattern III 
(whole grains ,dairy products, eggs, leafy green vegetables ,other vegetables (raw and cooked), 
legumes/nuts/seeds, potatoes, boiled/mashed, pickled food, fruits, tea (black/green)).  
 
 Quartile I Quartile II Quartile III Quartile IV p 
n    99   100    97    99  
Age (median [IQR])  54.0 [51.7, 58.5] 
 56.6 [52.7, 
61.2] 
 55.7 [52.3, 
62.2] 
 56.6 [52.7, 
61.9] 0.031 
Sex, female (%)    12 (12.1)     15 (15.0)     16 (16.5)     14 (14.1)  0.851 
Ethnicity (%)                 0.549 
   White    96 (97.0)     91 (91.0)     93 (95.9)     93 (93.9)   
   Black     2 ( 2.0)      7 ( 7.0)      2 ( 2.1)      4 ( 4.0)   
   Hispanic     1 ( 1.0)      2 ( 2.0)      2 ( 2.1)      2 ( 2.0)   
Risk group (%)                 0.555 
   Heterosexual    27 (27.3)     34 (34.0)     23 (23.7)     24 (24.2)   
   Men-who-have-Sex-with-
Men    56 (56.6)     53 (53.0)     62 (63.9)     62 (62.6)   
   Injecting drug users     8 ( 8.1)      6 ( 6.0)      7 ( 7.2)      3 ( 3.0)   
   Other     8 ( 8.1)      7 ( 7.0)      5 ( 5.2)     10 (10.1)   
University education, yes (%)     9 ( 9.1)      8 ( 8.0)     16 (16.5)     22 (22.2)  0.011 
Dwelling alone ,yes (%)    45 (45.5)     41 (41.0)     36 (37.1)     40 (40.4)  0.698 
Current smoking, yes (%)    45 (45.5)     33 (33.0)     28 (28.9)     20 (20.2)  0.002 
BMI (%)                 0.868 
   Normal (>=18.5 - 25)    58 (58.6)     55 (55.0)     47 (48.5)     52 (52.5)   
   Overweight (>=25 - 30)    28 (28.3)     34 (34.0)     33 (34.0)     33 (33.3)   
   Obese (>=30)    10 (10.1)      9 ( 9.0)     14 (14.4)     13 (13.1)   
   Underweight (<18.5)     3 ( 3.0)      2 ( 2.0)      3 ( 3.1)      1 ( 1.0)   
Depression, yes (%)    14 (14.1)      7 ( 7.0)     23 (23.7)     15 (15.2)  0.012 
Diabetes, yes (%)     5 ( 5.1)      7 ( 7.0)      5 ( 5.2)      6 ( 6.1)  0.93 
Hypertension, yes (%)    29 (29.3)     40 (40.0)     30 (30.9)     36 (36.4)  0.359 
Lipid lowering drugs, yes (%)    24 (24.2)     32 (32.0)     21 (21.6)     21 (21.2)  0.262 
Virally suppressed, yes (%)    94 (94.9)     96 (96.0)     93 (95.9)     96 (97.0)  0.914 
CD4 (median [IQR]) 604.0 [458.0, 741.5] 
632.5 [506.5, 
837.5] 
684.0 [534.0, 
829.0] 
617.0 [505.0, 
810.0] 0.084 
Years on ART (median [IQR])  14.0 [8.8, 20.4] 
 15.0 [9.1, 
20.6] 
 14.9 [9.1, 
20.2] 
 14.1 [7.3, 
20.3] 0.698 
On NRTI, yes (%)    79 (79.8)     78 (78.0)     79 (81.4)     84 (84.8)  0.65 
On NTRTI, yes (%)    48 (48.5)     53 (53.0)     46 (47.4)     45 (45.5)  0.748 
On NNRTI, yes (%)    27 (27.3)     31 (31.0)     27 (27.8)     32 (32.3)  0.838 
On PI, yes (%)    25 (25.3)     29 (29.0)     28 (28.9)     25 (25.3)  0.878 
On INTI, yes (%)    58 (58.6)     57 (57.0)     58 (59.8)     54 (54.5)  0.892 
Physical activity (%)                 0.172 
   Never    33 (33.3)     30 (30.0)     34 (35.1)     27 (27.3)   
   1-4 times a month    14 (14.1)      5 ( 5.0)     13 (13.4)      8 ( 8.1)   
   1-2 times a week    16 (16.2)     20 (20.0)     23 (23.7)     22 (22.2)   
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 Quartile I Quartile II Quartile III Quartile IV p 
   >=3 times a week    36 (36.4)     45 (45.0)     27 (27.8)     42 (42.4)   
Dietary change in the last two 
years (%)                 0.401 
   No    92 (92.9)     94 (94.0)     89 (91.8)     85 (85.9)   
   Became vegetarian     1 ( 1.0)      1 ( 1.0)      0 ( 0.0)      1 ( 1.0)   
   Other change     6 ( 6.1)      5 ( 5.0)      8 ( 8.2)     13 (13.1)   
 
 
P-values represents chi-square test for categorical variables, ANOVA for numeric normal and 
Kruskal-Wallis Rank Sum Test for non-normally distributed.  
 
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; INTI, integrase inhibitor; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase 
inhibitor; NTRTI, nucleotide reverse transcriptase inhibitor; PI, protease inhibitor. 
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Supplementary Table 4. Demographic and clinical covariates by quartiles of dietary pattern IV 
(pizza, deep fried foods, salty snacks, ice cream/pudding, desserts/sweet snacks, confectionary 
sugars/syrups, fruit juice/drinks).  
 Quartile I Quartile II Quartile III Quartile IV p 
    n=99   n=102    n=95    n=99  
Age (median [IQR])  56.5 [52.9, 64.3] 
 54.6 [52.0, 
58.4] 
 56.1 [51.7, 
59.5] 
 55.3 [51.8, 
60.3] 0.069 
Sex, female (%)    12 (12.1)     11 (10.8)     16 (16.8)     18 (18.2)  0.376 
Ethnicity (%)                 0.751 
   White    96 (97.0)     94 (92.2)     89 (93.7)     94 (94.9)   
   Black     3 ( 3.0)      5 ( 4.9)      4 ( 4.2)      3 ( 3.0)   
   Hispanic     0 ( 0.0)      3 ( 2.9)      2 ( 2.1)      2 ( 2.0)   
Risk group (%)                 0.314 
   Heterosexual    32 (32.3)     26 (25.5)     26 (27.4)     24 (24.2)   
   Men-who-have-Sex-with-
Men    49 (49.5)     60 (58.8)     58 (61.1)     66 (66.7)   
   Injecting drug users     6 ( 6.1)      9 ( 8.8)      6 ( 6.3)      3 ( 3.0)   
   Other    12 (12.1)      7 ( 6.9)      5 ( 5.3)      6 ( 6.1)   
University education, yes (%)     7 ( 7.1)     14 (13.7)     22 (23.2)     12 (12.1)  0.012 
Dwelling alone ,yes (%)    44 (44.4)     47 (46.1)     30 (31.6)     41 (41.4)  0.167 
Current smoking, yes (%)    33 (33.3)     36 (35.3)     24 (25.3)     33 (33.3)  0.448 
BMI (%)                 0.468 
   Normal (>=18.5 - 25)    46 (46.5)     55 (53.9)     50 (52.6)     61 (61.6)   
   Overweight (>=25 - 30)    40 (40.4)     32 (31.4)     34 (35.8)     22 (22.2)   
   Obese (>=30)    11 (11.1)     13 (12.7)      9 ( 9.5)     13 (13.1)   
   Underweight (<18.5)     2 ( 2.0)      2 ( 2.0)      2 ( 2.1)      3 ( 3.0)   
Depression, yes (%)    15 (15.2)     17 (16.7)     16 (16.8)     11 (11.1)  0.647 
Diabetes, yes (%)    13 (13.1)      2 ( 2.0)      5 ( 5.3)      3 ( 3.0)  0.003 
Hypertension, yes (%)    44 (44.4)     37 (36.3)     28 (29.5)     26 (26.3)  0.036 
Lipid lowering drugs, yes (%)    33 (33.3)     29 (28.4)     19 (20.0)     17 (17.2)  0.031 
Virally suppressed, yes (%)    95 (96.0)     98 (96.1)     93 (97.9)     93 (93.9)  0.581 
CD4 (median [IQR]) 651.0 [489.5, 874.5] 
606.0 [484.2, 
802.2] 
647.0 [496.5, 
771.0] 
678.0 [511.5, 
822.5] 0.572 
Years on ART (median [IQR])  14.4 [9.3, 20.4] 
 13.8 [7.6, 
20.3] 
 14.2 [9.0, 
20.6] 
 15.5 [9.7, 
20.2] 0.852 
On NRTI, yes (%)    77 (77.8)     78 (76.5)     74 (77.9)     91 (91.9)  0.016 
On NTRTI, yes (%)    46 (46.5)     51 (50.0)     45 (47.4)     50 (50.5)  0.927 
On NNRTI, yes (%)    27 (27.3)     34 (33.3)     33 (34.7)     23 (23.2)  0.254 
On PI, yes (%)    28 (28.3)     26 (25.5)     22 (23.2)     31 (31.3)  0.606 
On INTI, yes (%)    54 (54.5)     62 (60.8)     50 (52.6)     61 (61.6)  0.492 
Physical activity (%)                 0.004 
   Never    38 (38.4)     43 (42.2)     17 (17.9)     26 (26.3)   
   1-4 times a month     9 ( 9.1)     11 (10.8)      7 ( 7.4)     13 (13.1)   
   1-2 times a week    20 (20.2)     18 (17.6)     28 (29.5)     15 (15.2)   
   >=3 times a week    32 (32.3)     30 (29.4)     43 (45.3)     45 (45.5)   
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 Quartile I Quartile II Quartile III Quartile IV p 
Dietary change in the last two 
years (%)                 0.8 
   No    89 (89.9)     91 (89.2)     89 (93.7)     91 (91.9)   
   Became vegetarian     0 ( 0.0)      1 ( 1.0)      1 ( 1.1)      1 ( 1.0)   
   Other change    10 (10.1)     10 ( 9.8)      5 ( 5.3)      7 ( 7.1)   
 
 
P-values represents chi-square test for categorical variables, ANOVA for numeric normal and 
Kruskal-Wallis Rank Sum Test for non-normally distributed.  
 
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; INTI, integrase inhibitor; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase 
inhibitor; NTRTI, nucleotide reverse transcriptase inhibitor; PI, protease inhibitor. 
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Supplementary Table 5. Factors correlating with total cholesterol, separately for patients on 
(n=98) and not on lipid lowering drugs (n=297) in two linear mixed-effect models with adjustment 
to the variables listed.  
 Not on lipid lowering drugs On lipid lowering drugs 
 Beta 2.5 % 97.5 % P value Beta 2.5 % 97.5 % P value 
Age  0.010 -0.009 0.028 0.314  0.004 -0.025  0.032 0.823 
Female sex, vs. Male  0.574  0.198 0.949 0.004  0.258 -0.579  1.107 0.587 
Risk group: MSM vs. HET -0.061 -0.383 0.261 0.718 -0.247 -0.732  0.256 0.379 
Risk group: IDU vs. HET -0.398 -0.951 0.155 0.172 -1.148 -2.023 -0.278 0.022 
Risk group: Other vs. HET  0.039 -0.401 0.480 0.865 -0.599 -1.825  0.592 0.381 
On NRTI,  yes vs. no -0.016 -0.338 0.306 0.926 -0.327 -0.935  0.268 0.337 
On NTRTI, yes vs. no -0.236 -0.490 0.018 0.078 -0.546 -0.980 -0.076 0.037 
On NNRTI, yes vs. no  0.171 -0.115 0.457 0.257  0.157 -0.280  0.626 0.540 
On PI, yes vs. no -0.078 -0.359 0.202 0.595  0.191 -0.243  0.669 0.464 
On INTI, yes vs. no  0.080 -0.173 0.333 0.547 -0.182 -0.610  0.281 0.470 
Physical activity 1-4 times a month vs. 
none  0.105 -0.297 0.507 0.619 -0.070 -0.839  0.760 0.878 
Physical activity 1-2 times a week vs. 
none  0.019 -0.308 0.346 0.912 -0.160 -0.797  0.501 0.663 
Physical activity >=3 times a week vs. 
none -0.102 -0.382 0.178 0.488 -0.732 -1.166 -0.232 0.008 
ln(dietary pattern I + 1)  0.234  0.011 0.457 0.047  0.352 -0.039  0.747 0.115 
ln(dietary pattern II + 1)  0.055 -0.456 0.565 0.839 -0.159 -1.239  0.863 0.791 
ln(dietary pattern III + 1)  0.054 -0.220 0.328 0.708  0.439 -0.168  0.996 0.186 
ln(dietary pattern IV + 1) -0.024 -0.323 0.275 0.878 -0.378 -0.904  0.111 0.189 
fasting cholesterol, yes vs. no -0.089 -0.406 0.227 0.592  0.113 -0.520  0.581 0.734 
 
Abbreviations: Abbreviations: HET, heterosexual; IDU, injecting-drugs-users; INTI, integrase 
inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse 
transcriptase inhibitor; NTRTI, nucleotide reverse transcriptase inhibitor; PI, protease inhibitor. 
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